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Zusammenfassung 
 
Die faszinierende phänotypische und funktionelle Vielfalt der unterschiedlichen 
Zelltypen in Säugetieren lässt sich zu einem großen Teil auf epigenetische Signale 
zurückführen. Diese steuern zusammen mit der DNA Sequenz die 
Genexpressionsprogramme der Zelle. Eines der wichtigsten epigenetischen Signale 
ist die DNA Methylierung, ihre besondere Bedeutung wurde bereits in frühen 
genetischen Studien erkannt. Trotz jahrzehntelanger Forschung ist ein umfassendes 
Verständnis der Steuerung und Regulation der Aktivität von DNA-Methyltransferasen 
bisher nicht erreicht worden. Diese Arbeit umfasst drei Forschungsansätze mit dem 
ultimativen Ziel, mechanistische und methodische Einblicke in die Etablierung und den 
Erhalt von DNA-Methylierungsmustern zu erzielen. 
Im ersten Projekt dieser Arbeit wurde eine Kombination von biochemischen und 
zellulären Methoden dazu genutzt, um die zelluläre Rolle des potentiellen Chromatin 
Remodelers HELLS, eines essentiellen Cofaktors für DNA Methyltransferasen in 
Zellen, zu untersuchen. Unter Verwendung von Chromatin Fraktionierungs Assays und 
Mikroskopie basierenden Techniken war es mir möglich zu zeigen, dass die ATPase 
Aktivität von HELLS für dessen hohe Mobilität im Zellkern sowie für dessen Fähigkeit 
zur Dissoziation von dicht gepacktem Chromatin verantwortlich ist. Darüber hinaus 
wurde auch festgestellt, dass das H3K9me3-Netzwerk eine wichtige Rolle bei der 
Interaktion von HELLS mit Heterochromatin spielt. Zusammenfassend legt diese 
Studie den ersten Beweis dafür dar, dass die Hydrolyse von ATP für die 
Wechselwirkung zwischen HELLS und Chromatin wichtig ist. Dieses Ergebnis legt 
nahe, dass der schnelle Austausch von HELLS an repetitiven DNA Sequenzen dazu 
führen könnte das die Rekrutierung von epigenetischen Enzymen wie beispielsweise 
DNA Methyltransferasen ermöglicht wird. Dies wiederum hätte eine lokale 
Stabilisierung von reprimierenden Proteinkomplexen an Heterochromatin zur 
Konsequenz. 
Im zweiten Projekt dieser Arbeit wurde die mögliche Wechselwirkung zwischen der de 
novo DNA Methyltransferase DNMT3A und dem 5mC Leseprotein MeCP2 untersucht. 
Aufbauend auf früheren Daten unseres Labors, welche eine direkte Interaktion 
zwischen der TRD Domäne von MeCP2 und der ADD Domäne von DNMT3A zeigten, 
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die eine inhibierende Wirkung auf die enzymatische Aktivität von DNMT3A in vitro hat, 
konnte ich zeigen, dass beide Proteine auch im Gehirn von Mäusen miteinander 
interagieren; des Weiteren konnte ich in Zelllinien die MeCP2 stabil überexpremieren 
den Inhibitionseffekt nachweisen. Außerdem war es mir möglich durch die 
Verwendung von DNMT3A Varianten, die in einer Konformation arretiert sind und ein 
neues Werkzeug zur Untersuchung der allosterischen Regulation dieses Enzymes 
darstellen, den Mechanismus der Inhibierung von DNMT3A durch MeCP2 zu erklären. 
Mit diesem Ansatz konnte ich zeigen, dass MeCP2 die allosterisch geschlossene, 
inaktive Konformation von DNMT3A stabilisiert, ein Effekt welcher durch die Zugabe 
von unmodifiziertem Histon H3 aufgehoben werden konnte. Diese Ergebnisse wurden 
unterstützt durch eine Bisulfit-Sequenzierungsanalyse des Methyloms von 
Gehirnzellen eines Mecp2 Knockout Mausmodells. Zusammenfassend geben die 
Ergebnisse dieses Projektes einen einmaligen Einblick in die Regulation der Aktivität 
von DNMT3A und sie unterstützen ein Modell, in welchem das Enzym unter der 
kombinierten Kontrolle von MeCP2 und den N-terminalen Modifikationen von Histon 
H3 steht. Dementsprechend fungiert MeCP2 entweder als Repessor oder als Aktivator 
der DNA Methylierung. 
Im dritten Projekt dieser Arbeit, lag der Fokus schließlich auf der Entwicklung und 
Anwendung einer neuen Methode, welche es zum ersten Mal möglich machen sollte, 
epigenetische Modifikationen ortsspezifisch und in lebenden Säugetierzellen zu 
visualisieren. Dieser dringende  technologische Bedarf wurde durch die Entwicklung 
modularer epigenetischer Biosensoren für die Lebendzellmikroskopie gedeckt, welche 
auf dem Prinzip der Fluoreszenz Komplementation basieren. In diesen Werkzeugen, 
wurde die hohe Sequenzspezifität von Ankerproteinen wie ZFs, TALEs und 
CRISPR/Cas9 mit der großen Vielseitigkeit von Chromatin-Lesedomänen als 
natürliche Detektormodule für die Erkennung von DNA Methylierung und Histon 3 
Lysin 9 Trimethylierung kombiniert. Mit diesem Ansatz war es mir zum ersten Mal 
möglich, beide Modifikationen gezielt an spezifischen endogenen DNA Sequenzen in 
unterschiedlichen Maus und humanen Zelllinien zu detektieren. Des Weiteren konnte 
ich ortsspezifische Signaländerungen dieser Modifikationen nach der Zugabe von 
Inhibitoren oder der Induktion epigenetischer Enzyme beobachten. Diese Werkzeuge 
können entweder in ihrer gegenwärtigen Form oder in Kombination mit den 
momentanen Weiterentwicklungen im Bereich des Genom Targeting und der 
Mikroskopie unser Verständnis dafür erweitern, wie spezifisch epigenetische Signale, 
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wie beispielsweise DNA Methylierung, während der embryonalen Entwicklung und der 
Entstehung von Krankheiten, gesetzt, gelöscht und aufrechterhalten werden. 
Zusammengenommen zeigen die Ergebnisse dieser Doktorarbeit wie die 
synergetische Nutzung biochemischer und zellulärer Methoden es ermöglicht, tiefe 
Einblicke in das epigenetische Signalnetzwerk, welches die Methylierung von DNA bei 
Säugetieren reguliert, zu erhalten. 
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Abstract 
 
The mesmerizing phenotypical and functional diversity of mammalian cell types is to a 
large extent attributed to epigenetic signals that work together with the DNA sequence 
to determine gene expression programs. DNA methylation is one of the most important 
types of epigenetic signals and its paramount role was recognized in early genetic 
studies. Still, even after decades of active research, a comprehensive understanding 
of the mechanisms that regulate the chromatin targeting and activity of DNA 
methyltransferases has not been achieved. In this work, three main directions of 
research were undertaken, with the ultimate goal of shedding mechanistic and 
methodological insights into the generation and maintenance of DNA methylation 
patterns. 
In the first project of this thesis, a combination of biochemical and cellular experiments 
was used to assess the cellular role of the putative chromatin remodeler HELLS, an 
essential cofactor of DNA methyltransferases. By employing chromatin fractionation 
assays and microscopy-based techniques, I could show that the ATPase activity of 
HELLS is necessary for the high nuclear mobility of the protein and its ability to get 
released from compacted chromatin sites. In addition, the H3K9me3 pathway was also 
found to play an important role in the exchange of HELLS at heterochromatin. Taken 
together, this work provides the first evidence for a role of ATP hydrolysis in the 
association between HELLS and chromatin and hints at a model where the fast 
exchange of HELLS at repetitive DNA sequences might enhance the local recruitment 
of epigenetic enzymes, such as DNA methyltransferases (DNMTs). This could 
subsequently lead to the local stabilization of silencing complexes at heterochromatin. 
In the second project of this thesis, the putative interaction between the de novo DNA 
methyltransferase DNMT3A and the 5mC-reading protein MeCP2 was addressed. By 
building on previous data from our laboratory, which documented a direct interaction 
between the TRD domain of MeCP2 and the ADD domain of DNMT3A, causing an 
inhibition of DNMT3A activity in vitro, I could show that these proteins also interact in 
the mouse brain and the inhibitory effect of this interaction is also observed in stable 
cells lines overexpressing MeCP2. Furthermore, by using conformationally locked 
DNMT3A variants as novel tools to study the allosteric regulation of this enzyme, I 
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could elucidate the mechanism of the inhibition of DNMT3A by MeCP2. Accordingly, I 
found that MeCP2 stabilizes an allosterically closed conformation of DNMT3A, an 
effect that could be successfully relieved by addition of unmodified histone H3. These 
results were supported by whole genome bisulfite brain methylome analysis of a 
Mecp2 knockout mouse model. Collectively, the findings derived from this project offer 
unprecedented insights into the regulation of DNMT3A activity and propose a model in 
which the enzyme is under the combined control of MeCP2 and H3 tail modifications. 
Accordingly, depending on the modification status of the H3 tail at target sites, MeCP2 
can act as either a repressor or activator of DNA methylation. 
Finally, in the third project of this thesis, the focus was placed on the development and 
application of a novel method that would enable for the first time the locus-specific 
visualization of epigenetic modifications in living mammalian cells. This urgent and 
unmet technological need was solved by developing a set of modular fluorescence 
complementation-based epigenetic biosensors for live cell microscopy applications. In 
these tools, the high DNA sequence specificity of engineered anchor proteins such as 
ZFs, TALEs, and CRISPR/Cas9 proteins, was combined with the great versatility of 
chromatin reading domains as natural detector modules of DNA methylation and 
histone 3 lysine 9 trimethylation. With this approach, I could detect both of these marks 
for the first time, at defined, endogenous DNA sequences in different mouse and 
human cell lines. Furthermore, I could follow the changes in the levels of these 
epigenetic modifications with locus-specific resolution after treatment with epigenetic 
inhibitors or the induction of epigenetic enzymes. It is anticipated that either in their 
present form or in combination with the ongoing developments in genomic targeting 
and microscopy technologies, these tools will greatly improve our understanding of 
how specific epigenetic signals, like DNA methylation, are set, erased and maintained 
during embryonic development or onset of disease. 
Taken together, the results of this doctoral thesis demonstrate how a synergistic use 
of biochemical and cellular methods allows to derive deep insights into the epigenetic 
signaling network centered around the regulation of mammalian DNA methylation. 
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1 Introduction 
1.1 Foundations of Epigenetics 
The development of a multicellular organism, with its constituting tissues and organs, 
is a reproducible cascade of events, which involves the coordination of two main 
processes: an increase in cellular mass as well as a phenotypic and functional 
differentiation of the expanding cellular populations (Moris et al., 2016). This arising 
functional diversity is mesmerizing taking into account that nearly all cells of the 
organism share the same genetic code and have a common gene repertoire (~ 20,000 
in humans). One of the main molecular contributors to this cellular heterogeneity is 
epigenetics. The term was coined in 1942 by Waddington, and was defined as 'the 
branch of biology which studies the causal interactions between genes and their 
products which bring the phenotype into being’ (Waddington, 2012).  This description 
was used to explain changes in phenotype, for which little mechanistic understanding 
was available (Allis and Jenuwein, 2016; Waddington, 1942). This theoretical 
framework was further elaborated to describe embryonic tissue development and 
differentiation and took shape in an illustration referred to as ‘Waddington’s epigenetic 
landscape’ (Figure 1a). In this, a cell is represented by a marble beginning to roll off 
at the top of a mountain valley and following one of the several existing paths down 
the landscape. At the end of its trajectory, the marble comes to rest into one of the 
depicted local energy minima, representing one defined differentiation state. The 
further the cell travels down the branching points, the more restricted its differential 
potential becomes. Importantly, the trajectory taken by the cell is non-random. This is 
guided by specific gene regulatory networks, which chart the shape of the epigenetic 
landscape, and determine the path of the marble at the branching points (Figure 1b). 
Figure 1| Waddington’s epigenetic landscape. a) In Waddington’s illustration, the cell, depicted as a 
marble, travels down the landscape by opting for a specific set of branching points, which stand for 
developmental decision events. At the end of the journey the cell has reached its full differentiation 
potential. b) The landscape is underpinned by gene regulatory networks, depicted as pegs under the 
hills and valleys. Both images were adapted after (Moris et al., 2016) 
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Today, we would argue that Waddington’s landscape is a metaphor for how alternative 
cellular programs can be realized based on epigenetic principles. 
With the booming development of the field, the definition of the term epigenetics was 
further refined and gradually narrowed to ‘‘the study of changes in gene function that 
are mitotically and/or meiotically heritable and that do not entail a change in DNA 
sequence.’’ (Wu and Morris, 2001). Noteworthy, by contrast to Waddington’s definition, 
the new conceptualization makes heritability a necessary part of the epigenetic notion 
(Deans and Maggert, 2015).  
We now know that epigenetic signals fundamentally control cellular diversity by 
transducing the inheritance of gene expression patterns. This is achieved by regulating 
the local interpretation of the genetic code and not by modifying the underlying DNA 
sequence (Allis and Jenuwein, 2016). As a result, even if all cells share the same 
genetic code including the common repertoire of genes, only a subset of genes will be 
expressed in a particular cell type at a given developmental stage. Three main 
categories of signals were described to be essential for the establishment of a stably 
inheritable epigenetic state (Figure 2) (Berger et al., 2009). At the top of the cascade, 
the ‘Epigenator’ is found. This is a signal that originates from the extracellular 
environment and is able to activate an intracellular pathway. It acts as a priming factor 
for the ‘Epigenetic Initiator’, which responds by targeting a specific chromosomal locus. 
Here it is able to instruct a change in the local epigenetic environment. This newly 
Figure 2| The epigenetic pathway. The epigenetic pathway relies on three categories of signals, which 
contribute to the establishment of a stably inherited epigenetic state. The ‘Epigenator’ (blue) originates 
from the environment and triggers the signaling cascade. In response to this, the ‘Epigenetic initiator’ 
(red), which has DNA sequence specificity, targets a specific chromosomal locus where it instructs 
changes in the epigenetic landscape. The inheritance of these changes is taken over by the ‘Epigenetic 
Maintainer’ (green). The image was taken from (Berger et al., 2009). 
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enforced state is finally sustained by ‘Epigenetic Maintainers’. These factors do not 
have absolute DNA sequence specificity and are dependent on initiators for locus-
specific recruitment. Hence, while maintainers are indispensable for sustaining the 
local epigenetic state, they are not capable of initiating it.     
1.2 Chromatin organization: regulator of the genetic code 
Each human cell contains approximately 2 meters of DNA if stretched end-to-end; yet 
the nucleus, the organelle where this genetic information is stored, is only about 10 μm 
in diameter. A back-of-the-envelope calculation reveals that the human genetic code 
must be condensed by circa 105-fold in order to fit into the nucleus. To resolve this 
immense spatial constrain, the genome is tightly compacted by a dedicated set of 
specialized and highly conserved proteins, which are able to bind to and fold DNA into 
structures with increasingly higher levels of organization (Figure 3) (Li and Zhu, 2015). 
This hierarchically packed nucleoprotein complex is referred to as chromatin (from the 
Greek ‘khroma’, colored,  because of its staining properties (Filion et al., 2011)). This 
structure establishes a key control mechanism of gene expression in eukaryotes 
(Luger et al., 2012). The outmost importance of chromatin architecture and compaction 
is immediately evident from the dry matter composition of the yeast interphase nucleus, 
which consists of about 70-80% protein, 20-30% RNA and only ~2% DNA (Rozijn and 
Tonino, 1964). 
Figure 3| Higher order packaging of the genetic material within the nucleus of a eukaryotic cell. 
The DNA is serially folded intro structures with increasingly higher orders of compaction, depicted here 
in a schematic manner. At low-compaction levels, atomic structures are shown. The image was taken 
from  (Chakravarthy et al., 2005). 
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The basic building block of the chromatin fiber is the nucleosome (Figure 4). This elicits 
an initial ~ 7-fold linear compaction of genomic DNA and consists out of 147 bp DNA 
wrapped in 1, 7 superhelical turns around an octamer containing two copies of each of 
the four core histone proteins: H2A, H2B, H3, H4 (Luger et al., 1997). The high affinity 
of histone proteins for DNA give rise to a highly stable structure that restricts the access 
of DNA-binding proteins and acts as an inherent barrier for nuclear processes such as 
transcription, DNA replication, and DNA repair (Grigoryev and Woodcock, 2012). An 
initial high-resolution X-ray structure of the nucleosome core revealed that two main 
phosphates per strand per helical turn are responsible for making direct contact 
between the DNA backbone and the core histone proteins. The DNA helix forms 
contacts primarily with the paired-loop and paired-end-of-helix elements in the histone 
fold domains. Highly conserved, arginine residues point towards the minor groove to 
facilitate DNA positioning, bending and superhelical shape (Davey et al., 2002; Luger 
et al., 2012; Luger et al., 1997). 
Interestingly, in spite of this stability, the nucleosomal structure is also highly dynamic. 
In vitro and in living cells, nucleosomes were shown to be subjected to thermal 
fluctuations that induce a spontaneous partial unwrapping of the compacted DNA, in a 
process known as ‘chromatin breathing’. This is a short-lived structural state during 
which the last 10-20 bps of DNA that make contacts to the histone octamer, dissociate, 
thereby transiently exposing the underlying DNA sequence for binding by high-affinity 
DNA-binding factors (Luger et al., 2012). In addition to these passive events, the 
accessibility of the nucleosomal sequence can also be actively regulated by multi-
Figure 4| The structure of the nucleosome core particle. a) View of the core particle down the DNA 
superhelix axis. Each type of histone protein is color-coded and shown as ribbon traces. b) View of the 
core particle perpendicular to the superhelical axis. The image was taken from  (Dutnall and 
Ramakrishnan, 1997). 
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subunit ATP-dependent chromatin remodeling complexes. These enzymes use the 
energy derived from ATP hydrolysis to alter the nucleosome structure or positioning, 
thereby regulating the access of transcription factors to their cognate DNA sites (Hota 
and Bruneau, 2016).  
Neighboring nucleosomes are connected by 10-70 bps of linker DNA in a ‘beads-on-
a-string’ highly flexible polymer (Figure 5a) (Olins and Olins, 1974). Chromatin 
architectural proteins, such as the linker histone H1, further promote and stabilize the 
condensation of this 10-nm array into an ordered and highly important secondary 
structure: the 30-nm fiber (Li and Reinberg, 2011). This serves as a basis for additional 
loops or hierarchical coiled structures that mature in the form of single chromosomes 
(Figure 3) (Razin and Gavrilov, 2014). Despite considerable efforts during the last 
three decades, however, the precise molecular organization of the ‘bead-on-a-string’ 
arrays into the secondary structure of chromatin, the 30-nm fiber, remained a matter 
of intense debate (Grigoryev and Woodcock, 2012; Lieberman-aiden et al., 2009; Rao 
et al., 2014; Travers, 2014).  
The 30-nm fiber was first visualized by electron microscopy, upon Mg2+ addition to 
chromatin released from chicken erythrocytes (Razin and Gavrilov, 2014). Subsequent 
X-ray diffraction studies of the released chromatin proposed that the 30-nm fiber is 
organized as a solenoid or a ‘one-start’ helix. Here the nucleosomes coil around a 
central cavity with ∼ 6 nucleosomes per turn, so that each nucleosome in the fiber 
interacts with its fifth and sixth neighbor nucleosomes (Figure 5b) (Finch and Klug, 
1976). Follow up electron microscopy studies, using chromatin that has been snap-
frozen immediately after its release from the nucleus, lead the formulation of an 
alternative model: the zig-zag or ‘the two-start’ helix. Here, each nucleosome binds to 
its second neighbor (Figure 5b) (Woodcock et al., 1984). In spite of this progress, the 
heterogeneous properties of nucleosomes in native chromatin with different 
sequences/linker lengths and different histone compositions/modifications make it 
difficult to precisely deconvolute the detailed structure of chromatin fibers (Zhu and Li, 
2016).  
The need of chromatin with defined composition was addressed by the development 
of new methods that allowed the in vitro assembly of designer chromatin fibers using 
unmodified, recombinant histones and regular tandem repeats of unique nucleosome 
positioning DNA sequences (Dorigo et al., 2004). This advancement facilitated the 
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dissection of the key parameters that are important for the assembly of the chromatin 
fiber (Zhu and Li, 2016). Using this system, Song and colleagues have recently 
provided fundamental structural insight into the composition of the 30-nm fiber (Song 
et al., 2014). By employing 3D cryo-EM on in vitro reconstituted arrays of 12 
nucleosomes, assembled in the presence of linker histone H1 and with different 
nucleosome repeat lengths, the authors succeeded for the first time to unequivocally 
identify the path followed by the linker DNA and pinpoint the arrangement of the 
individual nucleosomes within the 30-nm fiber. These structures showed a histone H1 
dependent left-handed twist of repeating tetranucleosomal structural subunits, within 
which the four nucleosomes zigzag back and forth with a straight linker DNA (Figure 
5c). These study resolved the fundamental issue as to whether the 30-nm fiber is built 
as a one-start or a two-start model, and revealed that the chromatin fiber is double-
helical, like the DNA it packages (Song et al., 2014). This biochemical work recently 
received support from three studies showing that nucleosomes are organized into 
discrete ‘‘nucleosome clutches’’ or ‘‘tetranucleosomal folding motifs’’ along the 
Figure 5| Arrangement of nucleosomes into chromatin fibers with increasingly high levels of 
compaction. a) Low-ionic strength chromatin spread showing the ‘beads on a string’ 10-nm fiber. The 
Image was taken from (Olins and Olins, 2003). b) Schematic representation of the one-start (left) and 
two-start (right) 30-nm fiber. The numbers denote the nucleosomes in the arrays, while the red line 
indicates the path of the DNA. The image was adapted after (Quenet et al., 2012). c) Top: a 
representative cryo-EM micrograph of 30-nm fibers reconstituted on 12 x 187 bp DNA. The zoom-ins 
display four selected unsupervised classification generated areas. Bottom: a pseudo-atomic model build 
by directly stacking the cryo-EM structure of the fibers reconstituted on 12 x 187 bp DNA, on top of each 
other to form a continuous fiber. These images were taken from (Song et al., 2014). 
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chromatin fiber also in vivo (Grigoryev et al., 2016; Hsieh et al., 2015; Ricci et al., 
2015). The functional role of the tetranucleosomal unit was recently addressed by Li 
and colleagues (2016), using biophysical and genome-wide analysis. With these 
techniques, the authors revealed that the tetranucleosome is a stable secondary 
structure during hierarchical in situ condensation of chromatin fibers and that its 
stability is regulated by the histone chaperone FACT (Li et al., 2016). Taken together, 
the data included in this study indicate that the tetranucleosome might provide an 
additional level of gene regulation beyond the nucleosome. 
Although the higher order hierarchical folding of the chromatin fiber beyond the 30-nm 
scale, remains a matter of intense dispute, the major factors that affect chromatin 
organization have been elucidated. These epigenetic signals are DNA methylation, 
histone posttranslational modifications (PTMs) and non-coding RNAs (ncRNAs). 
These landmarks, together with ATP-dependent chromatin remodeling complexes lay 
the basis of an interconnected and highly dynamic epigenetic landscape and contribute 
to a fascinating increase in the information storage capacity of the genetic code. In the 
following sections, a more detail view on DNA and histone modifications as well as on 
chromatin remodeling complexes will be provided.  
1.3 Histone modifications and histone modifying enzymes 
1.3.1 Histone modification types 
Pioneering experiments performed by Allfrey, using acetate-2-C14 and methionine-
methyl-C14 as precursors, revealed already in the mid-1960s that histone proteins can 
be post-translationally modified and in particular acetylated (Allfrey et al., 1964). Since 
then, an astonishingly large number of post-translational modification (PTMs) types 
have been identified and mapped, such as lysine acetylation and methylation, 
phosphorylation, ubiquitination (Ub), ADP-ribosylation, arginine methylation, 
citrullination, and SUMOylation (Figure 6) (Arnaudo and Garcia, 2013). Noteworthy, 
while modern mass spectrometry methods have discovered more than 200 different 
flavors of histone modifications, not all of these PTMs are equally abundant indicating 
that for some, the functional roles might be rather discrete (Leroy et al., 2013; Rothbart 
and Strahl, 2014). Out of the 20 standard amino acids coded by the ribosome, lysine 
stands out as the hotspot for enzymatic PTMs. This essential α-amino acid is usually 
located in the outer hydrophilic surface of proteins, where its flexible side-chain that 
contains a terminal ε-amino group, is solvent exposed and forms ionic interactions and 
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hydrogens bonds in proteins, DNA and by interacting with water molecules. Lysine is  
not only the most modified amino acid, but also the one which is subjected to the widest 
range of PTMs (Figure 6) (Andrews et al., 2016; Bischoff and Schlüter, 2012; Mann 
and Jensen, 2003).  Among these, acetylation and methylation of lysine residues have 
emerged as two of the key modulators of chromatin-templated processes and will be 
addressed in further detail in the following sections.  
A first indication of the regulatory role of histone PTMs was provided by the high-
resolution X-ray structure of the nucleosome. This revealed that histone proteins have 
disordered N and C-terminal tails, which protrude out of the nucleosomal core and can 
make contacts with neighboring nucleosomes (Figure 4) (Luger et al., 1997). This lead 
Figure 6| Modifications found on histone proteins. fo, formylation; ma, malonylation; su, 
succinylation; glu, glutarylation; ub, ubiquitination; cit, citrullination; oh, hydroxylation; ar, ADP 
ribosylation; og, O-GlcNAcylation. The image was taken from (Andrews et al., 2016). 
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to the hypothesis that the post-translational modification of histone proteins might 
mediate inter-nucleosomal interactions and thereby influence chromatin organization 
(Bannister and Kouzarides, 2011). A plethora of follow up investigations have 
demonstrated that PTM of histone proteins can indeed directly regulate histone-histone 
and histone-DNA contacts, particularly when occurring in the histone fold or the 
globular domains (Cosgrove and Wolberger, 2005; Cosgrove et al., 2004; Rothbart 
and Strahl, 2014). For instance, elegant in vitro experiments employing semi-synthetic 
or genetically modified nucleosomes showed that the acetylation of the octamer core 
on  histone H3 at lysines 56,122 and 155, weakens histone-DNA interactions leading 
to increased nucleosome mobility and DNA unwrapping (Manohar et al., 2009; 
Neumann et al., 2009; Shimko et al., 2011; Simon et al., 2011). Notably, acetylation is 
not limited to the histone core, but can also be found on numerous lysines residues 
within the histone tail, such as H3K9, H3K14, H3K18, H4K5, H4K8, and H4K12. This 
hyperacetylation reduces the positive charge of histone proteins, disrupting the 
electrostatic interactions between histone and DNA (Bannister and Kouzarides, 2011; 
Kouzarides, 2007). Apart from the additive charge neutralization effect, histone 
acetylation, in particular at H4K16, can also have a direct effect on higher-order 
chromatin structure. This mark perturbs the interaction between the unmodified tail of 
H4 and the acidic patch on H2A, inhibiting the formation of the 30-nm fiber (Horikoshi 
et al., 2013; Shogren-Knaak et al., 2006). In addition to the direct physical effect of 
some PTMs on chromatin structure, a large body of work demonstrated that the high 
regulatory power of PTMs resides in their ability to recruit protein effectors (also 
referred to as histone binding domains or readers of PTMs) (Musselman et al., 2012). 
These specialized proteins are able to dock onto specific histone PTMs and direct 
defined downstream events on chromatin. This regulatory mechanism is particularly 
potent in the case of lysine methylation. Unlike other modifications, such as acetylation, 
methylation does not lead to a change in the overall charge of the lysine. Instead, it 
alters the hydrophobic character and the size of the modified residue. This change in 
properties is detected by PTM readers and translated into downstream biological 
effects. Among the large number of histone PTMs, lysine methylation is one of the 
most versatile types of chemical modifications. This is because the flexible terminal ε-
amino group can accompany 4 different chemical states. As such, the residue can be 
found either in an unmodified form (me0) or accommodating up to three methyl groups 
(me1, me2, and me3). Depending on the methylation index and the position of the 
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modified lysine within the histone tail, the epigenetic mark can have different effects 
on gene regulation (Martin and Zhang, 2005). The canonical sites for lysine methylation 
comprise six residues on histone H3 (K4, K9, K26, K27, K36, and K79), K20 of histone 
H4 and K26 of histone H1. Apart from K79, these are all located in the N-terminal tail 
of histone proteins (Musselman et al., 2012).Interestingly, modifications of different 
lysines can have opposing regulatory roles. For instance, H3K4me3 and H3K36me3 
marks are strongly associated with active genes, when found at promoter or within 
gene bodies, respectively (Figure 7a). By contrast, di and trimethylation at position K9 
or K27 are marks that abundantly decorate silenced genes (Figure 7b) (Zhou et al., 
2011). Due to its high relevance for the present work, the pathways responsible for 
setting, reading and maintaining of the H3K9me3 modification will be covered in depth, 
in the next section.  
1.3.2 The H3K9me3 pathway and its involvement in constitutive 
heterochromatin formation  
The H3K9me3 mark has important regulatory roles in the repression of both genic and 
intergenic regions of metazoan genomes (Kim and Kim, 2012). This modification can 
Figure 7| Overview of the main types of histone modifications and their distribution over a gene 
locus. A representative distribution is shown for both a transcriptionally active (a) and a silenced (b) 
gene. The image was taken from (Kooistra and Helin, 2012). Importantly, the quality of the plotted 
profiles heavily depend on the specificity the used antibodies used in the assay (Kungulovski et al., 
2015a).  
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be introduced by several enzymes, including SETDB1 (or ESET), SUV39H1, 
SUV39H2, EHMT1 (GLP), and EHM2 (G9A) (Kim and Kim, 2012). Among these, 
SETDB1 is highly expressed in embryonic stem (ES) cells and involved in maintaining 
the pluripotency and self-renewal properties of ES cells. While EHMT1/EHM2 are 
active at genic regions found in open chromatin, broadly referred to as euchromatin,  
the SUV39H1 enzyme together with its homologue SUV39H2 are involved in the 
establishment and maintenance of H3K9me3 at constitutive heterochromatin (Kim and 
Kim, 2012; Peters et al., 2001; Tachibana et al., 2002; Yuan et al., 2009). This type of 
highly compacted chromatin is mainly formed at the gene-poor regions around the 
centers or at the ends of mammalian chromosomes, rich in tandemly repeated DNA 
sequences. The presence of this repressive histone mark at this sites is essential for 
preventing harmful genomic rearrangements provoked by spontaneous recombination 
events of the repetitive DNA (Saksouk et al., 2015). 
Su(var) genes were initially discovered by genetic screens on centromeric position 
effects in Drosophila melanogaster (Reute and Spierer, 1992) and Saccharomyces 
pombe (Allshire et al., 1995). The products of Su(var) genes suppress position effects 
variegation (PEV), and were reported to be involved in the formation of silent chromatin 
domains (Wallrath, 1998). SUV39H1 was the first identified histone-specific lysine 
methyltransferase (KMT) (Rea et al., 2000). The enzyme belongs to the family of 
conserved S-adenosyl-L-methionine (AdoMet) dependent KMTs. It possesses a 
conserved, catalytically active SET domain, surrounded by a pre-and post-SET domain 
important for regulation the catalytic activity (Dillon et al., 2005). The crystal structure 
of the S. pombe CLR4 homologue (Min et al., 2002) as well as other members of the 
family (Dillon et al., 2005), revealed that the SET domain forms a β fold that contains 
a series of curved β-strands that form a knot-like structure, packed together with the 
pre-and post-SET domains. Characteristic for SET-domain proteins is the fact that the 
binding site for the histone substrate and the cofactor AdoMet are located on opposite 
faces of the SET domain. The target lysine is inserted into a deep and narrow 
hydrophobic channel that runs through the core of the domain, such that the target 
nitrogen is positioned in close proximity to the methyl donor (Figure 8) (Dillon et al., 
2005). Biochemical work using the Neurospora crassa DIM-5 homolog, demonstrated 
that this unusual arrangement is important for the processive methylation of the target 
lysine by the SET superfamily members (Zhang et al., 2003).  
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In addition to the catalytically active SET domain at the C terminus, SUV39H enzymes 
also contain a chromodomain in their N-terminal part. The crystal structure of the 
chromodomain of SUV39H1 showed that it is able to recognize and bind to 
K9me2/me3-modifications on histone H3 (Wang et al., 2012). Fluorescence 
polarization assays revealed an intermediate affinity binding with a Kd of 20±4 µM for 
H3K9me3, and a Kd of 29±12 µM for H3K9me2. No binding to histone H3K9me0/1 
was observed (Wang et al., 2012). Like in other methyllysine readers, the modified 
lysine is recognized by the hydrophobic compact core within the chromodomain, that 
builds an aromatic cage consisting out of residues V45, L48, Y60, V62, W64, Y67, L80, 
I85, and L86. All of these amino acids are also conserved in the chromodomain family 
(Wang et al., 2012). With the chromodomain crystallization, it became apparent that 
within the SUV39H1 enzyme two important functions are merged: the setting and the 
read-out of repressive H3K9me2/3 marks. The importance of this connection was 
underlined by mutation studies reporting that either deletion of the chromodomain or 
point mutation of the conserved amino acids, W64A or Y67A, impaired the activity of 
the enzyme even if its catalytic SET domain was intact (Chin et al., 2006). In the 
following section, the biological relevance of this connection will be addressed, with a 
particular focus on pericentromeric heterochromatin, as one of the major target sites 
of SUV39H enzymes.  
Figure 8| Structure of the DIM-5 SET domain, in complex with the H3K9me3 peptide and cofactor 
byproduct S-adenosyl-L-homocysteine (AdoHcy). The peptide and AdoHcy are depicted in pink.  
Hydrogen bonds are shown as dashed lines. The image was taken from  (Dillon et al., 2005). 
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1.3.3 The involvement of the H3K9me3 pathway in the formation and 
maintenance of heterochromatin at pericentromeres  
Constitute heterochromatin is formed at gene-poor genomic regions, which are 
believed to be conserved between cell types. This is conceptually and mechanistically 
contrasting to the second branch of repressed chromatin, facultative heterochromatin, 
which involves silencing of genes that have to be repressed upon environmental cues 
(Saksouk et al., 2015). The bulk of constitutive chromatin forms at pericentromeric 
regions. These areas of the genome are abundant in repetitive DNA sequences. The 
sequence of these repeats greatly varies between different chromosomes as well as 
between organisms, indicating that the organization, rather than a specific DNA motif, 
is important for the pericentromeric function  (Figure 9) (Saksouk et al., 2015). For 
instance, mice centromeres consist mainly of minor satellites, while pericentromeres 
are built out of major satellite repeats. By contrast, in humans, centromeres consist 
predominantly of α satellites, while pericentromeres have chromosome-specific 
satellite sequences, which include satellite I, II and III motifs (Saksouk et al., 2015).  
Regardless of their DNA sequence, the unifying theme is that due to their repetitive 
content, these genomic sites need be repressed. Indeed, in several abnormal 
situations, like cancer, defects in the heterochromatic signaling pathway can result in 
deleterious chromosomal rearrangements, involving pericentromeric regions (Ehrlich, 
2003). The importance of these genomic elements is further underlined by proteomic 
studies, discovering around 50 different chromatin regulators that are enriched at 
pericentromeric heterochromatin and responsible for maintaining its compact structure 
(Saksouk et al., 2015; Soldi and Bonaldi, 2013).  
The role of SUV39H enzymes in the regulation of pericentromeric heterochromatin was 
highlighted by genetic studies. These revealed a selective depletion of H3K9me3 at 
Figure 9| Organization of constitutive heterochromatin in M. Musculus and H. Sapiens. Schematic 
representation of repeat composition of centromeric and pericentromeric chromatin domains. The 
approximate length of the different repetitive elements is indicated. The image was adapted after 
(Saksouk et al., 2015) 
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pericentromeric regions but not at other genomic sites marked by this modification, 
which hinted towards a specific targeting mechanism. The loss of the silencing mark 
was accompanied by a local increase in transcription (James and Elgin, 1986; Saksouk 
et al., 2015). While Suv39-/- embryos survive the initial developmental stages, 
indicating that the enzyme does not play a role in early development, they do show 
some lethality in the later embryonic stages as well as decreased viability. This is 
molecularly underpinned by abnormal segregation effects of chromosomes followed 
by disruption of spermatogenesis and increased cancer risk (Peters et al., 2001). 
While the steps that are involved in the initial recruitment of SUV39H to chromatin, 
remain to be elucidated, the cascade of events responsible for the sustained 
maintenance of H3K9me3 at pericentromeric sites is clearer. This relies on the 
interplay between SUV39H and heterochromatin protein 1 (HP1), a small but very 
versatile chromosomal protein. HP1 contains a chromodomain that is able to bind to 
H3K9me3 with higher affinity than the corresponding chromodomain of SUV39H 
(Figure 10a) (Bannister et al., 2001; Jacobs et al., 2002). The binding pocket for the 
N-methyl group becomes ordered upon peptide binding and consists of three 
conserved aromatic amino acids, Y24, W45, and Y48, forming a so-called aromatic 
cage into which the ammonium group is inserted (Figure 10b). The crystal structure of 
the chromodomain in complex with the methylated histone peptide revealed that the 
H3 tail binds through an induced-fit mechanism and adopts an extended β-strand-like 
conformation. The peptide lies antiparallel with two β regions of the chromodomain, 
Figure 10| HP1, a specific reader of H3K9me3. a) Schematic representation of the HP1 domain 
composition. The chromodomain, responsible for H3K9me3 binding, and the chromoshadow domain, 
important for homodimerization, are depicted in green and blue, respectively. b) Stereogram showing 
the K9me2 (yellow) and K9me3 (red) – modified H3 peptides, in complex with the HP1 chromodomain 
(blue and green, respectively). Dashed lines indicate the van der Waals contacts between the domain 
and the peptide. The image was taken from (Jacobs et al., 2002). 
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completing a three-stranded β sheet and the overall β-sandwitch fold (Jacobs et al., 
2002; Nielsen et al., 2002). 
 
The initial localization of HP1 at pericentromeric heterochromatin might dependent on 
its interaction with RNA. Indeed, sense-oriented repeat transcripts were shown to bind 
to the HP1 hinge domain (Maison et al., 2002, 2011; Mozzetta et al., 2015; Muchardt 
et al., 2002). Through direct protein-protein interaction between the HP1 
chromoshadow domain and the SUV39H N-terminus, the enzyme is recruited to 
chromatin (Schotta et al., 2002; Yamamoto and Sonoda, 2003). This is followed by the 
introduction of novel H3K9me3 marks which further stabilize the binding of SUV39H 
through its own chromodomain. This results in an increased recruitment of HP1, the 
association of which can be stabilized through the formation of homodimers via its 
chromoshadow domain (Yamamoto and Sonoda, 2003). This positive feedback loop 
results in self-propagating cycles of H3K9me3, causing the spreading of the 
heterochromatin domain (Figure 11) (Wang et al., 2014).  The importance of the 
feedback loop between HP1 and SUV39H becomes apparent from mutational and loss 
of function studies. Accordingly, in Suv39h1h2-/- double knockout (SUV39DKO) cells, 
the enrichment of HP1 at pericentromeric heterochromatin was dramatically reduced 
(Peters et al., 2001), while reintroduction of a HP1 interacting-deficient SUV39H in 
these cells, resulted in diminished accumulation of the enzyme at pericentromeres, 
and low recovery of H3K9me3 (Muramatsu et al., 2016).  This effect was dependent 
on the expression levels of the enzyme, suggesting that HP1 is not the only factor 
responsible for SUV39H recruitment at these sites. 
Figure 11| SUV39H-mediated spreading of the H3K9me3 mark. The stable HP1-SUV39H1 complex, 
subsequentially reads and sets the silencing trimethyl mark on H3K9, in a positive feedback loop that 
leads to the formation of broad heterochromatic domains and spreading of the silencing signal. This 
process is supported by the ability of HP1 to form homodimers, through its chromoshadow domain.  The 
image was adapted after (Mozetta et al., 2015). 
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DNA methylation is another essential epigenetic signal that regulates chromatin-
templated processes, in addition to the posttranslational modification of histone tails. 
In the following chapter, the biological role of this mark, as well as the setting, control, 
and readout of the signal will be covered in more detail. 
1.4 DNA methylation  
DNA methylation was first discovered in 1948, by Hotchkiss who used paper 
chromatography to investigate the purine and pyrimidine base composition of calf 
thymus DNA (Hotchkiss, 1948). Since then, the existence and role of this initially 
mysterious mark have become objects of intense investigation. This modification 
occurs predominantly on the fifth carbon of cytosine bases, 5mC, and can be found in 
eukaryotes ranging from fungi to vertebrates. While, the significance and function of 
DNA methylation vary greatly between organism, a large body of work has uncovered 
that for mammals, DNA methylation is a vital modification, which plays essential roles 
in embryonic development and adult tissue homeostasis (Messerschmidt et al., 2014).  
In mammals, DNA methylation occurs predominantly at palindromic CG sites, on both 
DNA strands. Out of the 56 million CG sites, 60-80% are methylated, which 
corresponds to 4-6% of all cytosines (Laurent et al., 2010; Lister et al., 2009). 
Noteworthy, modified CG sites are mutagenic hotspots, since their hydrolytic 
deamination can give rise to TG mismatches (Jurkowska et al., 2011). By contrast, 
spontaneous deamination of unmethylated cytosine bases occurs 2-4 times more 
slowly in vitro, and since this gives rise to uracil, an unnatural DNA base, it can be 
more readily recognized and corrected by dedicated repair systems, in cells (Krokan 
et al., 2000; Shen et al., 1994). The mutagenic potential of C5 methylated cytosine led 
to a selective depletion of CG sites from mammalian genomes during molecular 
evolution. For instance, in the human genome CG dinucleotides are underrepresented 
by a factor of 5 in comparison to other dinucleotide combinations (Jurkowska et al., 
2011). While being globally underrepresented in inter- and intra-genic regions, CG 
dinucleotides are abundant at repetitive DNA elements gene regulatory elements. For 
instance, in gene promoters, they cluster in CG islands (CGI), 500-2000 bp long 
regions that have a GC content above 50% and a ratio of observed-to-expected 
number of CpG dinucleotides above 0.6 (Gardiner-Garden and Frommer, 1987; Takai 
and Jones, 2004). 5mC displays a bimodal distribution. As such, while 60%-90% of 
‘single’ CG sites are methylated (depending on the cell type), CGI remain 
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predominantly hypomethylated (Deaton and Bird, 2011; Messerschmidt et al., 2014). 
CG islands are found in the promoter regions of about 70% of all human genes 
including most housekeeping and tissue-specific genes (Saxonov et al., 2006).  The 
survival of these CG-rich clusters in the mammalian genome might be explained by 
the fact that in the germline, CGIs have no or little methylation, thereby posing little 
mutagenic drift risk at this stage (Shen et al., 2007; Weber et al., 2007).  
The methylation status of CG sites changes dynamically during cellular differentiation.  
While CG-dense promoters are unmethylated in the germline, some progressively gain 
methylation during development. This enforces a stable gene repressive state as the 
cells become increasingly committed (Borgel et al., 2010; Meissner et al., 2008). 
Repetitive elements such as pericentromeric repeats are also abundantly decorated 
with 5mC. At these sites, the mark works in concert with the H3K9me3 pathway to 
repress their latent transcriptional activity, and ensure proper chromosome alignment 
and segregation (Messerschmidt et al., 2014). Apart from its regulatory role at CGIs 
and repetitive elements, DNA methylation plays important roles in processes such as 
X-chromosome inactivation in females, parent-of-origin specific gene expression 
through imprinting, alternative splicing and enhancer activity (Anastasiadou et al., 
2011; Aran et al., 2013; Bartolomei, 2009; Ferguson-Smith, 2011; Hellman and Chess, 
2007; Jones, 2012).  
1.4.1 The mammalian DNA methylation machinery  
DNA methylation is introduced by the family of DNA methyltransferases (DNA MTases 
or DNMTs) which comprises 4 active enzymes DNTM1, DNMT3A, DNMT3B, DNMT3C 
and the related but inactive regulatory factor DNMT3L (Figure 12) (Jurkowska et al., 
2011). The recently identified DNMT3C evolved via a duplication of Dnmt3b in rodent 
genomes and is found in male germ cells (Barau et al., 2016). From the structural 
composition, mammalian MTAses can be broadly subdivided into two parts: a large 
multidomain N-terminal part with regulatory functions, and a C-terminal catalytic part. 
The latter is conserved between prokaryotic and eukaryotic cytosine C5 DNA MTases 
and accommodates the active center of the enzyme with 10 conserved amino acid 
motifs that are diagnostic for all C5 DNMTs (Cheng, 1995; Jurkowska et al., 2011). 
The transfer of the methyl group from the cofactor AdoMet to the C5 position of the 
cytosine occurs within the AdoMet-dependent MTase fold. This consists of a mixed 
seven-stranded sheet, formed by 6 parallel β strands and the seventh strand inserted 
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anti-parallelly between strands 5 and 6. Motifs I and X are involved in cofactor binding, 
motifs IV, VI and VIII are responsible for catalysis, while the non-conserved region 
between motifs VIII and IX, plays a role in DNA recognition and specificity (Cheng, 
1995; Jeltsch, 2002, 2006; Jurkowska et al., 2011). DNMT3L has a crippled catalytic 
domain, lacking motifs IX and X, which renders the protein enzymatically inactive 
(Bourc’his et al., 2001). One of the most interesting structural and mechanistic feature 
of DNMTs is their mechanism of modifying the cytosine base, which became apparent 
with the first crystal structures of C5 bacterial methyltransferases HhaI and M. HaeIII, 
in complex with DNA (Cheng, 1995; Cheng et al., 1993; Jeltsch, 2002; Reinisch et al., 
1995; Roberts, 1995).  This is conserved in mammalian MTase, and involves base 
flipping of the target cytosine out of the DNA helix and its burying in a hydrophobic 
pocket in the active center (Jeltsch, 2002, 2006). The transfer of the methyl group 
involves a nucleophilic attack of the catalytic cysteine located in the PCQ motif, leading 
to the formation of a covalent bond between the enzyme and the cytosine target base 
(Figure 13). This is followed by the addition of the methyl group to C5, deprotonation 
and finally, cleavage of the covalent bond between the enzyme and the DNA (Jeltsch, 
2006; Jurkowska et al., 2011).  Although the addition of a single methyl group does not 
change the Watson-Crick paring of the modified base, the presence of the hydrophobic 
group within the major groove of the DNA, was reported to lead to a subtle bending 
and twisting effect in crystal structures of methylated DNA oligonucleotides (Tippin and 
Sundaralingam, 1997). Cytosine methylation was also shown to influence the 
sequence dependence of nucleosome occupancy and an interplay between 
nucleosome positioning and the activity of DNMTs has been observed (Chodavarapu 
et al., 2010; Collings et al., 2013; Kelly et al., 2012; Portella et al., 2013). While the  
Figure 12| Domain structure of mammalian DNMT proteins.  The proteins are broadly split into two 
parts: the N-terminal part, with regulatory roles, and the C-terminal, containing the motifs important for 
catalysis. Each characterized domain is correspondingly colored and annotated. The roman numbers 
were used to annotate the catalytic motifs. The image was taken from (Jeltsch and Jurkowska, 2016). 
 19 
 
5mC signal is chemically not as versatile as the PTMs of histone proteins, its 
involvement in gene regulation is multifactorial (Figure 14). This is dependent on the 
number, status and genomic position of the modified CG sites (Reddington et al., 
2013).  The clearest downstream effect of 5mC remains its influence on the recruitment 
of methylation-sensitive proteins and on the binding of transcription factors (Machado 
et al., 2015; Patel, 2016). 
1.4.2 The classical model of DNA methylation inheritance 
The four active DNA methyltransferases have important, non-overlapping functions. 
As such, the initial methylation patterns are set by DNMT3A and DNMT3B, which are 
called de novo DNMTs and use unmethylated DNA as substrate (Figure 15) (Chédin, 
2011; Okano et al., 1999). Dnmt3a is maternally provided and is predominantly 
expressed in oocytes and early preimplantation embryos. The enzyme has important 
roles in establishing the differential methylation patterns at imprinting control regions 
(ICRs) in male and female gametes (Kaneda et al., 2004; Kato et al., 2007; 
Messerschmidt et al., 2014). Dnmt3b is transcribed upon zygotic gene activation and 
is mostly expressed at the blastocyst stage predominantly in the epiblast lineage 
(Watanabe et al., 2002). The fact that the two de novo enzymes have partial non-
Figure 13| Chemistry of the DNA methylation reaction. The image was taken from  (Jurkowska and 
Jeltsch, 2016) 
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overlapping functions became apparent from knock-out studies. While deletion of 
Dnmt3b is embryonically lethal, Dnmt3a knockouts are partially viable (Okano et al., 
1999). The activity of both DNMT3A, in particular at ICR, in gametes, is supported 
through the interaction partner DNMT3L (Bourc’his et al., 2001). The importance of this 
Figure 14| Effects of DNA methylation on gene regulation. a) Schematic representation of the 
different types of CG methylation patterns found in the mammalian genome. b) Gene body methylation 
has been linked to an effect on RNA processing (by excluding the methylation sensitive CTCF protein) 
and intragenic transcription initiation. c) Involvement of DNA methylation at orphan CGI, CGI that are 
not associated with the 5’end of annotated genes. Here, the 5mC signal was proposed to block abnormal 
transcription initiation and differentially recruit chromatin regulators. d) DNA methylation of distal 
regulatory elements is proposed to modulate transcription factor binding. The image was taken from  
(Reddington et al., 2013). 
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crosstalk is demonstrated by the fact that Dnmt3l knockout mice lack de novo 
methylation in the germline, which causes sterility in males and embryonic lethality of 
maternal null-derived embryos (Bourc’his et al., 2001; Messerschmidt et al., 2014).  
Later in development, the perpetuation of the initial methylation pattern is taken over 
by the maintenance methyltransferase DNMT1 (Figure 15).  This is important since 
after each round of DNA replication, hemimethylated DNA is created, where only the 
parental strand carries the 5mC mark. DNMT1 uses hemimethylated DNA as substrate 
and is responsible for restoring the methylation pattern on the newly synthesized 
daughter strand. It has a higher affinity for the hemimethylated template which is 
essential for restricting the methylation activity to maintenance functions and limiting 
its de novo methylation potential (Goyal et al., 2006; Hermann et al., 2004; Song et al., 
2012). The expression of DNMT1 is under tight temporal control. As such, its 
expression is activated by cell-cycle-dependent transcription factors in S phase, which 
leads to a high expression in mitotic cells (Kishikawa et al., 2003).  The enzyme is 
recruited to replication foci through interaction with its PCNA-interacting binding 
partner, UHRF1. UHRF1 specifically attracts DNMT1 to the parental strands and 
orients the enzyme towards the newly synthesized daughter strand (Avvakumov et al., 
2008; Bostick et al., 2007; Sharif and Koseki, 2011; Sharif et al., 2007). In addition to 
its recruitment role, the protein was also reported to stimulate the activity of DNMT1 by 
a factor of 5 in vitro and increase the specificity of DNMT1 for hemimethylated CG sites 
(Bashtrykov et al., 2014). Deletion of mouse Dnmt1 is lethal at gastrulation, this 
Figure 15| The classical site-specific DNA methylation inheritance model. In the initial stage, the 
de novo methylation machinery sets the 5mC mark on the unmethylated DNA. This pattern is accurately 
maintained during each DNA replication cycle by Dnmt1. Active demethylation can occur though the 
action of TET enzymes, which reprogram the DNA methylation patterns. The image was adapted after 
(Jeltsch and Jurkowska, 2014) 
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resulting out of a dramatic global loss of DNA methylation (Brown and Robertson, 
2007; Kurihara et al., 2008). Interestingly, loss of UHRF1 cases similar defects (Sharif 
and Koseki, 2011; Sharif et al., 2007).  By suppressing the maintenance MTase 
activity, passive DNA methylation takes place, which results in around 50% loss of 
5mC with each new DNA replication round. In addition to this, active demethylation 
through the enzymatic activity of TET enzymes was also documented (Figure 15) (Ito 
et al., 2011a; Véron and Peters, 2011). Active demethylation was proposed to have 
regulatory roles on DNA methylation, for instance by preventing erroneous methylation 
of CG islands (Williams et al., 2012).  
1.4.3 A revised model of DNA methylation inheritance  
A significant body of work has recently demonstrated that despite its elegance, the 
classical inheritance model of DNA methylation, where DNMT3A and 3B set the initial 
5mC pattern that is subsequently copied by DNMT1, is an oversimplification (Jeltsch 
and Jurkowska, 2014). Instead, DNA methylation is most appropriately described by a 
dynamic process of ongoing methylation and demethylation events in which the 
functions of DNMT1 and DNMT3 enzymes partially overlap (Jeltsch and Jurkowska, 
2014; Jones and Liang, 2009; Riggs and Xiong, 2004). The proposal of this revised 
model was catalyzed by several experimental observations that were not in agreement 
with the classical site-specific DNA maintenance concept.  
First, while the classical inheritance model would predict that all cells of one tissue 
display identical DNA methylation patterns, bisulfite conversion followed by 
sequencing to elucidate the methylation status of individual CG sites, did not confirm 
this hypothesis. The analysis revealed that the average methylation density profile of 
a particular DNA region is preserved, instead (Jones and Liang, 2009; Zhang et al., 
2009). This outcome is in agreement with biochemical studies showing that while 
DNMT1 has a 10-40-fold preference for hemimethylated sites, this does not suffice for 
an accurate copying of the methylation status of the around 56 million CG sites in the 
human genome (Bashtrykov et al., 2012a, 2012b; Jeltsch and Jurkowska, 2014; Song 
et al., 2012).  
A second argument for the revised model is based on genetic studies in mice and 
mammalian cell lines, showing that deletion of DNMT3A and DNMT3B leads to loss of 
methylation at repetitive elements, even in the presence of a fully functional DNMT1 
(Chen et al., 2003; Dodget et al., 2005; Egger et al., 2006).These results indicate that 
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DNMT3A and 3B are involved in the maintenance of DNA methylation levels as well. 
Recently, cytosine-C5 methylation at asymmetric sequences, particularly in CA 
context, was discovered in human stem cells, germ cells and differentiated neuronal 
progenitors (Guo et al., 2014c, 2014d, Lister et al., 2009, 2013; Pinney, 2014).  This 
modification can be introduced by DNMT3A, enzyme with high expression in the 
tissues that contain the most abundant levels of non-CG methylation (Arand et al., 
2012; Shirane et al., 2013). Since template strand information cannot be used for non-
palindromic methylated sequences, the stable presence of CA methylation in the 
human genome is a strong indicator for the permanent need for the de novo activity of 
DNMT3A in certain cell types (Jeltsch and Jurkowska, 2014).  
Finally, the discovery of TET enzymes, raised awareness about the continuous 
requirement for active de novo MTase to counteract active DNA demethylation (Arand 
et al., 2012; Métivier et al., 2008; Williams et al., 2012).  
Together, these four key arguments support the revision of the classical model for DNA 
methylation inheritance and highlight the importance of regulatory factors in the 
targeting and control of the DNA methylation machinery (Jeltsch and Jurkowska, 
2014). Moreover, with this refined concept, corrections of errors that occur during the 
setting and maintenance of DNA methylation patterns can be explained.    
1.4.4 Waves of DNA methylation during development 
The dynamic changes in DNA methylation profiles are essential for re-establishing the 
cellular identity in the early embryo. While mammalian sperm cells show high levels of 
DNA methylation, the oocytes display a progressive increase in 5mC levels with 
cellular maturation (Guo et al., 2014b; Smith et al., 2014). Mature mouse sperm 
contains 80-90% overall CG methylation, while the maternal genome displays lower 
global methylation levels of ~ 40% (Messerschmidt et al., 2014). There are two 
dramatic waves of global DNA methylation reprogramming during development 
(Figure 16). The first takes place shortly after fertilization, where the methylomes of 
both sperm and oocyte are erased in order to provide a blank environment for setting 
the methylation profiles required for the pluripotency of the blastocyst inner cell mass 
(ICM) (Ciernia and LaSalle, 2016). During this process, the heavily methylated paternal 
genome undergoes predominantly active demethylation by TET3, while the maternal 
genome loses its 5mC levels mostly through passive, replication-dependent dilution 
(Guo et al., 2014a; Oswald et al., 2000; Shen et al., 2014). Interestingly, despite this 
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radical reprogramming, the imprinted genes, and some repeats remain methylated 
during this stage (Jurkowska and Jeltsch, 2013; Moore and Haig, 1991).  Following 
implantation, the ICM starts to acquire tissue-specific differentiation properties, which 
are molecularly coupled with a sharp increase in 5mC levels across the genome 
(Messerschmidt et al., 2014).  
The second and most dramatic round of epigenetic reprogramming occurs during 
gametogenesis (Figure 16). Here, 5mC is globally removed, including at parental-
inherited imprints. This hard reset occurs predominantly through passive 
demethylation facilitated by the silencing of the de novo DNA methylation machinery, 
nuclear exclusion of the DNMT1 interactor, UHRF1, and shortening of the cell cycle to 
16h (Chuva De Sousa Lopes et al., 2008; Hajkova et al., 2002; Kagiwada et al., 2012; 
Sasaki and Matsui, 2008). Following embryonic day E12.5 sex-specific development 
of mouse precursor germ cells (PGCs) ensues which occurs with different kinetics 
between female and male precursor germ cells (PGCs) (Kagiwada et al., 2012). While 
by E16.5 male PGCs have achieved 50% global DNA methylation, female germ cells 
Figure 16| The dynamics of the DNA methylation landscape across human development. The 
changes occurring in the levels of DNA methylation present in CG (5mCG) as well as in non-CG (5mCH) 
context, are shown on separate axis. The two global waves of DNA methylation reprogramming 
occurring at implantation and during the development of PGCs are correspondingly annotated and color-
coded. In addition, the methylome profiles of the postnatal human bran, at defined developmental 
stages, are displayed. The image was taken from (Ciernia and LaSalle, 2016). 
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display low levels of 5mC. In females, remethylation of gametes is initiated at birth 
during the growth phase of the oocyte (Kota and Feil, 2010; Saitou and Yamaji, 2012).   
DNA methylation profiles are also highly dynamic across the lifespan of the organism 
with most differences occurring in the transition from fetal to early postnatal life (Figure 
16) (Ciernia and LaSalle, 2016). For instance, by comparing 25 fetal to 300 postnatal 
samples, a large change in 5mC levels were discovered in the methylome of the human 
frontal cortex, in-between fetal and postnatal stages (Jaffe et al., 2016). A global 
restructuring of the epigenetic landscape could be observed, with > 50% of CG sites 
of the over 6,000 differential methylation regions (DMRs) and 896 multiple-kilobase 
regions being affected (Jaffe et al., 2016). These strong changes in DNA methylation 
were largely attributed to the alteration in the cellular composition of the brain in-
between the two analyzed time-points, with fetal cortex containing more progenitor-like 
cells, while postnatal tissue consisting predominantly out of linage-specified cells 
(Ciernia and LaSalle, 2016; Jaffe et al., 2016).    
The combined control of the targeting and activity of the DNA methylation machinery 
is essential for a precise spatiotemporal regulation of the function of DNMT enzymes, 
and thereby for the accurate setting and maintenance of the cellular methylation 
profiles (Jeltsch and Jurkowska, 2016). Due to its high relevance for the present work, 
the targeting and regulation of DNMT3 enzymes will be covered in more detail in the 
following section. Particular emphasis will be placed on the spatiotemporal regulation 
of DNMT3 enzymes via interaction with chromatin and other proteins (Jeltsch and 
Jurkowska, 2016).   
1.4.5 Control of DNA methylation 
1.4.5.1 Chromatin-guided spatiotemporal control of DNMT3 enzymes  
The regulatory N-terminal part of the enzymatically active de novo DNA 
methyltransferase 3A and 3B takes part in the chromatin targeting of the proteins 
(Dhayalan et al., 2010; Ge et al., 2004; Noh et al., 2015; Zhang et al., 2010). Two 
distinct functional domains are present in the N-terminal part: the ADD (ATRX-DNMT3-
DNMT3L) and the PWWP (Pro-Trp-Trp-Pro) domain. As indicated by the name, the 
ADD domain is also found in the catalytically inactive factor DNMT3L. This protein does 
not contain a PWWP domain, however (Jurkowska et al., 2011). N-terminally to the 
PWWP domain, both DNMT3A and DNMT3B contain a non-conserved region that was 
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shown to bind DNA and contribute to the tight association of the enzymes to chromatin 
(Suetake et al., 2011). While the definite role of this region awaits further elucidation, 
based on the low sequence identity between the two proteins (only 10.9%), it is 
tempting to speculate that this area might be involved in differential genomic targeting 
of DNMT3A and DNMT3B activities (Jeltsch and Jurkowska, 2016; Rondelet et al., 
2016). 
The PWWP domain is a member of the ‘Royal’ superfamily of domains that recognize 
methylated lysines on the histone tail through a conserved aromatic cage (Qin and 
Min, 2014; Rondelet et al., 2016). In the case of DNMT3 enzymes, this domain was 
reported to specifically bind to H3K36me3, a mark associated with gene body 
methylation in ES cells and the elongation phase of transcription (Baubec et al., 2015; 
Dhayalan et al., 2010; Hahn et al., 2011; Lee and Shilatifard, 2007). Structurally, the 
domain consists of an antiparallel β-barrel-like fold formed by five β-strands (β1–β5). 
A short 310  helix is found between the strand β4 and β5 (η2) and a short insertion motif 
is present between strands β2 and β3 (η1). Within the conserved Pro-Trp-Trp-Pro 
motif, the first proline is replaced by a serine in both, DNMT3A and DNMT3B (Rondelet 
et al., 2016). Recently, the first position of the Pro-Trp-Trp-Pro motif has been shown 
to regulate the PWWP domain stability and oligomerization (Hung et al., 2015). The 
importance of the PWWP for the chromatin targeting of the DNMTs is demonstrated 
by the decreased methylation levels observed at human pericentromeric repeats, when 
the H3K36me3 binding is abolished through an S270P exchange in the DNMT3B 
aromatic pocket. Furthermore, generation of the corresponding PWWP pocket mutant 
within DNMT3A, revealed a partial loss in the heterochromatin localization of the 
enzyme, upon its overexpression in mouse fibroblasts (Chen et al., 2004; Dhayalan et 
al., 2010). Crystal structure of the DNMT3B PWWP domain, in complex with the 
H3K36me3 peptide (Rondelet et al., 2016), revealed that the trimethylammonium 
group is inserted into a Phe-Trp-Trp-Asp cage stabilized by intermolecular hydrogen-
bonding interactions between the backbone of the peptide and the domain. In addition 
to the H3K36me3 binding, the PWWP domain of both DNMT3A and DNMT3B was 
reported to show a relatively weak non-specific interaction with DNA, through a basic 
surface adjacent to the histone binding site (Purdy et al., 2010; Qiu et al., 2002).  
Structural superposition with the previously studied LEDGF PWWP domain indicated 
that the positively charged basic patch is positioned on the DNA wrapped around the 
histone core and might form contacts with the phosphate backbone of the DNA helix. 
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This might further enhance the selectivity of the PWWP for H3K36me3-modified 
nucleosomal particles (Rondelet et al., 2016).  The central role of K36 methylation in 
targeting of DNMT3 enzymes was recently confirmed in yeast and mouse male 
germline cells (Jeltsch and Jurkowska, 2016; Morselli et al., 2015). Here, a positive 
correlation between H3K36me3 and DNA methylation by DNMT3B was observed. 
Moreover, the analysis revealed a strong preference of DNMT3B for methylating non-
nucleosomal linker DNA. This is in line with biochemical data, demonstrating that wild-
type DNMT3A is more active on native chromatin by comparison to the PWWP-pocket 
mutant, and that linker DNA is the preferred substrate when using in vitro reconstituted 
chromatin (Dhayalan et al., 2010; Zhang et al., 2010).   
In addition to the PWWP domain, DNMT3 proteins also contain an ADD domain. This 
structure comprises three subdomains: a GATA-like zinc finger, a PHD finger with 
cross-braced topology and a long C-terminal α-helix that stems out of the PHD finger 
subdomain and forms extensive hydrophobic contacts with the GATA finger (Jeltsch 
and Jurkowska, 2016). The ADD domain is essential for the regulation of DNMT3 
proteins, as it was shown to specifically readout H3 tails unmethylated at K4 and serve 
as a protein-protein interaction platform (Guo et al., 2015c; Ooi et al., 2007; Otani et 
al., 2009; Zhang et al., 2010). Binding is disrupted by any large modification on K4 
such as di-and trimethylation or acetylation (Noh et al., 2015; Otani et al., 2009). 
Recognition of the unmodified histone H3 tail has drastic effects on the activity and 
chromatin targeting of the enzyme, with the mechanism responsible for this regulatory 
effect being recently elucidated in a seminal structural study by Guo et al. (Figure 17) 
(Guo et al., 2015c). The authors have uncovered that the ADD and the catalytic 
domains (CD) of DNMT3A adopt an autoinhibitory conformation, with the two domains 
folding into two individual structural modules connected by a linker that is packed 
against a hydrophobic surface of the CD domain (Figure 17a and b). A loop region 
formed by the aa 526-531 extends out of the ADD domain and is inserted in the CD 
domain into a pocket built mainly of hydrophobic residues. This conformation brings 
three acidic residues (D529/D530/D531) and three hydrophobic residues 
(Y526/Y528/Y533) from the side of the ADD domain in close proximity to the 
hydrophobic pocket (Figure 17).  This interaction blocks the DNA-binding affinity of 
DNMT3A, consequentially inhibiting catalysis. Interestingly, the addition of the 
H3K4me0 peptide could allosterically relieve this autoinhibitory effect, through binding 
to the ADD domain at the ADD-CD interface, disrupting the intramolecular interaction 
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and causing of a large conformational rearrangement within the enzyme (Figure 17c 
and e) (Guo et al., 2015c; Jeltsch and Jurkowska, 2016).  Noteworthy, a stimulatory 
effect on the enzymatic activity could only be observed for H3K4me0 and not for 
H3K4me3-modified peptides (Guo et al., 2015c). This biochemical observation is in 
line with several genome-wide studies, where an anti-correlation between H3K4me3 
and DNA methylation was observed (Hodges et al., 2009; Meissner et al., 2008; 
Messerschmidt et al., 2014; Weber et al., 2007). H3K4me3 is found in 75% of all 
human active gene promoters in several cell types and has a key role in mammalian 
gene expression (Bernstein et al., 2012). The mark abundantly decorates CGIs, which 
are present at many gene promoters and are usually free of DNA methylation (Edwards 
et al., 2010; Meissner et al., 2008; Mikkelsen et al., 2007). This indicates that H3K4me3 
and 5mC are antagonistic epigenetic signals and the crosstalk between these two 
pathways is in part mediated by the ADD domain of DNMT3 enzymes. This hypothesis 
was recently experimentally confirmed by exogenous introduction of DNMT3B into 
Saccharomyces cerevisiae. The budding yeast is a good model system for this type of 
analysis, since it lacks endogenous DNA methylation while possessing the conserved 
Figure 17| Allosteric control of DNMT3A activity by the H3K4me0 tail. a) Ribbon representation of 
the active, open conformation of the ADD (blue)-CD(pink)-CDNMT3L(green), in complex with the 
unmodified H3 peptide (yellow). The autoinhibitory form, obtained in the absence of the peptide, is 
shown for reference in b. c) Superimposition of the active and autoinhibitory form of the ADD-CD-
CDNMT3L complex, highlighting the large conformational change triggered by the H3K4me0 binding. d) 
Ribbon representation of the ADD-CD structure, documenting the residues which are important for 
mediating the contact between the two domains. e) Allosteric activation model of DNM3A by the 
unmodified histone H3, as proposed by Guo et al (2015c). The image was taken from (Guo et al., 2015c) 
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histone sequences and many of the PTMs found in higher eukaryotes (Hu et al., 2009). 
In this setup, the authors observed an anti-correlation between introduced 5mC and 
H3K4me3 levels (Morselli et al., 2015). Reciprocally, deletion of set1, the product of 
which is responsible for setting the H3K4me3 mark in yeast, led to a spreading of DNA 
methylation into promoter regions (Morselli et al., 2015). Consistent with this, 
expression of a DNMT3A variant, with an engineered ADD domain that was rendered 
insensitive to H3K4 methylation, resulted in ectopic DNA methylation of genes 
associated with early embryonic lineages and subsequent abnormalities in ESC 
differentiation (Noh et al., 2015). Interestingly, hypermethylation at H3K4me3/CGI loci 
was less efficient (< 30%) than at intergenic regions (> 60%), suggesting that there are 
additional factors that contribute to the protection of gene promoters from DNA 
methylation (Noh et al., 2015).  Together, these results highlight the importance of a 
regulated DNMT3 activity for proper cellular differentiation and development.   
Noteworthy, the cross-talk between the H3K4me3 pathway and DNA methylation is bi-
directional, with hypermethylated loci being more resistant to gene reactivation. This 
was recently demonstrated in an elegant synthetic biology approach, where the SET 
domain of human PRDM9, was fused to custom-made DNA binding domains, for locus-
specific trimethylation of H3K4 (Cano-Rodriguez et al., 2016). Here, the authors have 
observed that targeting PRDM9 to promoters that carry abundant DNA methylation, 
resulted in only transient re-expression of the gene locus. By contrast, genes that 
carried no or low DNA methylation were more readily activated (Cano-Rodriguez et al., 
2016).  
1.4.5.2 Regulation of DNMT3 enzymes by interacting proteins  
In addition to reading the H3K4 modification status, the ADD domain of DNMT3 
enzymes serves as an interaction knob with several proteins involved in chromatin 
regulation. Accordingly, the ADD domain of DNMT3A was reported to directly interact 
with members of the H3K9me3 silencing pathway such as SUV39H1 (Fuks et al., 
2003a) and SETDB1 (Li et al., 2006). In the case of SETDB1, this interaction appears 
to be essential for the methylation and consequent repression of a set of promoters in 
cancer cells. Interactions with the H3K9me3-reading proteins HP1α and β as well as 
with the histone deacetylase HDAC1 were also reported (Fuks et al., 2003a).  
Together, these data propose a model in which the chromatin targeting of the DNA 
methylation machinery occurs to a large extent through interaction with other important 
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epigenetic silencers that through their concerted action enforce a highly repressive 
local chromatin environment. This hypothesis is supported by experimental data 
stemming from several knockout studies. Analysis of embryonic stem cells isolated 
from Suv39h1/h2-/- mice revealed reduced levels of DNA methylation at major satellite 
repeats. This effect appeared to be genomic-context specific, as other classes of 
repetitive and parasitic elements such as minor satellites and C-type retroviruses 
showed unaffected DNA methylation levels (Arand et al., 2012; Du et al., 2015a; 
Lehnertz et al., 2003). Similarly, knockout of Setdb1 also resulted in selective depletion 
of DNA methylation at a number of germline-specific genes (Karimi et al., 2011).  
The PWWP domain was also reported to function as a protein interaction platform, in 
addition to its readout of H3K36me3-modified tails. Here, the ZHX1 (zinc-fingers and 
homeobox protein 1) was reported to interact with DNMT3B and enhance DNA 
methylation-dependent transcriptional repression (Kim et al., 2007). Noteworthy, 
protein interactors can also negatively influence the enzymatic activity of DNMT3s. A 
member of this category of regulators is the SAL-like 3 (SALL3) protein, which was 
shown to bind to the PWWP domain of DNMT3A. Through this interaction, the 
chromatin association as well as the enzymatic activity of DNMT3A were diminished 
(Shikauchi et al., 2009).  
1.4.5.3 The chromatin remodeler HELLS 
The most mysterious regulator of DNMT3 enzymes remains arguably the putative 
chromatin remodeler HELLS (helicase, lymphoid-specific)  (Briones and Muegge, 
2012).  The involvement of this protein in the control of DNA methylation in mammals 
became clear in early knock-out studies, where thin layer chromatography 
quantification revealed 50% loss in the global levels of 5mC in the DNA isolated from 
Hells-/- mice. Detailed investigation showed that affected sites were highly 
heterogeneous,  comprising mainly repetitive elements but also single-copy sequences 
like the imprinted region of the H19 gene, these effects being detectable in a broad 
array of tissue types (Briones and Muegge, 2012; Dennis et al., 2001). The effect of 
the protein on DNA methylation was even earlier discovered in Arabidopsis thaliana in 
a forward genetic screen for factors involved in the maintenance of DNA methylation. 
Here, the lack of the A. thaliana DDM1 (decrease in DNA methylation 1) protein, led to 
a 70% reduction in genomic DNA methylation levels, progressively correlated with an 
increase in mutations and stable epialleles at dispersed sited in the genome, which 
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eventually culminated in morphological abnormalities (Jeddeloh et al., 1999; Vongs et 
al., 1993). The gene encoding for the murine DDM1 homolog, HELLS, was first cloned 
by degenerative PCR to identify novel helicase superfamily members in T-cell 
precursors (Jarvis et al., 1996). Although its expression was initially characterized in 
lymphoid cells, follow-up investigations revealed that the protein is present in many 
tissues, with elevated expression in actively dividing cell types (Briones and Muegge, 
2012; Geiman and Muegge, 2000; Geiman et al., 1998; Jarvis et al., 1996).  The human 
gene was cloned from human leukemic cells and it is known as LSH (Lymphoid-specific 
helicase), HELLS (helicase, lymphoid-specific), PASG (proliferation associated gene) 
or SMARCA6 (SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 6) (Briones and Muegge, 2012; Lee et al., 2000). The 
important and non-redundant role of HELLS is highlighted by the embryonic lethal 
phenotype displayed by the Hells-/- mice (Geiman et al., 2001; Sun et al., 2004). These 
animals show severe developmental defects manifested by kidney necrosis, reduced 
embryonal growth, abnormal regulation of developmental important genes such as the 
Hox cluster, incomplete differentiation of ES cells in in vitro cultures and impaired 
hematopoiesis (Fan et al., 2008; Geiman et al., 2001; Sun et al., 2004; Yan et al., 
2003a).  
Based on the domain composition, DDM1, and its homolog HELLS were classified as 
a member of the SNF2 family of chromatin remodelers, proteins which contain a 
domain that is homologues to the helicase-like ATPase domain of the Saccharomyces 
cerevisiae Snf2 protein (Figure 18) (Laurent et al., 1992). This Snf2 domain comprises 
two tandem RecA-like folds and seven conserved helicase-related sequence motifs 
(Eisen et al., 1995; Flaus et al., 2006; Meehan et al., 2001). While Snf2 family members 
lack canonical helicase activity and are thereby not able to separate nucleic acid 
strands, they are able to induce ATP-dependent torsional strain to DNA, which 
Figure 18| Schematic representation of the SNF2-like ATPases that are homologous to mouse 
LSH. These are human PASG, Arabidopsis Thaliana DDM1, and Saccharomyces cerevisiae YFR038w. 
The percentage of amino acid identity for both the ATPase domain as well as for the full length proteins 
were correspondingly annotated. The image was adapted after (Meehan et al., 2001). 
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provides the necessary force to remodel nucleosomes (Ryan and Owen-Hughes, 
2011). Depending on the family member, this can have different effects on the local 
structure of chromatin. The action of Snf2 proteins can result in sliding or exchange of 
nucleosome, or disassembly of nucleosome histone content (Ryan and Owen-Hughes, 
2011). This large diversity of outputs might be controlled by accessory domains and/or 
interacting proteins outside the Snf2 domain. Indeed, many Snf2 proteins were found 
to reside in large multi-protein complexes (Clapier and Cairns, 2009). Through this, the 
activity of Snf2 proteins can be modulated or recruited to different chromatin 
compartments. 
By contrast to other members of the family, native HELLS was found to be 
predominantly present as a free monomer in nuclear extract of human cells, as 
analyzed by size exclusion chromatography (Myant and Stancheva, 2008). This 
indicates that HELLS might be incorporated in unstable or not very abundant 
complexes. Indeed, alternative methods such as co-immunoprecipitation have 
uncovered that HELLS can participate in a metastable repressive protein complex that 
contains DNMT1, DNMT3B, HDAC1 and/or HDAC2 (Myant and Stancheva, 2008; Zhu 
et al., 2006). In vitro pull-down experiments with recombinant proteins have further 
pinned down the region of HELLS through which the interactions take place, as well 
as the order of assembly of the complex. Accordingly, the N-terminal portion of HELLS 
(amino acids 1 to 226), containing a predicted coiled-coiled motif, was shown to be 
necessary and sufficient for co-immunoprecipitating the two DNMTs. While the 
interaction with DNMT3B was direct, the association with DNMT1 was mediated by the 
de novo methyltransferase. DNMT1 was responsible for the further recruitment of 
HDAC enzymes (Myant and Stancheva, 2008). In line with these data, Hells 
knockdown in mouse cells was associated with an increase in histone acetylation and 
H3K4me3 levels on repetitive elements, coupled with a depletion in DNA methylation 
and an elevated number of transcripts produced from satellite, Sine and Line1 repeats 
(Huang et al., 2004). This upregulation of repetitive elements might be in part 
responsible for the genomic instability observed for the Hells-/- cells and animals 
(Briones and Muegge, 2012).  
Despite its drastic and widespread effects on the DNA methylation levels, mechanistic 
insight into how HELLS controls the DNMT machinery is sparse. Through analogy to 
the better characterized A. thaliana homologue DDM1, the current view proposes a 
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chromatin scanning role for HELLS, where the protein continuously samples the 
nuclear environment to open target chromatin regions, which pose accessibility 
challenges to the activity of DNMT enzymes (Figure 19) (Briones and Muegge, 2012; 
Brzeski and Jerzmanowski, 2003; Myant and Stancheva, 2008; Zemach et al., 2013). 
Indeed, unlike DNMT1 that works on nucleosome-depleted newly replicated DNA, the 
DNMT3 enzymes must work on chromatinized template (Chédin, 2011).  High 
resolution mapping of de novo methylation events in reconstituted chromatin systems 
revealed that by comparison to linker DNA, nucleosomal DNA is largely devoid of CG 
methylation when subjected to in vitro methylation (Felle et al., 2011). This result is 
supported by cellular data, documenting an increase of de novo methylation with CG 
density, and an exclusion from nucleosomes (Baubec et al., 2015). Together, these 
studies indicate that stably positioned nucleosomes pose an inaccessible barrier for 
the de novo methylation machinery and that efficient methylation requires the activity 
of chromatin remodelers for dynamic nucleosome repositioning or disruption (Termanis 
et al., 2016). In cells, this effect might be particularly strong at highly compacted sites 
such as pericentromeric heterochromatin. This hypothesis was supported by work in 
Arabidopsis, where the remodeler DDM1 was found to promote the access of the DNA 
methylation machinery at highly compacted DNA sequences that are enriched in the 
linker histone H1 (Figure 19) (Zemach et al., 2013).  While the requirement of active 
chromatin remodeling for efficient DNA methylation is indisputable, the chromatin 
remodeling activity of mammalian HELLS remains a matter of intense debates. 
Mechanistic investigations have been challenging, because unlike DDM1, recombinant 
HELLS is not able to reposition nucleosomes in vitro and displays a poor but DNA-
stimulated ATPase activity (Brzeski and Jerzmanowski, 2003; Burrage et al., 2012). 
The functionality and importance of ATP hydrolysis for the function of HELLS has been 
Figure 19| The chromatin remodeler DDM1 facilitates the access of DNMTs to compacted 
chromatin substrates. The model proposes that through its action DDM1 is capable of counteracting 
the thigh association between the linker histone H1 (yellow) and the nucleosome, and though this 
generate accessible DNA templates that can be methylated by DNMT enzymes The image was taken 
from (Pikaard, 2013).  
 34 
 
hinted at by in vivo studies, where deletion of HELLS exons 10-12, which leads to the 
truncation of the catalytic Snf2 domain,  resulted in DNA methylation defects in mice, 
as well as premature aging and upregulated expression of senescence-associated 
markers (Sun et al., 2004). It remains nevertheless unclear, whether the ATPase 
activity of HELLS together with its associated chromatin remodeling function directly 
contribute to this wide range of effects.   
According to its classification HELLS contains the signature motifs of SNF2 enzymes, 
an ATP binding pocket encompassing Walker A and B motifs (Flaus et al., 2006). 
Within the conserved GKT box, the protein contains a lysine residue (K237), which was 
shown to be essential for ATP binding and hydrolysis, in several other canonical 
chromatin remodelers (Deuring et al., 2000; Rowbotham et al., 2011; Shen et al., 
2000).  Exchanging this residue for glutamine was reported to generate an HELLS 
variant, which was not longer able to promote efficient phosphorylation of the histone 
variant H2AX, and through this impair the efficient repair of DNA double-strand breaks 
in mammalian cells (Burrage et al., 2012). Despite this biological insight, the effect that 
the lack of ATPase activity has on the chromatin association properties of HELLS 
remained a matter of speculation. In this work, I took advantage of the HELLS K237Q 
variant to investigate whether ATP hydrolysis plays a role in the interaction between 
HELLS and highly compacted chromatin in cells.     
1.4.6 DNA methylation readout 
60-80% of all CG dinucleotides in the mammalian genome are C5-methylated. While 
this modification does not dramatically alter the structure of the DNA helix, it exerts its 
effect predominantly by serving as a docking site for 5mC-binding proteins that in turn 
act as recruiters for chromatin-modifying complexes (Fournier et al., 2012; Patel, 
2016).  There are several groups of proteins that can interpret and locally modulate 
DNA methylation patterns. These include the family of methyl-CG-binding domain 
(MBD) proteins that recognize fully methylated CG dinucleotides, the Kaiso family of 
zinc finger (ZF) proteins, which preferentially bind methylated CG sites within longer 
specific sequences,  and the SET-and-Ring finger-associated (SRA) domain family, 
whose members recognize hemimethylated DNA sites generated after replication (Du 
et al., 2015b; Filion et al., 2006; Hendrich and Bird, 1998; Liu et al., 2013b; 
Prokhortchouk et al., 2001; Unoki et al., 2004).  The MBD and the ZF binding domains, 
dock onto the major groove of the DNA and form specific hydrogen bonds to 
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discriminate between the DNA bases (Buck-Koehntop et al., 2012; Ho et al., 2008; Liu 
et al., 2012; Scarsdale et al., 2011; Zou et al., 2012). By contrast to this, mammalian 
SRA proteins, recognize the hemimethylated CG site through base flipping of the 
modified base out of the double helix and into a hydrophobic binding cage (Arita et al., 
2008; Avvakumov et al., 2008; Hashimoto et al., 2009; Liu et al., 2013b; Rajakumara 
et al., 2011). Owing to the high relevance for this work, in the following section, 
particular emphasis will be placed on the MBD family, the members of which are critical 
regulators of the transcriptional state of the epigenome (Du et al., 2015b).  
MBD proteins mainly act as transcriptional repressors, although depending on the 
chromatin context, activator roles were also reported (see below). To date, the family 
consists of eleven proteins, identified predominantly through sequence similarity, and 
known to contain a MBD domain. Apart from the conserved 70-85 amino acid-long 
MBD, which has the ability to bind single symmetrically methylated CG dinucleotides, 
each member of the family contains unique accessory domains. This reflects the 
heterogeneous and non-overlapping functions of the family members (Du et al., 
2015b). For instance, while some proteins contain a transcriptional repression domain 
(TRD), which serves as a protein-protein interaction platform, other members, such as 
MBD1, are equipped with domains that can recognize unmethylated DNA sequences 
(Tachibana et al., 2002). Two members of the MBD group will be covered in depth in 
the following sections: the founding member of the family, methyl-CG-binding protein 
2 (MeCP2), and the largest member of the family, methyl binding protein 1 (MBD1).  
1.4.6.1 The chromatin regulator MeCP2 
1.4.6.1.1 MeCP2: protein structure 
MeCP2 was discovered in 1992 by Bird and co-workers in a search for proteins 
capable of binding to methylated CG dinucleotides (Lewis et al., 1992). Follow-up in 
vitro investigations revealed that the DNA-binding affinity of the protein is enhanced 
when the sequence flanking the methylated CG site is A/T rich (Klose et al., 2005). 
The structural basis of this preference was found to lie within the three AT-hook motif 
sequences that are present in MeCP2 (Baker et al., 2013; Lewis et al., 1992; Lyst et 
al., 2016). These are short DNA-binding motifs that use an intrinsic RGRP consensus 
sequence to form contacts with the wide minor groove of AT-rich sequences (Hendrich 
and Bird, 1998; Ragione et al., 2016). Recent biochemical and cellular work has 
demonstrated that within MeCP2, AT-hook 1, exhibits the most robust DNA binding, 
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with AT-hook 2 being much weaker and AT-hook 3 having an interrupted and probably 
dysfunctional RGRP motif (Lyst et al., 2016).  
Noteworthy, while the AT-hooks stabilize the association of MeCP2 with chromatin, the 
MBD domain remains the primary interaction surface (Ragione et al., 2016). The 
preference of the MBD domain for methylated over unmethylated DNA is 2-3-fold for 
both the murine and the human protein (Fraga et al., 2003; Nikitina et al., 2007a). The 
X-ray structure of the DNA-bound domain revealed that the MBD-DNA interface is 
stabilized by the hydration of the methyl group on at the cytosine C5 position. In 
addition to this domain, MeCP2 contains a TRD that mediates interactions with co-
repressor complexes, a nuclear localization signal (NLS), and a C-terminal domain 
involved in binding of DNA and other proteins (Bienvenu and Chelly, 2006; Ebert et al., 
2013; Ragione et al., 2016).   
Human MeCP2 was purified to homogeneity and its structure was characterized in 
great depth by ultracentrifugation, circular dichroism and limited protease digestion 
(Adams et al., 2007; Ragione et al., 2016). This analysis highlighted the structural 
peculiarities of the protein, with around 60% of MeCP2 being intrinsically disordered 
and displaying random coil-like hydrodynamic properties (Figure 20) (Adams et al., 
2007; Hite et al., 2009). These results indicated that MeCP2 might heavily rely on 
protein interactors for adopting a folded structure and provided a basis for 
understanding the in vitro and in vivo multifunctionality of this important chromatin 
Figure 20| MeCP2 domain organization and folding properties. The domains that make up the 
MeCP2 protein as identified by partial proteolysis (diamonds) are correspondingly annotated. In the 
lower part of the figure, a FoldIndex plot is shown, documenting predicted disorderd (black) and ordered 
(gray) regions. The image was adapted after (Hite et al., 2009).  
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regulator (Adams et al., 2007; Ragione et al., 2016). The increasing number of reports 
that uncover novel and diverse MeCP2 interactors come to support this view. 
1.4.6.1.2 MeCP2 interacts with multiple partners and has ambivalent effects on 
transcription 
Probably the best-characterized member of the list of interactors is the Sin3A/HDACs 
co-repressor complex that interacts with MeCP2 through the TRD domain. This 
interaction is responsible for recruiting the complex to DNA, leading to the 
deacetylation of neighboring nucleosomes and finally suppression of gene repression. 
The early elucidation of this cascade of events largely contributed to the traditional 
classification of MeCP2 as a transcriptional repressor (Jones et al., 1998; Nan et al., 
1998). In addition to deacetylation, a link between MeCP2 and trimethylation of 
H3K9me3 was observed in some neuronal target genes. Here, a complex that includes 
CoREST (co-repressor for element-1-silncing transcription factor) locally recruits 
Sin3A/Suv39H1 for cumulative gene silencing by combined deacetylation and 
methylation of histone tails (Ballas et al., 2005; Fuks et al., 2003b). Sin3A-independent 
complexes were also discovered, where the corepressors SMRT (silencing mediator 
for retinoid and thyroid receptors) and N-CoR (nuclear receptor corepressor 1) were 
characterized as interaction partners (Kokura et al., 2001).  Interestingly, the missense 
mutation R306C occurring in the MeCP2 TRD, which is the second most frequent 
mutation occurring in the neurodevelopmental Rett syndrome, abolishes the interaction 
between MeCP2 and the NCoR-SMRT co-repressor complex in in vitro assays. This 
is associated with the development of a Rett phenotype in heterozygous transgenic 
mice (Baker et al., 2013; Ebert et al., 2013; Heckman et al., 2014; Lyst et al., 2013). 
This outcome underlines the importance of an intact interaction network centered 
around the chromatin regulator MeCP2.  
The traditional view of MeCP2 as a bona fide transcriptional repressor has been 
challenged by a series of recent reports (Ragione et al., 2016). The protein is most 
abundantly expressed in the adult brain where it reaches near histone-octamer levels 
and plays critical roles in chromatin organization together with linker histone H1. The 
protein levels steadily increase during the differentiation of neuronal cells in mice, rats 
and humans, where it seems to be more important for the maturation and maintenance 
of neurons, rather than for cell fate decisions (Cohen et al., 2003; Guy et al., 2011; 
Skene et al., 2010). Its high expression in the brain provides a molecular basis for the 
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broad range of neurodevelopmental diseases associated with MeCP2 mutations (Katz 
et al., 2016) (see below). Surprisingly, transcriptional profiles of the brain isolated from 
Mecp2-null mice have revealed only subtle changes of gene expression levels in 
comparison to wild-type animals (Tudor et al., 2002). Nevertheless, gene expression 
profiling of specific brain areas (i.e. hypothalamus and cerebellum), have uncovered 
dramatic changes in gene expression for thousands of genes. Strikingly, most of these 
appeared to be downregulated in the absence of MeCP2, indicating that the protein 
may also function as a transcriptional activator (Ben-Shachar et al., 2009; Chahrour et 
al., 2008; Sugino et al., 2014). This multivalent effect of MeCP2 could be attributed to 
the fact that the protein interacts with co-factors that, depending on the chromatin 
environment, can have either transcriptional repressive and activating roles (Ragione 
et al., 2016). Together, these findings highlight the importance of cell-type-specific 
analysis for a full mechanistically understanding of the functions of this versatile 
protein.  
1.4.6.1.3 Chromatin distribution of MeCP2 
Since its discovery, it has been known that MeCP2 is particularly enriched at mouse 
chromocenters (Lewis et al., 1992). Binding to this type of highly compacted chromatin 
is dependent on DNA methylation and requires the intact MBD (Nan et al., 1996; Yang 
et al., 2016). Here the protein appears to play important roles in the clustering of 
centromeres into groups of increasing size during differentiation. These cellular 
observations are in line with biochemical work documenting the ability of MeCP2 to 
compact chromatin fibers in vitro (Brero et al., 2005; Georgel et al., 2003; Nikitina et 
al., 2007a, 2007b). The importance of MeCP2 for differentiation-induced 
chromocenters clustering became apparent from studies using MeCP2-null neurons. 
These cells exhibited more abundant and smaller chromocenters that unlike for the 
wild-type counterparts failed to cluster during differentiation and following neuronal 
depolarization (Singleton et al., 2011). The direct involvement of MeCP2 in regulating 
the structure of chromatin indicates that the protein may rather act as a global 
modulator of transcription, rather than a gene-specific transcriptional repressor 
(Singleton et al., 2011; Skene et al., 2010).  
The global role of MeCP2 is supported by data coming from chromatin 
immunoprecipitation (ChIP)-on-chip assays in the human SH-SY5Y neuronal cell line, 
revealing that 60% of the MeCP2 binding sites lie in intergenic regions. Interestingly, 
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when found at gene promoters, MeCP2 appeared to function rather as a transcriptional 
activator. In line with this, only 2,2% of the highly methylated genes displayed MeCP2 
binding, contrasting with the 5mC-guided transcriptional repressive role proposed for 
the protein (Yasui et al., 2007). Accordingly, in the brain, more than half of MeCP2 
molecules were found to reside in open chromatin, and MeCP2 overexpression led to 
an upregulation of gene expression (Guy et al., 2011). The abundance of MeCP2 in 
the brain, as well as the high number of available methylated cytosine, make it 
improbable that the protein acts a classical ‘point-and-shoot’ transcriptional regulator. 
Instead, the locus-specific action of MeCP2 is most probably under the combined 
control of PTMs and protein interactors (Guy et al., 2011). 
In a seminal study, Lister et al., have discovered that in both the mouse and human 
brain, the DNA methylation landscape is dynamically reconfigured during development 
(Lister et al., 2013) (Figure 16). By performing high resolution methylome analysis of 
the mammalian frontal cortex at key developmental stages, the authors found that 
unlike other differentiated cell types, such as glial cells, neurons show a progressive 
DNMT3A-driven increase of non-CG methylation (CH methylation or mCH, in which H 
= A, C, or T). In the adult mouse and human neuronal genome half of the methylated 
cytosines were present at non-CG sites, in particular at CA dinucleotides. Interestingly, 
non-CG methylation was depleted from neuronally expressed genes, suggesting an 
involvement of this modification in gene silencing (Lister et al., 2013). The contribution 
of DNMT3A to the setting of non-CG patterns in the brain was highlighted by a 
conditional knockout study, documenting that upon DNMT3A deletion, mCA levels 
dramatically dropped. By contrast, CG methylation remained largely unaffected (Gabel 
et al., 2015). Parallel to the increase in non-CG methylation, methylated CG-sites 
appear to be converted in a Tet-dependent manner into hydroxymethylated 
dinucleotides (hmCG), particularly at transcriptionally active genes (Kinde et al., 2015; 
Lister et al., 2013). Indeed, hmC levels were found to be ~ 10 fold enriched in the brain 
by comparison to ES cells, accounting for 40%  of all modified CG sites in the 
cerebellum  (Gabel et al., 2015; Guo et al., 2014c; Lister et al., 2013).  This modification 
was shown to be enriched in the body of actively transcribed genes and depleted 
around the transcriptional start site (Kinde et al., 2015; Lister et al., 2013).  
Noteworthy, this major restructuring of the brain methylome including the increase in 
hydroxymethylation and non-CG methylation, is closely correlated with the buildup of 
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MeCP2 in neurons (Skene et al., 2010). The hypothesis that MeCP2 might have a 
broader binding specificity and could be involved in the readout of mCH and hmCH, 
was consequentially considered by many groups, the investigations of which gave rise 
to conflicting results (Feng et al., 2010; Gabel et al., 2015; Guo et al., 2014c; 
Hashimoto et al., 2012; Khrapunov et al., 2014; Lister et al., 2013; Meehan et al., 1992; 
Mellén et al., 2012; Spruijt et al., 2013; Valinluck et al., 2004; Xie et al., 2012). 
Motivated by the large amount of disparate data, Greenberg and co-workers recently 
formulated a unifying conceptual framework to explain the binding of MeCP2 to brain 
chromatin (Kinde et al., 2015). At the core of their model, lies the observation that 
conversion of methyl-cytosine into hydroxymethyl-cytosine impairs MeCP2 binding, 
selectively when it occurs CG context. By contrast, hydroxymethylated CA sites are 
bound as efficiently as mCA dinucleotides (Gabel et al., 2015). The authors propose 
that the wave of hmCG appearance in the mammalian brain would serve as a ‘kick-off’ 
signal to redistribute MeCP2 from the previously high-affinity mCG sites to the newly 
methylated CA dinucleotides (Kinde et al., 2015). Further work will be needed to 
explore the mechanisms behind this process.          
1.4.6.1.4 The involvement of MeCP2 in disease 
As described above, while MeCP2 is found in many tissues, the protein is most 
abundant in the mature brain (Shahbazian et al., 2002). Direct protein quantification 
revealed that there are around 16 million molecules of MeCP2 in adult neurons, with 
almost an order of magnitude less in glial cells, and 30-fold less in the liver (Skene et 
al., 2010). In line with its role in neuronal maturation and not neurogenesis, MeCP2 
levels are quite low at birth and, in mouse, display a dramatic increase in the first 3 
post-natal weeks (Kishi and Macklis, 2004; Skene et al., 2010). By this time, 
neurogenesis is largely complete, but synaptogenesis is ongoing (Guy et al., 2011). 
Due to its high abundance in the brain, it is not surprising that misregulation of MeCP2, 
either through mutations or aberrant protein expression levels, was linked to several 
neurodevelopmental diseases.            
The MECP2 gene is found on the X-chromosome, indicating that MECP2 mutations 
can have sex-specific outcomes (Adler et al., 1995). Indeed, mutations that severely 
affect the MeCP2 function are usually early lethal in males, whereas the mosaicism 
that arises due to random X-chromosome inactivation, leads to milder phenotypes in 
females (Amir et al., 1999; Schüle et al., 2008). Mutations affecting MECP2 are most 
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often associated with the neurodevelopmental Rett syndrome with ~95% of individuals 
with classical Rett phenotype carry mutations in MECP2 (Smeets et al., 2012).  
The Rett syndrome is characterized by an apparently normal postnatal development 
until 6-18 months of age, after which severe neurodevelopmental deficits start to 
appear. These include microcephaly, deterioration of motoric skills, features of autistic 
Figure 21| Clinical phenotypes associated with mutations in the X-linked MECP2 gene.  The most 
common phenotypes associated with deficiencies in MECP2 are documented in the two panels. A 
severe phenotype is more often associated with males (blue), since they have only one X chromosome. 
In some cases, preferential inactivation of the X chromosome that carries an intact MECP2, can also 
lead to severe defects in females (red). Nevertheless, females generally express hypomorphic alleles, 
displaying milder defects. The chronological order of symptom appearance was annotated on the Y 
axis. The image was taken from (Zoghbi, 2016). 
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behavior and intellectual disability (Zoghbi, 2016). The most common phenotypical 
changes associated with the development of the syndrome, together with their gender-
specific peculiarities are depicted in Figure 21.  Noteworthy, since the syndrome can 
be tracked down to mutations that affect only a single gene, it provides a complete 
environment for investigating the function of MeCP2, from its involvement in disease 
appearance to the pathological endpoint (Guy et al., 2011; Zoghbi, 2016). The self-
sufficiency of the syndrome is highlighted by the finding that reintroduction of Mecp2 
in adulthood, can rescue the Rett-like phenotype developed by the Mecp2 null mice 
(Lombardi et al., 2015).  
At the molecular level, over 80 unique missense and 140 unique truncating mutations 
have been identified in girls with Rett syndrome (Christodoulou et al., 2003; Lombardi 
et al., 2015). As shown in  Figure 22, where the most occurring mutations are 
documented, these are distributed over the whole protein, and cluster particularly in 
the MBD, hinting at a molecular connection between the 5mC signal and the 
development of the neurodevelopmental syndrome (Guy et al., 2011; Lombardi et al., 
2015).  
Interestingly, despite the fact that both DNMT3A and MECP2 are highly expressed in 
the brain, where they play important functions, and that the two proteins are members 
of the same epigenetic pathway, the potential interplay between them has not been 
addressed to date. In the present work, the molecular crosstalk between DNMT3A, the 
writer of DNA methylation, and MeCP2, the reader of DNA methylation, was 
investigated by a combinatorial approach involving in vitro and cellular analysis.   
Figure 22| Established Rett-causing mutations in the X-linked MECP2 gene.  Missense mutations 
were annotated in blue, while truncating mutations are shown in orange. The MBD domain is color 
coded in green. Truncating mutations present before R270 are associated with more severe symptoms 
by comparison to the more C-terminally located mutations. The image was taken from (Zoghbi, 2016). 
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1.4.6.2 The methyl-CG-binding domain protein 1 (MBD1) 
MBD1 stands out of the MBD family, owing to its unique and highly complex domain 
composition. The protein contains three specific CXXC domains, a transcriptional 
repression domain, and a canonical methyl binding domain. Interestingly, while the first 
two CXXC domains support the binding of MBD1 to methylated DNA, the third enables 
MBD1 to dock onto unmethylated genomic sites (Jørgensen et al., 2004; Li et al., 
2015a). The dual-affinity of the protein, might be responsible for the involvement of 
MBD1 in different epigenetic pathways, from DNA methylation to modification of 
histone tails (Fujita et al., 2000, 2003; Li et al., 2015a; Nakao et al., 2001; Ng et al., 
2000; Sarraf and Stancheva, 2004).  
The N-terminally located MBD remains the main interface that targets MBD1 to 
methylated CG islands of tumor suppressors and imprinted genes, where the TRD 
further recruits chromatin repressive complexes and induces gene silencing (Li et al., 
2015a). The first insights into the mechanistic recognition of the methylated CG 
dinucleotide were provided by an NMR-based structure of the MBD in complex with a 
methylated DNA oligo (Ohki et al., 2001). This revealed that four β-strands and an α-
helix build the central domain carrying two loops which project into the major groove 
and make contacts with the DNA (Ohki et al., 2001; Patel, 2016). More precisely, the 
hairpin-like loop L1 is responsible for forming contacts with the major groove of the 
DNA and for interacting with the methylated cytosine on one of the DNA strands 
Figure 22| Frequent Rett-causing mutations in the X-linked MeCP2 gene.  Missense mutations were 
annotated in blue, while truncating mutations are shown in orange. The MBD domain is color coded in 
green. Truncating mutations present before R270 are associated with more severe symptoms by 
comparison to the more C-terminally located mutations. The image was taken from (Lombardi et al., 
2015) 
3 Recogni ion of the sym etrically methylated CG site by the MBD of MBD1.  Schematic
representation of the protei -DNA con cts formed between the MBD domain and the DNA helix. The
m thylated CG sites are denoted with pink circles. Th DNA b ses that interact with the protein are
shown n black. The interactions between the MBD and t DNA helix are depicted with rows as
follows: hydrophobic (yellow), hydrogen bond (red), and electrostatic (blue). Red dashed arrows indicate 
hydrogen bonds involving backbone amide groups. The image was taken from (Ohki et al., 2001) 
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(Figure 23). The recognition of the 5mC on the complementary strand is more complex 
and involves loop L2 and a part of the α-helix that builds the central protein core. Here, 
the loop forms base-specific contacts in the major groove, whereas the helical segment 
makes contacts with the sugar-phosphate backbone. The methyl group is embedded 
in a hydrophobic pocket formed by 5 crucial residues: V20, R22, Y34, R44, and S45. 
Interestingly, this patch is able to access the strand-specific information of the 
methylated cytosine with the involved amino acids forming distinct interactions with 
each of the two 5mC (Figure 23) (Ohki et al., 2001; Patel, 2016). The importance of 
these residues is underlined by gel shift experiments showing that exchange of any of 
these amino acids to A compromised DNA binding (Ohki et al., 2001). These protein 
variants also displayed altered cellular localization patterns, when used in transient 
transfection of mouse fibroblasts, documenting the high dependency of MBD1 on an 
intact MBD domain for the proper recognition of 5mC sites. Importantly, the expression 
of an MBD1 variant lacking the MBD domain, but with intact CXXC domains, also 
displayed a diffuse localization and dramatically reduced enrichment at methylated 
sites (Fujita et al., 2000).   
Noteworthy, in addition to identifying the contact points that are necessary for 5mC 
recognition, the crystal structure also revealed that the MBD displays a small protein-
DNA interface, that is essentially restricted to the 5mC/5mC binding site (Ohki et al., 
2001). This suggests that the domain is able to access the methylation status of the 
cytosine base within a narrow area of the major groove and without extending into the 
minor groove (Ohki et al., 2001; Patel, 2016). The authors speculate that this 
recognition modus might allow the protein to easily bind to nucleosomal DNA, without 
encountering steric hindrances from the N-terminal tails of histone H2A, H2B, and H3, 
which protrude into the minor groove of the DNA helix. Therefore, unlike other DNA 
proteins that need to embrace the DNA for binding, the MBD of MBD1 can also dock 
on nucleosomal-wrapped DNA. Importantly, due to the small recognition motif, with the 
absence of apparent base-protein contacts outside of the CG dinucleotide sequence, 
the MBD appears not to be biased in the recognition of particular DNA sequences 
(Figure 23) (Ohki et al., 2001). Follow up biochemical experiments have indicated that 
the domain might have a preference for TCGCA or TGCGCA motifs, although here a 
longer construct was used for gel shift experiments (Clouaire et al., 2010). The high 
affinity of the protein for methylated cytosines, together with its low sequence bias, 
made the MBD a suitable tool for protein engineering approaches, in the search for 
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improved affinity reagents that recognize 5mC-rich genomic sites (see below) (Yu et 
al., 2010). In this study, the high specificity and affinity of the MBD domain for 
methylated CG dinucleotides was exploited to design novel epigenetic sensors that 
specifically recognize methylated genomic sites in living cells.  
1.5 Understanding epigenomic phenomena with state of the art 
profiling methods  
Unlike the genetic code, epigenetic modifications are metastable, with different marks 
having different degrees of stability and variability (Bheda and Schneider, 2014; 
Daxinger and Whitelaw, 2010; Heard and Martienssen, 2014; Kouzarides, 2007). 
While some epigenetic signatures are stably inherited across many cell divisions and 
even generations, others are rapidly erased (Bheda and Schneider, 2014). This 
heterogeneity is essential for the generation of a flexible and functional interface 
between the genome and the environment (Feil and Fraga, 2012; Herceg and 
Vaissière, 2011). Importantly, while epigenetic landscapes are indispensable for the 
functional specialization of cells during differentiation, they are not identical within a 
population of cells belonging to the same cell type (Chang et al., 2008; Landan et al., 
2012; Schwartzman and Tanay, 2015; Shalek et al., 2013). This high cell-to-cell 
variation together with the heterogeneous changes that appear in the epigenetic 
landscape over time poses several challenges to a complete understanding of how 
epigenetic states are set, maintained, and erased in both normal development and 
pathogenesis (Bheda and Schneider, 2014). Indeed, a large body of work documented 
that deregulation of epigenetic cascades is intimately linked to disease development, 
in particular, cancer. The high frequency and early appearance of alterations in the 
epigenetic landscape in malignancy have placed the understanding of epigenetic 
signals at the core of biomarker discovery, therapeutic intervention and prevention 
(Lima et al., 2010; Lister and Ecker, 2009; Umer and Herceg, 2013). This has targeted 
the development of increasingly refined methods for profiling epigenetic modifications, 
which was also one of the aims of this work. Therefore, in the following sections, an 
overview of the main techniques that enable the detection of histone modifications and 
DNA methylation will be provided. Inherent advantages and limitations will be 
described.       
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1.5.1 Methods for profiling histone modifications 
Analysis of histone modifications relies on two main workhorses: mass spectrometry 
(MS) and chromatin immunoprecipitation (ChIP). Each of these two techniques has 
massively contributed to the development of the chromatin field and comes with a 
unique set of advantages and drawbacks.  
1.5.1.1 Comprehensive mapping of histone modifications with mass 
spectrometry 
MS-based proteomic approaches have the unmatched power to provide an unbiased 
and comprehensive map of histone PTMs. Derivations of this technique have facilitated 
the discovery of new histone modifications, aided in elucidating the interplay between 
different histone marks and provided an accurate measure of the quantitative changes 
in transitions between distinct functional states (Britton et al., 2011; Garcia, 2009; 
Plazas-Mayorca et al., 2009; Sidoli et al., 2012; Soldi et al., 2014; Zee et al., 2011). In 
MS, a post-translational modification is detected as an increase in the mass of the 
peptide between the theoretical and the experimentally measured mass. Histone PTM 
analysis by MS can be performed via three main experimental workflows: bottom-up, 
middle-down and top-down. The bottom-up approach involves the enzymatic digestion 
of the histone proteins into small peptides, which are separated via chromatography 
before MS analysis, sequencing, and quantification (Chait et al., 2006). For this 
procedure, trypsin cleavage is routinely used, due to its high specificity for lysines and 
arginines (Olsen et al., 2004). In the case of histone proteins, which are lysine/arginine-
rich, this methodology comes nevertheless with two disadvantages: on the one hand, 
the enzymatic digestion leads to the generation of many very small peptides, which 
can pose problems for the chromatography run, as well as for the MS analysis; on the 
other hand, trypsin cleavage was shown to be blocked by modified arginine or lysines, 
giving rise to quantification issues (Karch et al., 2013). To circumvent these caveats, 
middle and top-down approaches were developed, involving rarely-cutting proteases 
such as AspN and GluC, and analysis of undigested proteins, respectively. These 
techniques are particularly useful for studying the co-occurrence of two or more PTMs 
(Karch et al., 2013). The major impact of the development of MS techniques is attested 
by the around 200 distinct histone modification types, which were discovered and 
mapped, with MS methods,  in the last 10 years (Arnaudo and Garcia, 2013). The 
major limitation of MS proteomic approaches is the fact that they lack DNA-sequence 
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information, thereby they are conceptually not able to provide locus-specific epigenetic 
information.  
1.5.1.2 Locus-specific analysis of histone modifications with chromatin 
immunoprecipitation 
The analysis of histone modifications with locus-specific resolution can be achieved 
through chromatin enrichment-based methods. These generally involve cellular lysis, 
followed by nuclease- or sonication-based chromatin fragmentation and precipitation 
of the nucleosomes of interest with affinity probes. To extract the genomic sequence 
information, the DNA associated with the immunoprecipitated histones is isolated and 
subjected to analysis by either quantitative PCR (qPCR) or high-throughput 
sequencing, depending on the amount of information required (Kimura, 2013).  
Two main types of affinity reagents have been used so far to retrieve modified 
nucleosomes: antibodies and recombinant proteins based on histone modification 
interacting domains (HIMDs) (Kungulovski et al., 2015a). Out of these, PTM-specific 
antibodies have been the traditional reagents employed for translating the language of 
histone marks into experimental observations. Recently, the reliability and quality of 
these reagents have however started to be questioned, as large lot-to-lot variability in 
specificity and binding affinity were observed (Baker, 2015; Bordeaux et al., 2010; 
Kungulovski et al., 2014). Availability of highly specific affinity reagents is particularly 
critical in the chromatin field, where histone modifications that participate in different 
biological pathways, can occur on amino acid motifs that are very similar in sequence 
(Kungulovski et al., 2014). To circumvent the caveats associated with antibodies, 
engineered histone modification interaction domains have been developed 
(Kungulovski et al., 2014). They exploit the inherent discriminative power encoded in 
chromatin readers, domains that are part of natural occurring chromatin effectors.  
These tools were successfully employed to study the genomic distribution of 
H3K9me3, H3K27me3, H3K4me0 and H3K4me3 modifications (Kungulovski et al., 
2014, 2016; Su et al., 2014). Among the advantages that recombinant binders have 
over antibodies are their constant quality and easiness to assess unspecific binding by 
generating mutants in the histone binding pocket. In addition, combinatorial histone 
marks can be more readily studied by using naturally occurring multi-domains or 
synthetically-fused single binders. This aspect remains so far difficult to address with 
antibody-based technology (Fuchs et al., 2011; Su and Denu, 2016).  
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Regardless of the reagent used for affinity enrichment, ChIP-based methods, as well 
as derivation thereof, significantly contributed to the generation of comprehensive 
maps of the epigenetic makeup for many cell types and tissues. The resulting near-
complete catalogues of functional elements available for many model organisms, 
provide a powerful screening platform for elements that are altered in malignancy 
(Bernstein et al., 2012; Consortium et al., 2015; Farh et al., 2015; Seumois et al., 2014; 
Yue et al., 2014).      
Noteworthy, while these methods provide fundamental insights into the mechanisms 
responsible for the setting and maintenance of epigenetic patterns, they are very often 
used on chromatin isolated from a population of cells, therefore averaging cell-to-cell 
heterogeneities (Bheda and Schneider, 2014). For improved assessment and 
understanding of the diversities occurring in-between epigenetic landscape, single-cell 
methods started to be developed.  
1.5.1.3 Genome-wide single-cell mapping of histone modifications: the next 
generation 
By building up on the advent of sequencing technologies, current methods enable the 
profiling of gene expression or genome organization down to the level of individual 
cells (Angermueller et al., 2016; Burton et al., 2013; Cusanovich et al., 2015; Levsky 
et al., 2002; Nagano et al., 2013; Ståhlberg and Bengtsson, 2010). Whereas DNA 
methylation can be recovered from the genomic material directly, profiling of histone 
modifications is performed indirectly, by chromatin immunoprecipitation followed by 
sequencing (ChIP-seq). This procedure enriches for the modification of interest 5-100-
fold over the genomic background, implying that a large proportion of the sequenced 
reads are nonspecific. To account for this, the immunoprecipitated material is usually 
sequenced with a high depth to distinguish positive signals from the background by 
statistical analysis (Schwartzman and Tanay, 2015). Applying the same approach to 
single cells remains problematic, as, without the statistical pooling, there is no reliable 
way to distinguish real signals from false positives. Moreover, when working with only 
one genome copy, there is a large risk of losing signal due to technical problems and 
not because the modification of interest is lacking. This can lead to false negative 
results. For this reason, methods that allow the genome-wide single-cell profiling of 
histone modifications are still under development (Schwartzman and Tanay, 2015).  
 49 
 
1.5.1.4 Live-cell imaging of histone modifications 
As described in the introduction, an important feature of epigenetic modifications is 
their inheritance. Despite the booming development of available detection methods, 
this aspect remained so far difficult to access, since most of the techniques require cell 
fixation or lysis. To achieve a bird’s-eye view on the dynamics of the epigenetic 
landscape, live cell microscopy-based methods were developed. These typically rely 
on in vivo fluorescence reporters, to visualize gene expression and inheritance of 
expression patterns in single live cells (Bheda and Schneider, 2014).  
1.5.1.4.1 Detection of histone modifications via Fabs and mintbodies 
To monitor histone modifications in living cells, two types of probes have been 
developed (Figure 24). The first approach relies on the direct detection of endogenous 
histone modifications using fluorescently-labeled modification-specific antigen binding 
fragments (Fabs) (Figure 24a) or genetically encoded modification-specific 
intracellular antibody probes (mintbodies) (Figure 24b) (Hayashi-Takanaka et al., 
2009, 2011; Rothbauer et al., 2006; Sato et al., 2013, 2016; Suzuki et al., 2016). Fab 
fragments are generated through protease digestion from the whole immunoglobulin 
G (IgG). For microscopy applications, these small fragments are then labeled with 
fluorescent dyes before being mechanically loaded or injected into living cells, where 
they enter the nucleus by passive diffusion through the nuclear pores (Figure 24a) 
(Kimura and Yamagata, 2014; Rader, 2009).  Residence time measurements by 
fluorescence recovery after photobleaching (FRAP), revealed that Fabs bind their 
Figure 24| Live cell imaging of histone modifications with Fab fragments (a) and mintbodies (b). 
a) Schematic representation of the Fab labeling technology. The lower part of the figure documents the 
application of fluorescently-labeled Fab fragments for the simultaneous detection of three distinct 
histone marks, in the nuclei of living mouse cells. b) Schematic representation of the mintbody approach. 
The lower panel documents the application of a H3K9ac-mintbody to monitor the increase in the levels 
of the histone mark, in live Drosophila embryos. The figure was adapted after (Shen, 2015) .    
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targets for a short  time ranging from <1 to >10 s depending on the histone modification, 
suggesting that these tools do not dramatically disturb cellular processes, even when 
loaded at high concentrations (Hayashi-Takanaka et al., 2011). Using this technique, 
H3K9 and H3K27 acetylation levels could be visualized in mouse preimplantation 
embryos (Hayashi-Takanaka et al., 2011). Triple labeling of H3K27me3, H3K9me2 and 
H3K27ac was also achieved (Figure 24a). A disadvantage of the Fab technology is 
that the fragments are diluted during cell divisions, making long-term imaging as well 
as living animal experiments infeasible (Bheda and Schneider, 2014).  To overcome 
this, genetically encoded mintbodies were developed. These can be constitutively 
expressed in vivo as fusions with fluorescent proteins. Using this method, the dynamics 
of H4K20me1 during the cell cycle and X chromosome inactivation could be 
successfully visualized (Sato et al., 2016). Although providing the first glimpses in the 
visualization of chromatin marks, this approach can result in high signal-to-noise ratio 
caused by the fluorescence of expressed but unbound mintbody probes (Bheda and 
Schneider, 2014). This limitation can become be particularly severe, the less abundant 
the histone modification under investigation is.    
1.5.1.4.2 Detection of the activity of epigenetic enzymes via FRET biosensors 
To circumvent the high background issue, a second approach was developed, relying 
on Förster resonance energy transfer (FRET) probes (Ito et al., 2011b; Lin et al., 2004; 
Nakaoka et al., 2016; Sasaki et al., 2009). With these sensors, the balance between 
modifying and de-modifying histone enzymes can be monitored (Figure 25a and b). 
The tools resort to intramolecular FRET between a donor and an acceptor fluorescent 
protein, which are typically incorporated in a tripartite system consisting out of a FRET 
Figure 25| FRET-based detection of histone tail modifications in living cells. a) Schematic 
representation of a tripartite FRET sensor, where a linker encoding for the target sequence of a histone 
modifying enzyme, is used to separate a CFP-tagged modification-specific reader from YFP. Successful 
modification of the linker sequences triggers a large intramolecular conformational change that brings 
the CFP and the YFP fluorophore in a FRET-productive spatial proximity. The figure was taken from 
(Shen, 2015) .b) Fluorescence microscopy image documenting an increase in FRET signal for a sensor 
designed to readout the acetylation levels of histone H4. The right-side image was taken 60 min after 
treating the cells with the histone deacetylase inhibitor Trichostatin A (Sasaki et al., 2009).  
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donor-fused modification-specific binder, a flexible linker containing an amino acid 
sequence motif to be modified by the investigated enzyme and a FRET acceptor. The 
enzymatic modification of the target sequence motif is recognized by the modification-
specific binder, initiating an intramolecular structural change that brings the donor and 
acceptor fluorophores in close spatial proximity, thereby giving rise to an increase in 
the FRET signal. The advantage of the FRET readout is that the signal is generated 
only when the two fluorophores are very close to each other, and particular spatial 
constraints are met (Vogel et al., 2006). Accordingly, an output signal is only produced 
if the central linker peptide gets modified, limiting the fluorescence background. With 
these tools, the levels of H4K12 acetylation could be successfully monitored in real-
time, by using the bromodomain of BRD2 (bromodomain-containing 2) as a 
modification-specific reader (Ito et al., 2011b). In addition, the increase in H4 
acetylation could be monitored in living cells, upon treatment with a histone 
deacetylase inhibitor (Figure 25b). 
Importantly, while these methodologies offer in vivo expression and reversible, low-
background advantages, they can be only used to monitor the global distribution of 
histone modifications and have no locus-specific resolution (Bheda and Schneider, 
2014).       
1.5.2 Methods for profiling DNA methylation  
A large number of experimental studies have demonstrated that deregulation of DNA 
methylation is intimately linked to many human malignancies, most notably cancer. 
Here, CG islands of tumor suppressor genes were reported to usually gain DNA 
methylation, while repetitive elements such as heterochromatic DNA repeats become 
frequently hypomethylated (Baylin, 2005; Baylin and Jones, 2011; Taberlay and Jones, 
2011). These changes may promote the growth, survival, and progression of the 
invasive tumors, thereby fostering malignancy (Baylin and Jones, 2011).  This, 
together with the dynamic changes that occur in DNA methylation levels during 
development, have placed the mapping of the 5mC mark at the core of novel method 
development.  
1.5.2.1 Methods to map 5mC in lysed cellular material  
Standard molecular biology techniques such as hybridization and sequencing, are not 
able to discriminate between methylated and unmethylated cytosine bases (Umer and 
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Herceg, 2013). Owing to this, DNA methylation profiling requires that the sample DNA 
undergoes certain pre-treatments, that can preserve and are sensitive to the 
modification status of the 5mC group. These include DNA digestion with methylation-
sensitive restriction nuclease, affinity enrichment with 5mC-specific probes, MS,  or 
bisulfite (BS) treatment (Umer and Herceg, 2013). The latter is the working horse of 
methylome analyses and involves the chemical treatment of the isolated DNA with 
sodium bisulfite. The key concept of the method is that this treatment leads to selective 
deamination of unmethylated cytosines to uracil. By contrast, the conversion of 
methylated bases has a much lower rate, and when the treatment is performed under 
optimal conditions, it leaves the modified bases unaffected. In subsequent PCR 
amplification, the uracil-derived from unmodified cytosines is replaced with thymine, 
while the methylated base leaves a cytosine footprint (Frommer et al., 1992). Coupling 
this method with the development of high-throughput sequencing has led to the 
generation of whole-genome DNA methylation landscapes, at single base resolution, 
for a broad range of cell types and conditions (Darst et al., 2010; Li and Tollefsbol, 
2011).   
Like the profiling of histone tails marks, methods routinely used for mapping 5mC suffer 
from two main limitations: the analysis of population-based averages and limited 
resolution power for the assessment of dynamic epigenetic changes, as these methods 
cannot be applied in living cells (Bheda and Schneider, 2014). Several new 
approaches were developed to address these issues. As such, the first single-cell 
methylome was published in 2014 and was based on a joined effort between the Reik 
and Kelsey labs (Smallwood et al., 2014). This novel platform involves isolation of 
single cells, followed by lysis and BS treatment for combined DNA fragmentation and 
chemical conversion of unmethylated cytosines to thymine. Sequencing adaptors are 
sequentially ligated to the resulting fragments, in a 5-times repeated process, to 
maximize the number of tagged DNA strands and generate multiple copies of the 
starting material. With this strategy, the authors were able to successfully assess the 
epigenetic heterogeneity that arises in-between embryonic stem cells, upon transitions 
in the culturing conditions (Smallwood et al., 2014). This pioneering report laid the 
basis for a plethora of follow up method development studies which contributed 
fundamental insights into the high heterogeneity of epigenetic landscapes (Farlik et al., 
2015; Guo et al., 2015a, 2015b).  
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1.5.2.2 Live-cell imaging of global DNA methylation levels 
By analogy to histone marks, microscopy-based methods were also developed for 
accessing the dynamics of the 5mC modification. This epigenetic mark comes however 
with the caveat that it is best exposed to antibody binding when DNA is single stranded. 
To this end, the cellular material needs to be subjected to acidic denaturation and high-
temperature hybridization, which make antibody-based approaches incompatible with 
live cell imaging (Jørgensen et al., 2006). For this reason, natural protein reading 
domains are more often exploited as a tool for the live-cell tracking of DNA methylation 
by comparison to the monitoring of histone modifications, where Fab fragments and 
mintbodies are more frequently used. The most established reader of DNA methylation 
for live-cell applications is the MBD of MBD1. As described above, this domain has the 
advantage that it recognizes 5mC in the native double-stranded DNA context, and it 
has a high specificity for symmetrically methylated CG dinucleotides (Jørgensen et al., 
2006). The development of this protein for live cell applications was ignited by a 
pioneering study where the authors were able to visualize for the first time, the 
dynamics of DNA methylation levels in preimplantation mouse embryos, upon injecting 
them with mRNA encoding for a GFP-tagged fusion of the MBD domain (Yamazaki et 
al., 2007). With this single-cell technology, the group found that centromeric repetitive 
sequences are hypomethylated in germ cells by comparison to somatic cells 
Figure 26| Generation and usage of the methylRO mouse reporter model. a) Neonate MethylRO 
mice (left) have similar phenotype to wild-type mice (right) and show whole-body red fluorescence. b) 
Time lapse imaging of embryonic stem cells during the differentiation process (tracked with OCT4-GFP). 
A strong increase in the MBD-RFP signal intensity is observed with time (indicated at the bottom right 
as day: hour: minute). The images were taken from (Ueda et al., 2014). 
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(Yamagata et al., 2007). The low toxicity and high specificity of this device was recently 
exploited for the development of a DNA methylation mouse reporter. Here, the authors 
generated a knock-in animal to ubiquitously express a RFP-fused MBD protein (Figure 
26a). With this, the mobility and pattern of heterochromatin, as well as the DNA 
methylation signal intensity could be dynamically tracked during cellular differentiation 
(Figure 26b) (Ueda et al., 2014). Although useful, this approach only reports on the 
global level of DNA methylation and lacks locus-specific resolution.  
1.5.2.3 Visualization of chromatin marks with single locus resolution  
While there are now many methods that enable the tracking of epigenetic modifications 
at various scales, no technological platform enables the detection of epigenetic marks 
at the level of single loci, in living cells. The paramount significance of the insight that 
could be achieved through such technologies, motivated several groups to develop 
methods that attempt to satisfy these criteria (Bheda and Schneider, 2014). For 
instance, locus-specific visualization of histone modifications was achieved by 
combining in situ hybridization with a proximity ligation assay (Gomez et al., 2013).   To 
achieve DNA sequence specificity, biotinylated complementary probes were used for 
hybridization. The biotin moiety was then recognized by a secondary antibody, to which 
a DNA oligo is coupled. Similarly, the histone modification was recognized via an 
antibody, to which a DNA oligo is linked. When the two probes bind in close spatial 
proximity, the two oligos can be used for several rolling-circle amplification cycles, to 
generate a product that can be labeled with fluorescent DNA probes. With this, the 
H3K4me2 status could be visualized at specific promoters of active genes in single 
smooth muscle cells, in mammalian tissue samples (Gomez et al., 2013). Although this 
method provides an elegant solution for the low signal associated with single-copy 
genomic loci, it is not compatible with live cell imaging, thereby providing only a 
snapshot of the dynamic epigenetic landscape.  
An in situ hybridization-based approach also recently enabled the sequence-specific 
visualization of DNA methylation at single cell level (Li et al., 2013). Here the authors 
took advantage of the differential reactivity of modified vs. unmodified cytosine for 
interstrand complex formation with osmium and bipyridine-containing nucleic acids. 
For this chemical treatment, the cellular material needed to be nevertheless subjected 
to fixation, thereby compromising the applicability of the method in living cells and 
preventing the assessment of dynamic changes in the 5mC mark, within single nuclei.       
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The most comprehensive solution for a method that allows dynamic imaging of locus-
specific DNA methylation changes was recently proposed by Jaenisch and co-workers 
(Stelzer and Jaenisch, 2016; Stelzer et al., 2015). The authors designed a novel 
readout system based on inserting a reporter construct consisting out of the minimal 
promoter of the imprinted Snrpn gene driving the expression of a fluorescent protein, 
downstream of the genomic locus of interest.  Since the Snrpn gene contains somatic 
DMRs, the methylation of the promoter of interest can extend into the Snrpn promoter 
and translate into a reduction of the fluorescent signal. This sequence was used to 
drive the expression of a fluorophore, which served as a signal amplifier (Figure 27a). 
With this tool, the authors could for the first time, dynamically visualize the methylation 
status of several endogenous single copy loci (Stelzer et al., 2015). While this method 
holds great promise for mechanistic studies with potentially broad implications for the 
field (Figure 27b), it still comes with a set of limitations. Among the most important is 
the fact that the methylation readout is indirect, as it depends on the spreading of DNA 
methylation into the Snrpn DMRs, which may occur with locus-specific kinetics. 
Moreover, the endogenous genomic locus needs to be synthetically modified in order 
Figure 27| Principle and potential applications of the methylation reporter system developed by 
(Stelzer et al., 2015). a) Schematic representation documenting the concept of the DNA methylation 
sensor. Accordingly, DNA methylation of the neighboring CGI spreads into the Snrpn gene promoter, 
leading to epigenetic silencing and no detectable fluoresce. By contrast, unmethylated CGI are 
associated with a positive fluorescent signal. b) Potential application areas for the sensor described in 
a) involve imaging of the dynamics of DNA methylation during cellular differentiation (top panel) or 
studying cell-to-cell heterogeneity upon perturbation (lower panel). The images were taken from (Stelzer 
and Jaenisch, 2016). 
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to introduce the fluorescence reporter and the methylation kinetics measurements are 
biased by the half-life of the reporter fluorophore.  To solve these issues, the 
development of methods that enable a direct targeting of genomic sites and facilitate 
the readout of their epigenetic status in live cells is imperative. This technological 
revolution is dependent on programmable tools that enable the live-cell visualization of 
user-defined DNA sequences. In the following section, technologies that enable locus-
specific genomic targeting will be described. Particular emphasis will be put on their 
application for live cell imaging approaches.  
1.6 Custom DNA-binding domains for imaging of user-defined 
genomic sites 
There are three main types of powerful tools that were developed for the sequence-
specific interrogation of genomic sites: zinc-finger proteins (ZFs), transcription 
activator-like effectors (TALEs) and the clustered regulatory interspaced short 
palindromic repeat (CRISPR)/Cas-based RNA-guided systems (Chen et al., 2016a; 
Gaj et al., 2013; Kungulovski and Jeltsch, 2016).  
1.6.1 Cys2-His2 zinc finger proteins 
The Cys2-His2 zinc finger domain is among the most common types of eukaryotic DNA-
binding motifs. An individual ZF domain consists of 30 amino acids that are arranged 
in a conserved ββα configuration. Residing on the surface of the α-helix and the loop, 
there are several important amino acids that engage in contacts with the major groove 
of the DNA duplex. Typically, each ZF domain recognizes a 3 bps-long motif, with 
varying levels of selectivity (Beerli and Barbas, 2002; Gaj et al., 2013; Mandell and 
Barbas, 2006). ZF proteins have laid the basis of the genome targeting revolution. This 
was initiated by the realization that individual zinc finger modules can be used to 
generate custom-made modular arrays, through which longer DNA sequences can be 
recognized. This technological advancement was facilitated by the structure-based 
discovery of a highly conserved linker sequence that enables the construction of 
synthetic arrays of 3-6 zinc-finger proteins with a footprint of 9-18 bps. Follow up 
biochemical investigations have characterized the relationship between protein length 
and specificity and critically inspected the potential crosstalk between neighboring ZF 
modules when arranged in one array (Liu et al., 1997; Segal et al., 2003). Importantly, 
with the extension of the target sequence length to 18 bps, this technology allowed for 
the first time, the specific targeting of unique, user-defined sequences in the human 
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genome (Beerli et al., 1998, 2000). In the past decade, the number of methodologies 
used for assembly of zinc finger arrays has increased dramatically, hinting at the large 
impact that this technology has had on genome-targeting applications (Gaj et al., 
2013). Custom-made arrays can now be commercially bought, allowing the 
investigators to bypass the time-consuming process of zinc-finger construction and 
validation (Gaj et al., 2013).   
The application of the zinc-finger technology for in vivo chromosome labeling was 
achieved with some delay and was pioneered by the group of Bert J. van der Zaal 
(Figure 28a). Together with his co-workers, he developed the first synthetic protein 
with which an endogenous DNA sequence could be labeled and tracked in living cells 
(Figure 28b) (Lindhout et al., 2007). The GFP-fused protein was designed to recognize 
a 9bp-long sequence within murine major satellite repeats and enabled the first 
visualization of these sites in living cells (Lindhout et al., 2007).      
1.6.2 TALE proteins 
TALEs, are proteins naturally secreted by the pathogenic bacteria Xanthomonas upon 
infection of plant hosts. The proteins recognize specific DNA sequences, about 20 
bases long, via a large DNA-recognition domain composed of a series of 33-35-amino 
acid repeat domains, each of them specifically recognizing a single base pair. The 
specificity of each module resides in two hypervariable amino acids, known as the 
Figure 28| Application of ZF proteins for live-cell labeling of endogenous genomic sites.                   
a) Schematic representation of a EGFP-fused modular zinc finger array, constructed by the fusion of 4 
individual zinc finger modules. The nucleotide triples recognized by each module are shown in the same 
color as the corresponding ZF. The image was taken from (Chen et al., 2016a). b) Fluoresce microscopy 
image showing the live cell labeling of mouse major satellite repeats with a polydactyl EGFP-fused ZF 
(green). The targeting specificity of the DNA-binding protein was validated by co-staining of the nucleus 
with DRAQ5 (red). Due to its bias for AT-rich sequences the dye is preferentially enriched at the ZF 
target sites. This is highlighted in the merged image (white).  The image was taken from (Lindhout et 
al., 2007) 
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repeat-variable di-residues (RVDs) (Deng et al., 2012; Mak et al., 2012). Like their ZF 
predecessors, individual TALE modules can be linked together into custom-made 
modular arrays that can be used for targeting of defined genomic loci. This technology 
has two main advantages over ZFs: there is no need to re-engineer the linker between 
repeats to construct long array, and since each module recognizes only a single base, 
there is a larger flexibility in the design of target sites, by comparison to ZFs that are 
triplet-confined (Gaj et al., 2013). Indeed, TALE arrays capable of binding 7-34 bp-long 
motifs could be successfully constructed (Garg et al., 2012). TALE systems are an 
attractive technological platform since the nucleotide binding code that links the RVD 
type to specified nucleotides is known (Doyle et al., 2012). This design nevertheless, 
comes with a severe drawback that impairs its applicability: since the individual TALE 
modules are genetically very similar, cloning them into large arrays poses an elevated 
technical challenge owing to their highly repetitive DNA. To overcome this issue, 
several methods have been developed to enable the error-prone assembly of TALE 
modules into custom-made arrays (Briggs et al., 2012; Cermak et al., 2011; Reyon et 
al., 2012; Schmid-Burgk et al., 2013).  
The first locus-specific imaging technology based on TALE proteins stemmed out of 
the group of Torres-Paddila (Miyanari et al., 2013). Here, the authors established a live 
cell imaging method to visualize endogenous repetitive genomic sequences in living 
mouse cells (Figure 29a and b). Fussing fluorescent proteins to TALEs of different 
sequence specificities enabled the spatial tracking of user-defined sequences in the 
Figure 29| Application of TALE proteins for live-cell labeling of endogenous genomic sites.                   
a) Schematic representation of a EGFP-fused TALE protein, designed to recognize an 18 bp-long DNA 
sequence.  The RVD modules responsible for nucleobase specificity were colored similarly to the 
nucleotide they recognize. The image was taken from (Chen et al., 2016a). b) Fluoresce microscopy 
image documenting the high DNA sequence specificity of a GFP-TALE protein (green) designed to bind 
to mouse major satellites. To independently validate the identity of the target sequence, the TALE-
transfected cells were subjected to fluorescent in situ hybridization (FISH) with a probe targeting major 
satellites (red). The green and the red signals appear to localize at the same genomic regions, 
highlighting the high specificity of the TALE construct. The image was taken from (Miyanari et al., 2013). 
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nucleus of cultured mouse cells, as well as in a living organism.  The generation of 
stable cell lines and live animals expressing these devices underlined the low toxicity 
of the proteins and their applicability. Furthermore, by taking advantage of single-
nucleotide polymorphism to differentially label parental chromosomes within on single 
nucleus, this study elegantly demonstrated the high specificity of the TALE technology. 
This pioneering work catalyzed the design and live cell microscopy application of 
TALEs with other sequence preferences (Fujimoto et al., 2016; Ma et al., 2013; Yuan 
and O’Farrell, 2016; Yuan et al., 2014).   
A caveat associated with the usability of TALE proteins for cellular applications is 
brought about by the large size of the protein, which might perturb the local chromatin 
environment of the labeled locus. This was assessed for a TALE designed to bind 
mouse satellite repeats, where histone H3 occupancy, as well as the level of 
trimethylated H3K9, were found to remain unaffected (Miyanari et al., 2013). However, 
the effect that TALEs might have when used to label protein-coding single copy genes 
as well as regulatory DNA sequences such as promoters and enhancers, remains to 
be elucidated (Chen et al., 2016a).  
1.6.3 The CRISPR/Cas9 system  
Recently, the CRISPR/Cas system has emerged as a potent alternative to ZF and 
TALE proteins for genome targeting applications. The system is naturally occurring in 
bacteria and archaea, where it provides acquired immunity against invading foreign 
DNA via RNA-guided DNA cleavage (Wiedenheft et al., 2012). CRISPR/Cas systems 
consist of 2 main components: a set of cas9 genes organized in operon(s) and the 
CRISPR array(s) comprising short repetitive elements DNA elements, separated by 
unique 30-40 bp-long sequences (spacers), which are derived from viral or plasmid 
origin (Marraffini, 2015). The CRISPR/Cas9-mediated adaptive immunity occurs in 
three steps. First, a small sequence of the invading DNA is inserted as a spacer motif 
into the CRISPR array. This is followed by the transcription of the locus to generate 
precursor RNAs (pre-crRNAs), which then undergo maturation to produce individual 
crRNAs, consisting of a repeat part and an invader-targeting spacer part. These 
crRNAs are finally recognized by nuclease-competent Cas9 proteins, which are guided 
to sites complementary to the crRNA spacer sequences to cleave the foreign nucleic 
acid (Doudna and Charpentier, 2014; Jiang and Doudna, 2015; Marraffini, 2015; van 
der Oost et al., 2014).  While the cascade of events that triggers the acquisition of new 
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spacers is not completely elucidated, chromosomal acquisition data from E. coli, 
indicated that a large contributor may be the nucleolytic processing of dsDNA brakes 
generated during the replication of the virus or the plasmid (Levy et al., 2015; Marraffini, 
2015). This immunization through spacer acquisition enables the bacterial population 
to rapidly acquire resistance to invading viruses (Marraffini, 2015).  
There are 3 main types of CRISPR-Cas systems (I, II and III), each using a distinct 
molecular mechanism for the recognition and cleave off the target DNA sequence. 
While types I and III require a large complex of Cas proteins for crRNA-guided 
targeting, type II is based on only one protein for RNA-guided DNA recognition and 
cleavage. This property is one of the key features that contributed to the extensive 
application of the type II CRISPR-Cas system in genomic targeting approaches 
(Doudna and Charpentier, 2014; Gasiunas et al., 2012; Hale et al., 2009; Haurwitz et 
al., 2010; Jinek et al., 2012). The high usability of the CRISPR-Cas system was 
influenced by three main findings. First, trans-activating crRNAs (tracrRNA), which are 
trans-encoded upstream of the type II CRISPR-Cas locus in Streptococcus pyogenes, 
were found to be essential for the maturation of crRNAs (Deltcheva et al., 2011). 
Second, the S.pyogenes Cas9 protein was shown to be a dual-RNA-guided DNA 
endonuclease. In follow-up engineering approaches, this requirement could be 
simplified, as the dual tracrRNA:crRNA was successfully merged into a single guide 
RNA (sgRNA) that retained 2 critical properties: the 20-nucleotide sequence at the 5’ 
end of the sgRNA, essential for Watson-Crick base pairing to the DNA site, and the 
double-stranded stem-loop structure at the 3’ end of the guide sequence, which is 
bound by Cas9. (Deltcheva et al., 2011; Jinek et al., 2012). Third, with the successful 
identification of the residues responsible for DNA cleavage activity in Cas9, a nuclease-
deficient version of the protein (deactivated Cas9 or dCas9) could be generated 
(Gasiunas et al., 2012; Jinek et al., 2012). The latter finding catalyzed a technological 
revolution in the field of genomic targeting as it provided a programmable RNA-guided 
DNA binding protein. Although other DNA targeting devices such as ZF and TALE 
proteins were already established at this time, the CRISPR/Cas9 technology was 
rapidly accepted and extensively implemented due to its unsurpassed flexibility. The 
main advancement is that while the RNA-guided CRISPR/Cas9 complexes can be 
easily re-targeted by designing new sgRNA, ZF and TALE repurposing involves de 
novo protein engineering, which can be very tedious and time-consuming (Chen et al., 
2016a; Kungulovski and Jeltsch, 2016).  
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The first live cell imaging application of the CRISPR/Cas9 technology was developed 
by the groups of Huang and Qi (Chen et al., 2013). The authors used an optimized 
GFP-tagged dCas9 protein to selectively visualize specific genomic sequences in living 
human cells (Figure 30a). In addition to imaging of repetitive telomeric sequences, this 
approach was the first to enable the successful visualization of non-repetitive genomic 
sites (Figure 30b). To this end, a cocktail of 73 distinct sgRNAs was used to target the 
dCas9 protein in a tiled manner along the MUC4 gene locus and amplify the fluorescent 
signal. This strategy highlights the unmatchable flexibility of the CRISPR/Cas9 
technology, as a comparable ZF or TALE-based approach would have involved the de 
novo design and validation of 73 different DNA binding proteins (Chen et al., 2013). 
Following this elegant proof-of-concept paper, the Cas9 labeling approach has been 
successfully employed by other groups, to observe the dynamics of specific 
chromosomal loci in living mouse embryonic and cultured human cells (Anton et al., 
2014; Chen and Huang, 2014; Knight et al., 2015). 
Figure 30| Application of the CRISPR/dCas9 technology for live-cell labeling of endogenous 
genomic sites. a) Schematic representation of a EGFP-fused dCas9 protein, describing its mechanism 
of sequence recognition. The dCas9 protein as well as the target site sequence are color coded in 
purple. The image was taken from (Chen et al., 2016a). b) Fluoresce microscopy image documenting 
the high flexibility of the CRISPR/dCas9 system. The EGFP-tagged protein displays a focal 
accumulation at 3 sites, when used to targeted single copy genes (middle panel), and multiple loci, when 
combined with a sgRNA recognizing repetitive telomeric sequences (right-hand pannel). The targeting 
specificity was validated by using a control guide RNA targeting the irrelevant GAL4 locus, where no 
distinct localization patterns were obtained. The image was taken from (Chen et al., 2013).  
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Importantly, by contrast to ZF and TALE proteins, the association of the dCas9-sgRNA 
complex with the target genomic site is based on inducing a local double-stranded DNA 
unwinding that might have negative effects on the local chromatin environment, for 
instance by disturbing nucleosomal positioning or binding of transcription factors (Chen 
et al., 2016a; Sternberg et al., 2014). To evaluate this effect, the dynamics of dCas9-
labeled telomeres was compared to the movement of these genomic sites when 
detected by fluorophore-tagged telomere-binding proteins such as TRF1. This 
comparison revealed that the dynamics of the telomeres as well as the integrity of 
telomere shelterin complexes were unperturbed, indicating that the dCas9-labeling 
technology has no detrimental effects on the local chromatin environment, at least not 
at the resolution of the experiment (Chen et al., 2013). Assessment of other genomic 
sites showed nevertheless that some sequences, such as enhancers, are more 
sensitive to dCas9 binding indicating that the influence of this technology on the local 
chromatin environment, has to be more intensively assessed on a locus-by-locus basis 
(Chen et al., 2013; Gilbert et al., 2014a, 2014b). 
All in all, the recent years have been marked by a boost in the availability of custom-
made DNA-targeting devices, which can be used to specifically detect and track 
endogenous genomic sites in living mammalian cells.  While each of these tools comes 
with a unique set of advantages and limitations, they all enable the ideally unperturbed 
visualization of endogenous genomic loci, without the need of exogenously modify 
these sites. In this work, this technological progress was used as a basis for the 
generation of novel epigenetic biosensors, with which the status and dynamics of 
specific epigenetic signals can be assessed at the level of endogenous genomic loci 
in living cells.      
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2 Principal aims of the study  
Since its discovery in 1948 by Hotchkiss, DNA methylation has become a topic of 
intense and exciting investigations. Although the importance of this mark was 
highlighted by early genetic studies and decades of active research, the epigenetic 
pathways centered around the 5mC signal are far from being fully understood 
(Jurkowska and Jeltsch, 2016). For instance, although mammalian DNMTs were 
identified almost  2 decades ago, the mechanisms that are responsible for controlling 
the chromatin targeting and enzymatic activity of these machineries are still poorly 
understood (Jurkowska and Jeltsch, 2016; Li et al., 1992; Okano et al., 1998).  
It was the aim of this work, to explore three main directions of research, with the 
ultimate goal of shedding mechanistic and methodological insights into the generation 
and maintenance of DNA methylation patterns. 
 
2.1 Investigation of the role played by ATP hydrolysis in the 
interaction of HELLS with chromatin 
 
In the first project, I aimed to study the role played by ATP hydrolysis in regulating the 
interaction (and implicitly the chromatin remodeling function) between chromatin and 
the putative remodeler HELLS. This protein is a not well-understood member of the 
DNA methylation pathway and the knock-out  of Hells was reported to lead to 50-70% 
reduction in global DNA methylation levels (Dennis et al., 2001). Currently, it is 
hypothesized that HELLS is necessary for facilitating the access of the DNA 
methylation machinery to sites of compacted chromatin, although an ATP-dependent 
or chromatin remodeling role could not be convincingly demonstrated for HELLS so far 
(Burrage et al., 2012; Dennis et al., 2001). The aim of the current study was to use the 
ATPase-deficient HELLS variant developed by Burrage et al. (2012) in order to 
systematically compare the chromatin association properties of this mutant with that of 
wild-type HELLS in a cellular-based approach. Insights from this work should 
contribute to a better understanding of how the association between HELLS and 
chromatin mediates the drastic effects that the protein has on the global DNA 
methylation patterns. 
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2.2 Investigation of the regulatory effects of MeCP2 on DNMT3A 
activity 
 
The aim of the second project was to address the interaction between the de novo 
DNA MTase DNMT3A and the 5mC reading protein, MeCP2. This study was based on 
previous findings from our lab documenting a direct interaction between MeCP2, and 
an inhibitory effect on DNMT3A activity in vitro. The goals of the present work were to 
test whether this interaction can be also detected at the level of endogenously 
expressed proteins, in the mouse brain, and if the inhibitory effect observed on 
DNMT3A activity in vitro is recapitulated in a cellular context, upon overexpression of 
MeCP2 in cell culture, as well as in the mouse brain, where both DNM3A and MeCP2 
are highly expressed. Furthermore, by taking into account the recently reported 
allosteric regulation of DNMT3 enzymes by interacting proteins, a third goal was to 
explore if the inhibition of DNMT3A via MeCP2 also occurs through an allosteric 
mechanism. Understanding the functional cross-talk between the readers and writers 
of DNA methylation could advance our knowledge of the feedback loops that are in 
place to control the activity of DNA methyltransferases.   
 
2.3 Development of epigenetic sensors for locus-specific detection 
of epigenetic marks in living mammalian cells 
 
In the third project, the focus was placed on the development and application of a novel 
method that would enable for the first time the locus-specific visualization of epigenetic 
modifications, in particular, DNA methylation, in living mammalian cells. This scientific 
strive was fueled by the fact that although the importance of epigenetic heterogeneity 
and dynamics is extensively acknowledged in the field of Epigenetics, no methods are 
currently available to enable the dynamic tracking of the status of target epigenetic 
modifications, with locus specific resolution (Bheda and Schneider, 2014). The aim of 
this project was to resolve this urgent and unmet technological demand by developing 
an array of modular epigenetic biosensors for live-cell microscopy applications. In its 
design and implementation, this technological platform was to be based on a 
combination between the recent advancements in the field of genomic targeting (Chen 
et al., 2016a)  and the high epigenetic mark specificity of naturally-occurring protein 
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reading domains (Kungulovski et al., 2015b; Yamazaki et al., 2007). For microscopy-
based visualization, it was planned to test and compare two types of fluorescent 
outputs, namely BiFC and FRET. The most robust system out of these was to be 
selected and incorporated into several sensors detecting different epigenetic marks 
and DNA sequences. The successful design and implementation of this novel 
technological platform should significantly contribute to a better understanding of how 
specific epigenetic signatures are set, erased and maintained during cellular 
development and pathogenesis. 
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3 Materials and methods 
Most of the methodology used in the course of this work is described in detail in the 
Method sections of Appendix 1-3. Techniques with high relevance for the results 
described here are summarized in a project-specific manner in the paragraphs bellow. 
Particular emphasis is put on the description of unpublished methodology.  
3.1 ATP hydrolysis regulates chromatin release of HELLS 
3.1.1 Cloning of mammalian expression vectors, tissue culture, and 
transfections 
The sequence encoding for the full-length mouse cells was sub-cloned from 
pGeneLSHF (Yan et al., 2003a) as an N-terminal fusion into pEYFP-C1 and pECFP-
C1 as described in the Methods section of Appendix 1. The K237Q mutation in the 
HELLS ATPase domain was generated via site-directed mutagenesis using the 
megaprimer mutagenesis protocol described in (Jeltsch and Lanio, 2002). The identity 
of both constructs was confirmed by sequencing covering the whole open reading 
frame.  
NIH3T3, HEK293 (American Type Culture Collection), iMEF and Suv39H1/H2 DKO (a 
kind gift of Dr. T. Jenuwein) were grown at 37°C in a humidified atmosphere, 5% CO2 
using Dulbecco’s modified Eagle’s medium high glucose supplemented with 10% heat 
- inactivated calf serum. The iMEF-specific extra supplements are described in the 
Methods section of Appendix 1. Transient transfections with either Fugene HD 
(Promega) or jetPRIME (peqlab) were performed according to the manufacture’s 
recommendations. Transfected cells were cultured for 24 – 72 h before being used for 
downstream analysis as described in the Methods section of Appendix 1. For 
mammalian protein purification, HEK293 cells were transfected with linear 
polyethyleneimine MW 250,000 (PEI) (Polysciences, Inc.) at a ratio DNA: PEI of 1: 3 
(w/w). The reagent preparation and transfection procedure were implemented as 
described in (Longo et al., 2013). 
3.1.2 Chromatin fractionation assay and western blot analysis 
To assess the chromatin interaction strength of wild-type and ATPase-deficient 
HELLS, NIH3T3 cells were subjected 72 h after transfection to a biochemical extraction 
protocol adapted after (Yan et al., 2003a) and described in more detail in the Methods 
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section of Appendix 1. Briefly, the harvested cells were first re-suspended in 
cytoskeleton (CSK) buffer containing 0.5% Triton X-100 (vol/vol) to solubilize proteins 
that only loosely associate with chromatin. Following a 3 min centrifugation step at 5 
000 x g, the resulting pellet was digested with RNase-free DNase I in CSK buffer with 
NaCl adjusted to 50 mM, to elute proteins that are tighter bound to chromatin. Finally, 
the nuclear matrix pellet remaining after a 3 min centrifugation step at 5 000 x g was 
solubilized in 8M urea, to release tight-binding chromosomal proteins. Equal volumes 
of protein extracts were then separated on a 15% SDS-PAGE by electrophoresis and 
transferred onto a nitrocellulose membrane. Following primary antibodies were used 
for detection: EYFP (Clontech, 632592), Lamin B (Santa Cruz, sc-6217) and HP1 
(Active Motif, 39979). Detection of horseradish peroxidase-coupled antibodies was 
performed by enhanced chemiluminescence with Western Lightning Plus ECL reagent 
(PerkinElmer) according to the manufacturer’s instructions. The resulting signal was 
visualized and analyzed as described in the Methods section of Appendix 1.  
3.1.3 Preparation and imaging of fixed cells 
For inspecting the cellular localization patterns of wild-type and ATPase-deficient 
HELLS, transfected NIH3T3 cells were fixed with 4% formaldehyde solution as 
described in the Methods section of Appendix 1. For 2% paraformaldehyde solution 
fixation, the original 4% stock was diluted in PBS shortly before fixation. Imaging was 
performed on a LSM 710 Zeiss confocal microscope, the imaging conditions are 
specified in the Methods section of Appendix 1.  
3.1.4 Live cell imaging and fluorescence recovery after photobleaching 
To examine the associate of wild-type and ATPase-deficient HELLS in the absence of 
formaldehyde cross-linking, live cell imaging was performed. The kinetic behavior of 
the proteins was analyzed by FRAP, as described in more detail in the Methods section 
of Appendix 1. Briefly, for FRAP experiments the cells were seeded on 35 mm 
Fluorodish cell culture dishes (World Precision Instruments). 24 to 48 hours after 
transfection, the growth media was replaced with imaging media containing no phenol 
red. Live cell imaging was performed on a LSM 710 Zeiss confocal microscope 
equipped with a Plan-Apochromat 63x/1.40 Oil DIC M27 objective and a XL-LSM 710 
S1 incubation chamber for temperature and CO2 control.  For bleaching, a circular 
region with a diameter of 1 µm was chosen, positioned to cover one of the visible 
pericentromeric heterochromatic foci. To accommodate for differences in protein 
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mobility, for wild-type HELLS, images were recorded at an interval of 300 msec. For 
the HELLS K237Q variant, the image recording time was increased to 1 second, to 
minimize photobleaching and account for the slower protein exchange rate. The FRAP 
work-flow included 9 pre-bleach images, 5 bleaching cycles with 100% laser intensity, 
and acquisition of up to 100 post-bleach images. During acquisition, the 514 nm laser 
line was turned down to 4% to minimize photobleaching and phototoxicity. Image 
analysis was performed by extracting the mean pixel intensity of the bleached area, 
over time and normalizing against fluctuations in laser intensity by dividing against the 
average mean fluorescence intensity of the 9 pre-bleached images. The signal was 
scaled according to the fluorescence decrease observed in an unbleached area of the 
same cell. To derive the half recovery time, t1/2, and the mobile fraction percentage, a 
double-component exponential model was used. Further details on data acquisition 
and analysis are provided in the Method section of Appendix 1.  
3.1.5 Recombinant HELLS expression and purification 
For 6xHis tag-mediated affinity chromatography, full-length HELLS was sub-cloned 
from the mammalian expression vector described above into the pET-28a (+) vector 
(Novagen), as a C-terminal 6xHis fusion. The BL21-CodonPlus(DE3)-RIL Escherichia 
coli protein expression strain was used for recombinant protein production. For this, 
the cells were grown in LB medium at 37 °C until an OD (600 nm) of 0.6 – 0.7. Protein 
expression was induced by addition of 1 mM of isopropyl-β-D-thiogalactoside (IPTG) 
followed by shifting the culture to 16 °C shaking at 160 rpm for 12 h. To support protein 
expression and folding, a final concentration of 5 mM MgSO4 and 50 µM ZnCl2 was 
present in the growth medium.  
For purification, the harvested cells were resuspended in sonication buffer (20 mM Tris 
pH 6.8, 500 mM KCl, 20 mM imidazole, 0.1% β-mercaptoethanol, 10% glycerol) 
including protease inhibitor (Sigma) and lysed by sonication with 20 cycles, 15 s, 30% 
power (BANDELIN SONOPLUS). The lysate was next cleared by centrifugation at 
18,000 rpm for 1 h 20 min and applied to a pre-equilibrated Ni-NTA column (Genaxxon 
bioscience). To remove impurities, the column was washed with 250 mL of wash buffer 
consisting of sonication buffer supplemented with 80 mM imidazole. Finally, the bound 
protein was eluted by increasing the final imidazole concentration to 300 mM. To 
remove the imidazole and decrease the salt amount, the eluted fraction with the highest 
concentration was dialyzed for 3 h against dialysis buffer (20 mM Tris pH 6.8, 200 mM 
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KCl, 0.1% β-mercaptoethanol, 10% glycerol). The purified protein was aliquoted and 
kept at -80 °C for long term storage. To assess the quality of the isolated protein, 10 
µL recombinant HELLS were run on a 16% SDS-PAGE which was transferred to 
nitrocellulose membrane for detection of His-tagged proteins. For this purpose, an anti-
his mouse monoclonal primary antibody (Roche Diagnostics, Cat. No. 11922416001), 
followed by an HRP-coupled anti-mouse secondary antibody (GE Healthcare, Car No. 
NA931V) were used.    
3.1.6 Isolation of HELLS-EYFP from HEK293 cells via GFP-Trap®  
72 h after transient transfection, HEK293 cells were harvested by scraping and 
resuspended in lysis buffer (20 mM HEPES, 500 mM KCl, 0.5% NP-40, 0.2 mM 
PMSF).  To facilitate the release of nuclear proteins, the lysate was passed periodically 
through a 26G needle, during the 30 min lysis time. The total lysate was cleared by 
centrifugation at 20,000 rpm for 15 min, followed by 1:4 dilution with lysis buffer lacking 
NP-40 and incubation with 30 µL GFP-Trap® agarose slurry (chromotek). Following a 
2 h binding time, the beads were washed with lysis buffer. The bound proteins were 
finally released by boiling for 10 min at 95°C in 50 µL 2x SDS-sample buffer. The quality 
of the eluted proteins was assessed by SDS-PAGE gel stained with colloidal 
Coomassie BB.  
3.2 Allosteric control of DNMT3A by MeCP2 
3.2.1 Cloning, bacterial expression, and recombinant protein purification 
For in vitro pull-downs and methylation assays, the TRD domain of MeCP2 (aa 170-
325) was cloned into pGEX-6P2 (GE Healthcare) as an N-terminal GST fusion. The 
ADD domain of DNMT3A (aa 472-610) was, in turn, cloned into pMAL-c2X (New 
England Biolabs) as an N-terminal MBP fusion. Site-directed mutagenesis was 
performed according to the protocol presented in (Jeltsch and Lanio, 2002) and as 
described in the Methods section of Appendix 2.  
The expression and purification conditions of TRD MeCP2, ADD DNMT3A, and 
DNMT3A2 were described in detail in the Methods section of Appendix 2. In brief, the 
BL21-CodonPlus(DE3)-RIL expression E.coli strain was used for protein production. 
Protein expression was induced by addition of 1 mM IPTG when the culture reached 
an OD600 of 0.6 – 0.8. The expression was routinely performed in LB medium, at 20 
°C. A final concentration of 5 mM MgSO4 and 50 µM ZnCl2 (for ADD and DNMT3A2) 
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was used in the growth medium to support cellular growth and the folding of Zn2+ - 
binding proteins. Cells were lysed by sonication and the pre-cleared supernatant was 
applied on a pre-equilibrated GST-sepharose 4B (GE Healthcare), Ni-NTA (Genaxxon 
Bioscience) or amylose column (New England Biolabs), depending on the affinity tag 
of the expressed protein (see the Methods section of Appendix 2). Bound proteins 
were eluted with sonication buffer supplemented with 10 mM reduced glutathione, 300 
mM imidazole or 10 mM maltose, respectively. The quality of the purified proteins was 
routinely assessed by SDS-PAGE gel stained with colloidal Coomassie BB.  
3.2.2 GST pull-down experiments 
To map the interaction interface between DNMT3A and MeCP2 and assess the 
strength of the observed binding, GST pull-downs were performed with recombinantly 
expressed proteins, as described in the Methods section of Appendix 2. Routinely, 20 
μL of Glutathione-Sepharose 4B beads, pre-equilibrated with interaction buffer (25 mM 
Tris pH 8.0, 100 mM KCl, 5 mM MgCl2, 10% glycerol, 0.1% NP-40, 200 μM PMSF) 
were used to immobilize 10-15 µg of the different GST-tagged proteins. Following 
washing, the putative His- or MBP-tagged interaction partner was added (10-15 µg) 
and the complex was allowed to form for 1 h at 4 °C with mixing end over end. 
Unspecific/week binding interactors were next removed by washing the beads with 
interaction buffer containing 300-600 mM KCl. Finally, the beads were re-suspended 
in SDS gel loading buffer and incubated for 10 min at 95 °C to release bound 
complexes. The resulting supernatant was loaded on a 12 % SDS-PAGE gel. Proteins 
were detected by Western blotting or Coomassie BB staining as indicated. Some 
experiments were conducted in the presence of recombinant hHistone H3.1 (M2503S, 
NEB), as detailed in the results section of Appendix 2. 
3.2.3 Endogenous co-immunoprecipitation assay 
To test if the interaction between DNMT3A and MeCP2 can also occur outside of the 
in vitro assays and cellular overexpression conditions, immunoprecipitation of 
endogenous DNMT3A was performed from mouse brain extracts (see detailed 
description in the Methods section of Appendix 2). In brief, whole brains from 16-week 
old C57Bl/N female mice were homogenized by grinding on liquid N2, followed by 
douncing in NP-40 lysis buffer with a tight pestle and sonication with EpiShear as 
described in the Methods section of Appendix 2. To facilitate the extraction of 
chromatin-associated proteins, the lysate was digested with Benzonase (Novagen) for 
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2h rotating at 4°C. Following pre-clearing with Protein A Sepharose CL-4B (GE 
Healthcare), 2.5 mg lysate were incubated overnight with either 15 µg anti-Dnmt3a 
antibody (sc-2070, Santa Cruz) or non-related rabbit IgG control (ab9106, Abcam). 
The antibody-bound complexes were retrieved by incubation with Protein A Sepharose 
beads, for 6 h, rotating at 4°C. After washing, the complexes were eluted by boiling in 
SDS gel loading buffer. The samples were next analyzed by western blot with an anti-
MeCP2 monoclonal antibody (Cell Signaling), followed by incubation with an HRP-
linked anti-rabbit IgG light chain specific antibody (Jackson ImuunoResearch).   
3.2.4 In vitro DNA methylation activity assay 
To assess the influence of the TRD domain on the DNMT3A2 activity,  in vitro 
methylation assays with various biotinylated DNA substrates and labeled SAM were 
performed, following the protocol of (Roth and Jeltsch, 2000) and as described in detail 
in the Methods section of Appendix 2. Routinely, 1 µM 30mer oligonucleotide DNA 
and 0.76 μM [methyl-3H]-AdoMet (PerkinElmer Life Sciences) were added to the 
reaction mixture and the samples incubated at 37 °C. The concentration of DNMT3A2, 
TRD and DNMT3 CD used in the assays are described in the Methods section of 
Appendix 2. To follow the time-course of the methylation reaction, aliquots of 2 µL 
were taken from the reaction mixtures in duplicates at time points between 2 and 30 
min and applied to one well of an avidin-coated microplate. The reaction was stopped 
by addition of excess of unlabeled SAM in buffer containing 500 mM NaCl. To release 
the bound DNA, the unspecific nuclease from Serratia marcescens was used. Finally, 
the released radioactivity was measured using liquid scintillation counting and the 
average count per minute of the duplicates was plotted against time. Linear regression 
was used to obtain the slopes of the initial linear parts of the time courses.  
3.2.5 Generation of stable cell lines and global DNA methylation analysis of 
HCT116 DNMT1 hypomorph cells  
To study the effect of MeCP2 on DNMT3A mediated methylation in cells, the HCT116 
DNMT1 hypomorphic cell line was used (kindly provided by Prof. Bert Vogelstein, 
HHMI, USA), with reduced levels of DNA methylation (Rhee et al., 2002). As described 
in more detail in the Method section of Appendix 3, the cells were grown in McCoy’s 
5A medium (Gibco) supplemented with 10% heat-inactivated calf serum and 2 mM L-
glutamine (Sigma), at 37 °C in a saturated humidity atmosphere containing 5% CO2. 
For stable cell line generation, the cells were transiently transfected with either pEYFP-
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MeCP2 or pEYFP, followed by drug selection with 0.5 mg/mL G418 (Sigma-Aldrich).  
Single clones were hand-picked and propagated in culture for circa 2 months before 
genomic DNA isolation. LC-ESI-MS/MS analysis of DNA methylation in genomic DNA 
was performed as described in (Bashtrykov et al., 2014; Schiesser et al., 2013).  
3.2.6 Isolation of genomic DNA for whole genome bisulfite sequencing and data 
analysis 
To analyze the effect of MeCP2 on DNA methylation in a biologically relevant setup, 
the methylome of the brain isolated from wild-type and MeCP2 KO mice was compared 
(for a detailed description see the Methods section of Appendix 2). To this end, the 
brain of one 6-8-week old wild type (C57BL/6J) and MeCP2 KO (B6.129P2(C)-
Mecp2m1.1Bird/J) male mouse, respectively, was obtained from the Jackson 
Laboratory (Bar Harbor, ME USA).  The tissue was mechanically disrupted by grinding 
in a mortar under liquid nitrogen, followed by Proteinase K digestion at 55°C for 4 
hours. The genomic DNA was next extracted with the PureLink® Genomic DNA Mini 
Kit (InvitrogenTM), according to the instructions of the manufacturer. The integrity of the 
isolated material was assessed by agarose gel electrophoresis.  
WGBS library preparation and analysis was performed in cooperation with the group 
of Alexander Meissner (Harvard), following the procedures described in the Methods 
section of Appendix 2. The library was sequenced for 100-bp paired-end reads on an 
Illumina HiSeq 2500 sequencer, and the reads were aligned to the mm9 version of the 
mouse genome. To identify differentially methylated regions, the data was binned into 
1kb tiles and the methylation was calculated as the coverage-weighted mean of 
methylation at CG sites within the tile.   
3.2.7 In vitro CDKL5 kinase assay  
To test if the TRD domain of MeCP2 can be phosphorylated by CDKL5, in vitro kinase 
reactions were set up, containing 15 µg wild-type or R306C GST-tagged TRD, 0.125 
µg recombinant CDKL5 (abcam, ab159606) and 2.5 µCi of [γ-32P]-ATP. The proteins 
were incubated for 1 h at 30°C in kinase assay buffer (25 mM MOPS, pH 7.2, 12.5 mM 
ß-glycerol-phosphate, 25 mM MgCl2, 5 mM EGTA and 2 mM EDTA, 0.25 mM DTT) 
according to the instructions of the manufacturer. The reactions were stopped by 
boiling in SDS gel loading buffer, followed by separation on 12% SDS-PAGE. The 
phosphorylation signal was detected by autoradiography.  
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3.3 Locus-specific visualization of chromatin modifications in living 
mammalian cells 
3.3.1 Cloning of BiAD anchor and detector modules for BiFC-based epigenetic 
sensors 
Details on the constructs used for the BiFC-based readout of locus-specific epigenetic 
modifications are found in the Methods sections of Appendix 3. In brief, three anchor 
modules were used for specific binding of target genomic sequences: a three-fingered 
ZF array for the recognition of a 9-bp long sequence within mouse major satellite 
repeats (5’-GGC GAG GAA-3’) (Lindhout et al., 2007), a TALE protein for the 
recognition of a 20-bp long sequence located within human alpha satellites (5’-TAG 
ACA GAA GCA TTC TCA GA-3’) (Ma et al., 2013) and a CRISPR/dCas9 system 
coupled with a sgRNA recognizing the alpha satellite repeats in the pericentromeric 
region of chromosome 9 (5’-TGG AAT GGA ATG GAA TGG AA 3’) (Ma et al., 2015).  
To detect the 5mC mark, the methyl binding domain of human MBD1 (aa 1-113) was 
amplified out of HEK293 according to the borders described in (Yamagata, 2010). For 
the recognition of H3K9me3, the chromodomain of mouse HP1β (aa 1-76) was isolated 
out of NIH3T3 cDNA. Binding pocket mutants were generated by megaprimer 
mutagenesis according to the protocol described in (Jeltsch and Lanio, 2002).  
To construct the BiFC-based biosensors, the anchor and detector modules were fused 
via Gibson assembly N- or C-terminally to the split Venus fragments (split site aa 210) 
as described in the Methods section of Appendix 3. To enable immunofluorescence 
and western blot detection a 3xFLAG tag was fused to all constructs. A 14 to 18aa-
long GS-rich linker was used to separate the anchor/detector modules from the split 
fluorophore.   
3.3.2 Cloning of BiAD anchor and detector modules for FRET-based 
epigenetic sensors 
To detect H3K9me3 levels at mouse major satellite repeats, the HP1β chromodomain 
and the three-finger ZF described above were fused N-terminally to the mVenus and 
mCerulean FRET fluorophores, respectively (Addgene plasmids no. 27794 and no. 
27796; (Koushik et al., 2006)). Cloning of the individual domains was performed using 
the Gibson assembly® mix (New England Biolabs®). A GS-rich 18-aa long flexible 
linker was used to separate the domains from the fluorophore. While the MBD domain 
contained an endogenous nuclear localization sequence, the SV40 NLS was used to 
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target the HP1β chromodomain to the nucleus. As a negative control for the FRET 
measurements, the SV40 NLS was fused to mVenus and used in the FRET assay 
instead of the ZF-Venus construct. As a positive control the Cerulean-5-Venus plasmid 
was used (Addgene plasmid no. #26394), where the two fluorophores are directly 
linked by a 5 aa-long linker (Koushik et al., 2006). All fusion constructs were expressed 
under the control of a CMV promoter.  
3.3.3 Cloning of epigenetic modification enzymes 
The cloning of the enzymes used for rescuing the DNA methylation and H3K9me3 
levels is described in more detail in the Methods section of Appendix 3. Briefly, a CMV 
promoter was used to drive the expression of full-length wild-type of catalytically 
inactive C1226A human DNMT1. The enzyme was fused LSSmKate2 (Addgene 
plasmid no. 54795) for microscopy-based detection. For cloning the dox-inducible 
SUV39H1 expression, the CDS encoding for the full-length mouse enzyme was cloned 
into the pSIN-TRE3G-PGK-Puro-IRES-rtTA3 backbone (Fellmann et al., 2013). Both 
the wild type and the catalytically inactive H324L variant were cloned as mRuby2 
fusions for microscopy-based detection (Addgene plasmid no. 54768). 
3.3.4 Cell lines 
The cell culture conditions used in this project are described in detail in the Methods 
section of Appendix 3. Cell lines used during the course of this work are: HEK293, 
NIH3T3 (American Type Culture Collection), wild-type and Suv39h1h2-/-  iMEFs (gift of 
Prof. Thomas Jenuwein, MPI Freiburg), p53−/− and p53-/-/Dnmt1−/− iMEFs (gift of Prof. 
Howard Cedar, Institute for Medical Research Israel-Canada), wild-type and HCT116 
DNMT1 hypomorphic cells (kindly provided by Prof. Bert Vogelstein, HHMI, USA).  
3.3.5 BiFC assay, data collection and analysis   
The constructs, amounts of plasmids as well as transfection reagents used for the BiFC 
assay are described in detail in Appendix 3, Methods and Supplementary Tables 1-4.  
Routinely, a plasmid encoding for the mRuby2 red fluorophore was transfected in 
parallel to the BiAD modules to facilitate the identification of successfully transfected 
cells. pcDNA3.1 (invitrogen™) was used as a carrier plasmid in the cases where the 
plasmid amount used for the modules and mRuby2 did not sum up to the total amount 
recommended by the manufacturers of the transfection reagent. The complementation 
signal was imaged 24-48 h after transient transfection with the BiAD modules. For this, 
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the slides were fixed for 10 min at RT with 4% formaldehyde and finally mounted in 
ProLong™ Diamond antifade (invitrogen™). 
The slides were imaged on a LSM 710 Zeiss confocal microscope equipped with a 
Plan-Apochromat 63 ×/1.40 Oil DIC M27 objective. The laser excitation wavelengths, 
as well as emission collection windows, are indicated in Appendix 3, Supplementary 
Table 5. For enhanced sensitivity, the BiFC channel signal was routinely directed to a 
QUASAR 34-channel photomultiplier unit (Carl Zeiss). Image analysis was performed 
in ImageJ 1.51a. The number of cells counted for each experimental set-up as well as 
the number of biological repeats and classification of the BiFC signals was documented 
in Appendix 3, Supplementary Table 6.  
3.3.6 Detection of H3K9me3 levels at mouse major satellite sequences with 
FRET by acceptor photobleaching 
For the FRET assay, NIH3T3 cells were seeded on high precision no.1.5 (170± 5 µm) 
glass slides (Carl Zeiss) and transfected with Fugene HD (Promega) according to the 
instructions of the manufacturer. Routinely 1.5 µg total DNA and a DNA: Fugene HD 
ratio of 1:4 were used. The DNA mixture consisted out of 750 ng plasmid encoding for 
the mVenus-tagged protein and 750 ng plasmid encoding for the mCerulean-tagged 
protein. For the fusion construct, mCerulean-5-mVenus 1500 ng plasmid were used. 
24 h after transient transfection with the corresponding plasmids, the cells were 
washed with PBSCa2+Mg2+ and fixed for 10 min at room temperature with 2 % freshly-
prepared formaldehyde solution. This was followed by a 30 min washing time with 
PBSCa2+Mg2+: This long washing time was important since it was previously shown that 
formaldehyde fixation quences mVenus and mCerulean differentially, and 20 min are 
needed for fluorescence recovery to reach steady state (Chen et al., 2006). The cells 
were mounted into freshly prepared Mowiol (Harlow and Lane, 2006) and kept at 8°C 
for long term storage. Before imaging, the slides were allowed to equilibrate at room 
temperature for at least 2 h to prevent movement artifacts caused by thermal 
fluctuations.   
The acceptor photobleaching workflow was adapted after (Verveer et al., 2006). Here 
it was important that the mounting media does not contain fluorescence stabilizers 
such that the mVenus photobleaching kinetics is not influenced. The slides were 
imaged on a LSM 710 Zeiss confocal microscope equipped with a Plan-Apochromat 
63 ×/1.40 Oil DIC M27 objective. The equipment was allowed to equilibrate for at least 
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30 min before performing the measurements such that the 514 nm laser line is 
stabilized. For mVenus bleaching, 8 iterations with the 514 nm laser power set at 80% 
were performed. For enhanced sensitivity, the mCerulean fluorescence (excited with 
the 405 nm diode) was routinely directed to the QUASAR 34-channel photomultiplier 
unit (Carl Zeiss). Each of the two fluorophores was imaged before and after mVenus 
bleaching. The 16-bit images were analyzed in ImageJ 1.51a where the fluorescence 
signal of the donor channel was visualized using the Fire lookup table (LUT) for 
improved detection of the fluorescence intensity in-between the imaging time points.  
3.3.7 5-aza-dC treatment 
To assess the dynamic range of BiAD sensor 2 to changes in DNA methylation levels, 
HEK293 were depleted of DNA methylation by 5-aza-dC (Sigma-Aldrich®, cat. no.  
A3656) treatment as described in the Methods section of Appendix 3. In brief, the 
treatment was performed over a period of 3 days at a final drug concentration of 2 µM 
in the cell culture medium. The drug was dissolved in 50% acetic acid and replaced on 
a daily basis. As a control, an equal volume of solvent was added to the cell culture 
medium. The efficiency of the demethylation treatment was assessed by digestion of 
genomic DNA isolated from the treated cells, with the 5mC-inhibited enzyme HpaII 
(New England Biolabs®). For the DNA methylation time course experiment, the cells 
were transfected fresh 2 days prior to the imaging time point (Methods section, 
Appendix 3). 
3.3.8 Generation and assay implementation of the Tet-SUV39H1-mRuby2 
doxycycline-inducible iMEFs 
To generate a suitable cellular model system for assessing the dynamic range of BiAD 
sensor 4, doxycycline-inducible cells lines were created by retroviral infection of the 
parental Suv39DKO iMEFs, with viruses delivering transgenes encoding for either the 
SUV39H1 or the catalytically inactive H342L mutant, both fused to mRuby2. A detailed 
description of the infection and drug selection procedure is provided in the Methods 
section of Appendix 3. To test the applicability of the BiAD sensor 4, the expression 
of the SUV39H1 variants was induced with 1 µg mL-1 doxycycline, 48 h before the cells 
were transfected with the biosensor modules. The cells were cultured in the presence 
of dox for another 48 h prior fixation for imaging. 
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4 Results 
4.1 An ATPase-deficient variant of the SNF2 family member HELLS 
shows altered dynamics at pericentromeric heterochromatin  
The easy access of the DNA methylation machinery to the target DNA, as it is 
embedded within the context of tightly wrapped chromatin, is essential for both 
mammalian embryonic development and adult tissues homeostasis. While the 
maintenance methyltransferase DNMT1 predominantly methylates the newly 
replicated DNA, which is mostly nucleosome-depleted, the de novo DNMT enzymes 
must work on a chromatinized substrate (Felle et al., 2011). Several experimental 
approaches have highlighted the severe accessibility challenge posed to the DNA 
methylation machinery by stably positioned nucleosomes and densely compacted 
chromatin. Accordingly, high-resolution methylome profiling performed upon 
reintroduction of DNMT3 enzymes in Dnmt triple knockout embryonic stem cells, 
revealed a predominant accumulation of methylated CG sites in linker DNA, and their 
exclusion from nucleosomal-bound DNA sequences (Baubec et al., 2015). This kinetic 
data set is supported by several in vitro and in vivo studies aimed at elucidating the 
effect that nucleosome positioning has on DNA methylation (Felle et al., 2011; Kelly et 
al., 2012).  
Among all genomic sites that carry the 5mC mark, the tightly compacted constitutive 
chromatin found at mammalian pericentromeres poses arguably the highest 
accessibility challenge for the de novo DNMT machinery (Huang et al., 2004). 
Pericentromeric regions are the embodiment of two antagonistic requirements. On the 
one hand, these sites need to be compacted in a dense heterochromatic structure, to 
prevent genomic instability caused by the spontaneous recombination of their highly 
repetitive DNA content (Soldi and Bonaldi, 2013).  On the other hand, pericentromeric 
DNA needs to be transiently exposed to allow the spatial access to a whole artillery of 
chromatin complexes, responsible for maintaining pericentromeric repeats in a silent 
epigenetic state. The transition between these two antagonizing chromatin 
environments is under the control of chromatin remodeling enzymes, proteins that use 
the energy derived from ATP hydrolysis to modulate the interaction between the DNA 
and the core histone proteins, thereby facilitating the access of epigenetic factors to 
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the chromatinized template  (Hota and Bruneau, 2016; Ryan and Owen-Hughes, 
2011).  
The putative chromatin remodeler HELLS is an important regulator of mammalian DNA 
methylation. The deep involvement of this protein in the DNA methylation pathway is 
highlighted by the 50-70% drop in global 5mC levels detected in Hells-/- cells. 
Importantly, repeat elements such as major satellites are among the sites that are most 
affected by the loss of HELLS, suggesting that this protein is important for facilitating 
the access of the DNA methylation machinery to sites of highly compacted chromatin 
(Dunican et al., 2013; De La Fuente et al., 2006; Yu et al., 2014). While this model 
recently received experimental support, as the Arabidopsis HELLS homolog DDM1 
was found to be required for the methylation of linker H1-rich heterochromatic sites, a 
nucleosome remodeling activity has so far not been demonstrated for the mammalian 
protein HELLS (Zemach et al., 2013). Therefore, it is still unclear if and how a putative 
chromatin remodeling property of HELLS, together with its associated ATPase activity, 
contribute to the biological function of the protein. In this project, an ATPase-deficient 
HELLS variant was used to investigate the of ATP hydrolysis in regulating the 
interaction between HELLS and chromatin.   The results of this work were summed up 
in a paper published in the Journal of Molecular Biology and attached here as 
Appendix 1. The main findings of this study are succinctly outlined in the following 
section.       
Although baculovirus-expressed HELLS failed to remodel nucleosomal arrays in vitro, 
the protein contains the conserved Walker A and B motifs, which are part of the ATP 
binding pocket of SNF2 enzymes (Burrage et al., 2012; Flaus et al., 2006). Targeted 
exchange of a conserved K residue within the GKT box to A or Q, was previously 
reported to inactivate the ATPase function of different remodelers, and generate an 
HELLS variant that was no longer able to promote efficient phosphorylation of the 
histone variant H2AX under DNA damage conditions (Burrage et al., 2012; Richmond 
and Peterson, 1996; Rowbotham et al., 2011). However, the effect of this mutation on 
the association between HELLS and chromatin has not been investigated to date.  
Wild-type HELLS was previously reported to localize to the nuclear compartment, 
where the protein was found to tightly associate with chromatin in actively proliferating 
cells. This interaction was dependent on the cell cycle and the confluence of the 
culture, with confluent G0-arrested cells having the least protein bound to chromatin 
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(Yan et al., 2003a). To assess whether the ATPase inactivating mutation influences 
the strength of chromatin binding by HELLS, I performed biochemical fractionation 
assays with G0-arrested NIH3T3 cells, 72 h after transient transfection with either the 
wild-type or the ATPase-deficient HELLS protein.  For this, the lysed cells were 
extracted step-wise with three buffers that differentially solubilize proteins depending 
on their chromatin binding strength (Figure 31) (Yan et al., 2003a). In line with previous 
reports showing a loose association of HELLS with G0 chromatin, the wild-type protein 
was predominantly detected in the Triton X solubilized fraction (around 60% of the total 
protein amount). By contrast to this, the ATPase-deficient mutant displayed a tighter 
association with chromatin, with only ~ 30% of the protein being released upon Triton 
X extraction and > 60% being detected in the urea-denatured pellet (Figure 31 and 
Appendix 1, Figure 1b).  The reliability of the cellular fractionation protocol was 
confirmed by inspecting the extraction pattern of endogenous HP1β and Lamin B 
proteins, which served as markers for the DNase-released and the urea-solubilized 
fraction, respectively (Figure 31). As a reference for the Triton X-released fraction, a 
separate extraction on cells transfected with an EYFP-NLS fusion was performed. This 
also revealed the expected release of the chromatin-inert fluorophore in the first 
extraction step (Appendix 1, Figure S1a).  Together, these results that were confirmed 
in 3 independent biological repeats (Appendix 1, Figure 1b), suggest that a functional 
ATPase domain is important for the release of HELLS from chromatin.  
Figure 31| The wild-type and the ATPase-deficient HELLS display differential association with 
chromatin. Western blot detection of exogenous HELLS in fractions isolated from NIH3T3 cells, 72 h 
post transient transfection with either the EYFP-tagged wild-type HELLS (left-hand panel) or the EYFP-
tagged ATPase deficient variant (right-hand panel). To assess the chromatin association strength of the 
two proteins, transfected cells were subjected to a stepwise extraction procedure, with buffers 
containing Triton X, DNase I and urea, respectively. Endogenous HP1β and Lamin B were used as 
references for the DNase I-released and urea-solubilized fraction, respectively. This figure was taken 
from Figure 1, Appendix 1.       
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Prompted by the outcome of the cellular fractionation assay, fluorescence microscopy 
was next employed to inspect whether these differences in chromatin association are 
also reflected in the cellular localization of the wild-type and the ATPase-deficient 
HELLS. To this end, mouse fibroblasts were transfected with the fluorophore-tagged 
proteins and imaged either in formaldehyde-fixed state (Appendix 1, Figure 2) or 
under live-cell conditions (Appendix 1, Figure 3). These experiments revealed that 
the mutant HELLS was predominantly associated with pericentromeric 
heterochromatin repeats, as detected by co-staining with the nuclear dies DAPI (for 
fixed cells) and DRAQ5 (for living cells). In contrast, the wild-type HELLS showed a 
rather fine-granular pattern and less frequent colocalization with mouse chromocenters 
(Appendix 1, Figure 2a, b and d; Figure 3; Figure S3). Interestingly, the proportion 
of cells displaying pericentromeric-localized wild-type HELLS varied depending on the 
imaging conditions. Accordingly, in formaldehyde-fixed cells, this localization was 
observed for only 4% of the counted population, whereas under live cell imaging 
conditions this increased to 59% (Appendix 1, Figure 2d and Figure 3). This variable 
localization was all the more surprising since pericentromeres were repeatedly shown 
to be the major site of HELLS activity (Huang et al., 2004; Yan et al., 2003a).  By 
contrast to wild-type HELLS, the K237Q variant displayed a strong pericentromeric 
localization in > 80% of the transfected cells, regardless of wheatear the imaging was 
performed on fixed or living cells. (Appendix 1, Figure 2d and Figure 3). Importantly, 
in co-transfection experiments using wild-type ECFP-HELLS and EYFP-HELLS 
K237Q, the difference in localization between the two proteins was still maintained 
under chemical fixation, indicating that this is not an artifact of the imaging setup 
(Appendix 1, Figure 2c). Taken together, these results demonstrate that the 
localization of wild-type HELLS is sensitive to formaldehyde fixation and that the 
ATPase-deficient variant has an altered interaction with the tightly compacted 
pericentromeric chromatin.   
Noteworthy, a similar formaldehyde dependent alteration of cellular localization 
patterns was previously reported for other nuclear proteins and was shown to be 
dependent on the nuclear mobility of these factors  (Schmiedeberg et al., 2009).  
Accordingly, rapidly moving proteins may not be as efficiently fixed at their target sites 
by comparison to less mobile proteins. The fact that the localization of the K237Q 
variant was not drastically affected by the fixation process hints at the different mobility 
of wild-type and ATPase-deficient HELLS at pericentromeric heterochromatin. To test 
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this hypothesis, FRAP experiments were next performed on cells transfected with 
either the wild-type or the ATPase-deficient HELLS. Since the differences in 
localization were the strongest at chromocenters, these sites were chosen to evaluate 
the mobility of the two protein variants. Strikingly, the two EYFP-tagged variants 
displayed a dramatically different bleaching behavior in the FRAP assay. Accordingly, 
while the K237Q HELLS was bleached with a high efficiency of 64%, the fluorescence 
signal was only reduced by about 34% for the wild-type protein (Figure 32a and 
Appendix 1, Figure 2c). In addition, the post-bleaching recovery of the fluorescence 
signal was distinct between the wild-type and the ATPase-deficient HELLS. While for 
the wild-type protein, the fluorescent signal recovered rapidly, in the case of the K237Q 
mutant, this occurred over a longer time scale. (Figure 32a and Appendix 1, Figure 
4a and b). Quantitative analysis of the FRAP data according to a 2-component 
exponential fit model revealed a 2-fold increase in the mobile protein fraction and a 
Figure 32| The wild-type and the ATPase-deficient HELLS show distinct dynamics at 
pericentromeric heterochromatin. a)  Representative time frames of exemplary FRAP series (pseudo 
colored) for the wild-type (top panel) and mutant HELLS (bottom panel). Images were taken at the 
indicated time points after the bleach pulse. The bleached chromocenters were indicated with the white 
arrows. For clarity, a zoom-in of the bleached area was included in the lower part of each time-point. 
The panel was adapted after Figure 4, Appendix 1.  b) Average % mobile fraction determined for the 
wild-type and ATPase-deficient HELLS. c) Average fluorescence half recovery time determined for the 
EYFP-tagged wild-type and ATPase-deficient HELLS. Error bars represent standard error of the mean 
based on measurements performed on 9 cells for wild-type HELLS and on 11 cells for the mutant 
protein. Panels b) and c) were taken from Figure 5, Appendix 1.  
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circa 5-fold shorter half recovery time (t1/2) for the wild-type HELLS, by comparison to 
the ATPase-deficient mutant (Figure 32b and c and Table 1). Together, these results 
indicate that the inability of HELLS to hydrolyze ATP slows down the exchange of the 
protein at compacted pericentromeric sites.   
Although it is known that pericentromeric repeats are the major sites of HELLS activity, 
the chromatin signals that trigger the recruitment of the protein to these sequences are 
not clear (Yan et al., 2003a). Since these sites are rich in H3K9me3, the localization of 
HELLS to chromocenters was next inspected in cells that do not express the 
SUV39H1/H2 proteins (Suv39DKO), enzymes responsible for setting the 
heterochromatic H3K9me2/3 mark (Maison et al., 2002). Interestingly, in these cells, 
the wild-type HELLS displayed a twofold increased enrichment at pericentromeres by 
comparison to its transfection in wild-type mouse fibroblast cells (89% vs 43%). An 
effect on the localization of the ATPase-deficient mutant could not be observed 
(Appendix 1, Figure 6b and c). These data indicate that while a defect in the 
H3K9me3 cascade does not influence the recruitment of HELLS to chromatin, this 
pathway might modulate the release of the protein from chromocenters.  
Collectively, the data provided by this study highlight for the first time the importance 
of a functional ATPase module for the interaction between HELLS and highly 
compacted chromatin and suggests that an intact H3K9me3 pathway may be involved 
in the release of the protein from these heterochromatic sites. 
To further dissect the functional difference between the wild-type and the K237Q 
HELLS variant, defined in vitro biochemical assays need to be employed. Since 
baculovirus-purified HELLS was reported to lack remodeling activity in vitro (Burrage 
et al., 2012),  I took advantage of the EYFP-tagged HELLS constructs to purify both 
protein variants from mammalian HEK293 cells. By comparison to bacterial and insect 
systems, mammalian cells are preferable for the expression of proteins of mammalian 
origin, since they provide a full set of post-translational modifications that can support 
protein folding and activity (Wurm, 2004). That PTMs are important for the folding of 
recombinant HELLS is highlighted by the fact that unlike the bacterially-expressed 
HELLS WT  HELLS K237Q      HELLS WT HELLS K237Q
61.3 ± 3.6 27.5  ±  2.1 0. 8 ±  0.1 4.8 ±  0.5
mobile fraction [%] recovery t1/2 [s]
Table 1| Mobility parameters determined for the wild-type and the ATPase-deficient HELLS based 
on the FRAP measurements 
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protein, which could only be obtained with a poor quality (Figure 33a), the mammalian 
expression system enabled me to purify the full-length HELLS to homogeneity and with 
little degradation (Figure 33b). Similar high-quality preparations could be obtained for 
both the wild-type and the ATPase-deficient variant (Figure 33b). These proteins can 
now be used to further dissect the importance of ATPase activity on the function of 
HELLS and assess whether a functional ATPase module affects the recruitment and 
activity of the DNMT machinery.     
Figure 33| Expression of HELLS in mammalian cells results in a better quality protein 
preparation. a) Coomassie-stained SDS-PAGE gel (left panel) and α-His western blot detection (right 
panel) of 6xHis-labeled HELLS isolated out of the BL21-CodonPlus(DE3)-RIL Escherichia coli protein 
expression strain. The expected size of the full-length HELLS-6xHis protein was annotated with a blue 
arrow. As visible on the Coomassie-stained gel, recombinant HELLS could not be obtained with good 
quality. The western blot detection of 6xHis signals revealed that recombinant HELLS underwent severe 
degradation during the expression and/or purification process. b) Coomassie-stained SDS-PAGE 
documenting the good quality of the EYFP-tagged wild-type and K237Q HELLS proteins, after their 
expression and EYFP-mediated isolation out of HEK293 cells. The expected size of the full-length 
EYFP-HELLS was annotated with a blue arrow. 
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4.2 Chromatin-dependent allosteric regulation of DNMT3A activity 
by MeCP2 
Accurate targeting and control of the mammalian DNA methylation machinery are 
essential for the setting and maintenance of the DNA methylation patterns (Jeltsch and 
Jurkowska, 2016). Recently, a seminal structural study dramatically contributed to our 
understanding of the chromatin-mediated control of DNMT3A activity (Guo et al., 
2015c). The authors found that the N-terminally located ADD domain can bind to the 
catalytic domain of the DNMT3A enzyme at two distinct sites: an allosteric open, and 
an inhibitory closed site (Figure 17a and b, in the Introduction section). Depending on 
the interface, different amino acids were shown to be responsible for making contacts 
between the ADD and the CD.  For instance, Y526 contacts the CD in the allosteric 
but not in the autoinhibitory conformation, whereas D531 contacts the CD in the 
autoinhibitory but not in the allosteric conformation. The binding of the ADD in the 
closed conformation was shown to block the access of the DNA to the active center 
and impair catalysis (Figure 17b). Interestingly, binding of unmodified histone H3 to 
the ADD domain triggered a large structural change, stabilizing the catalytically active 
conformation of the enzyme (Figure 17c). Based on these findings, the authors 
proposed a model in which the chromatin recruitment is temporally uncoupled from the 
activation of DNMT3 proteins, to ensure that the enzymes methylate the underlying 
DNA only when the neighboring nucleosomes carry appropriately modified histone tails 
(Guo et al., 2015c). Taking into account that the ADD domain was shown to function 
as a protein-protein interaction platform, it is conceivable that other proteins, apart from 
histone H3,  may also affect the activity of DNMT3 enzymes through an allosteric 
mechanism (Jeltsch and Jurkowska, 2016). Experimental support for this hypothesis 
is nevertheless lacking to date. 
The biological role of DNA methylation is to a large extent mediated by methyl binding 
proteins (Fournier et al., 2012). Among these, the chromosomal protein MeCP2 is one 
of the most prominent actors (Lewis et al., 1992; Meehan et al., 1992). Originally 
discovered due to its strong binding to symmetrically methylated CG, MeCP2 was also 
recently reported to recognize methylcytosine in a non-CG context (Gabel et al., 2015). 
Functionally, the protein is involved in many biological pathways where its influence on 
transcription was shown to be both negative and positive (Ragione et al., 2016). These 
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ambivalent effects might be in part mediated by the interaction of MeCP2 with proteins 
that depending on the chromatin environment can have either transcriptional 
repressive or activating roles (Ragione et al., 2016). Indeed, apart from the MBD 
domain, MeCP2 contains a TRD domain shown to mediate the interaction with other 
proteins and in particular with co-repressor complexes (Ballas et al., 2005; Fuks et al., 
2003b). The critical biological role of this 5mC binding protein is highlighted by the 
expression levels of MeCP2 in the adult brain, where the protein is nearly as abundant 
as the histone octamers (Skene et al., 2010). In this tissue, MeCP2 was recently 
reported to be involved in controlling the methylation-induced repression of long 
neuronal genes (Gabel et al., 2015). This was attributed to the mCA reader function of 
the protein. Mutations in MeCP2 are frequently associated with the occurrence of the 
neurodevelopmental Rett syndrome (Smeets et al., 2012).     
Interestingly, while both DNMT3 and MeCP2 are part of the same epigenetic pathway 
and are highly expressed in adult neurons, where they play important roles, the 
functional crosstalk between these two central epigenetic players has not been 
investigated to date (Guy et al., 2011). In this project, the possibility of a direct 
interaction between DNMT3A and MeCP2 was explored, and its mechanistic effects 
on DNMT3A activity were assessed. The resulting data were summarized in the form 
of a manuscript that has been submitted for review (attached here as Appendix 2). 
The main findings of this study are succinctly outlined in the following section.       
Previous work from our group has uncovered that recombinantly purified MeCP2 and 
DNMT3A can directly interact, and that this association has a negative effect on the 
activity of DNMT3A activity as based on in vitro methylation assays using the 
radioactively-labeled SAM cofactor (Appendix 2, Figure 2a and Figure 3a). The 
interfaces responsible for the interaction were mapped through in vitro pull-downs with 
serially truncated proteins. These proposed the ADD domain of DNMT3A and the TRD 
domain of MeCP2 as the two main interacting points (Appendix 2, Figure 2b-d). I 
validated the self-sufficiency of these domains for the interaction by performing pull-
downs with GST-tagged TRD and MBP-tagged ADD domains, where a direct binding 
between the two proteins could be detected (Figure 34a). The strength of their 
association was tested by performing the assay at 300 mM and 600 mM KCl. The 
detected binding was observed to be equally strong under both buffer conditions, 
highlighting the tight and specific association between the TRD and the ADD domain. 
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In addition to the wild-type TRD, the Rett R306C variant was also included in the assay. 
However, this protein was found to bind to the ADD domain equally well, indicating that 
this mutation does not perturb the interaction between the two domains. An equivalent 
pull-down was performed with the TRD domain and DNMT3A2, a naturally occurring 
shorter isoform of DNMT3A that has a truncated N-terminal part but still contains the 
ADD and PWWP domains (Chen et al., 2002). Also here, increasing the stringency of 
the pull-down by using 600 mM KCl did not weaken the interaction between DNMT3A2 
and the TRD of MeCP2 indicating that the interaction between the two proteins is not 
mediated by electrostatic interactions (Appendix 2, Figure 3c). Finally, to confirm that 
the two proteins are also able to form a complex in vivo, co-immunoprecipitation of 
endogenous DNMT3A from mouse brain protein extracts was performed. Also here 
MeCP2 could be specifically detected in the pulled-down material, but not in the IgG 
control (Appendix 2, Figure 2f). Collectively, these results show that MeCP2 is a 
novel, strong and biological relevant interactor of DNMT3A.    
Previous data from our lab have linked the association between MeCP2 and DNMT3A 
to a ~ 50% decrease in enzymatic activity (Appendix 2, Figure 4a-c). To inspect 
whether this effect depends on the concentration of TRD used in the assay, I performed 
in vitro methylation kinetics with increasing amounts of the TRD domain. Indeed, a 
strong inhibitory effect (> 95%) could be observed when using a 2.4 excess of TRD 
Figure 34| MeCP2 strongly interacts with DNMT3A in vitro has a concentration-dependent 
inhibitory effect on the activity of the enzyme. a) GST-pulldown with recombinant GST-TRD and 
MBP-ADD (the size of which was annotated with an arrow), performed under low and high salt 
conditions. The Rett TRD 306C mutant was included in parallel to the wild-type protein. The Coomassie-
stained SDS-PAGE gel documents a strong and salt-resistant direct interaction between the TRD and 
ADD domains. GST was used as a negative control, instead of the TRD-GST domain fusion. This panel 
was taken from Figure 3, Appendix 2. b) Inhibition of DNMT3A activity by addition of increasing 
amounts of TRD using an unmethylated 30 bp-long substrate, with a central CG site. Control refers to 
a reaction without added TRD. All error bars indicate the standard error of the mean for minimum 2 
biological replicates. This panel was taken from Figure 4, Appendix 2. 
 
 87 
 
(Figure 34b). By contrast, the non-interacting DNMT3A CD, which was used as 
negative control, displayed only a minor decrease in activity indicating that the 
inhibition of DNMT3A by TRD is not caused by competition for the DNA substrate or 
direct effects on the CD (Figure 34b). Importantly, kinetics measurements performed 
with a DNMT3B variant, created to mimic the borders of DNMT3A2, showed a 
comparable 50% inhibitory effect on the activity of the protein, in the presence of 3 µM 
TRD (Appendix 2, Figure S9). This suggests that MeCP2 affects the activity of 
DNMT3A and DNMT3B through the same mechanism.  
Finally, to test whether this strong in vitro effects are also recapitulated in a cellular 
context, I derived cell lines stably expressing the YFP-tagged full-length MeCP2 under 
the control of a constitutive CMV promoter. Following clonal selection and a 2-month 
culture period, genomic DNA was isolated and subjected to LC-MS/MS to quantify the 
global 5mC levels. The mass spectrometry analysis was performed in collaboration 
with the group of Dr. Thomas Carell, at the Ludwig-Maximilans University in Munich. 
To better track the potential changes in DNA methylation upon introduction of MeCP2, 
the HCT116 DNMT1 hypomorphic cell line was used for the experiments. These cells 
contain an impaired DNMT1 activity and display a drop of about 20% in the global DNA 
methylation levels (Egger et al., 2006; Rhee et al., 2002). In line with the in vitro data, 
a roughly twofold decrease in the global methylation levels could be detected in the 
genomic DNA isolated from two independent clones expressing EYFP-MeCP2. This 
effect was MeCP2-specific as a control cell line expressing only EYFP did not show a 
significant change in the global DNA methylation levels (Appendix 2, Figure 7a). 
Together, these data indicate that MeCP2 functions as a strong inhibitor of DNMT3 
activity both in vitro and in cells.  
Having clearly demonstrated that MeCP2 and DNMT3A are strong and direct 
interactors and that their association leads to a concentration-dependent inhibition of 
DNMT3A activity, the mechanistic of this effect was next addressed. As mentioned 
above, the interaction between MeCP2 and DNMT3A was found to be mediated via 
the ADD domain of the enzyme. This was recently reported to allosterically modulate 
the activity of DNMT3A (Guo et al., 2015c). To elucidate whether the association with 
the TRD domain influences the DNMT3A activity through an allosteric mechanism, two 
conformationally locked variants of the enzyme were prepared by site-directed amino 
acid exchange in the ADD domain (Figure 35a). To this end, the D531 residue was 
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exchanged to R to generate a DNMT3A variant that preferentially adopts an 
autoinhibitory conformation. To obtain a protein variant where the allosterically open 
conformation form is preferred, the Y536E exchange was introduced. Importantly, 
these mutations were performed in the context of the full-length DNMT3A2 enzyme to 
enable the analysis of the crosstalk between the ADD and the CD domains in the 
presence of the MeCP2 TRD. In vitro kinetic assays with the DNMT3 variants revealed 
that the D531R mutant selectively lost the inhibition by MeCP2 (Figure 35b). This 
finding suggests that through its interaction, the TRD domain allosterically stabilizes 
the autoinhibitory conformation of DNMT3A, causing an inhibitory effect on the 
enzymatic activity. Since the unmodified histone H3 was previously found to act as an 
allosteric activator of DNMT3A, kinetics, and pull-down experiments were performed 
in the presence of recombinant H3 to test whether this can relive the TRD-mediated 
inhibition. Indeed, both assays revealed that upon addition of unmodified H3, the 
interaction between the TRD and ADD was weakened, and the inhibitory effect lost 
(Figure 35c and Appendix 2, Figure 5c).  Together, these results indicate that the 
binding of H3 to the ADD domain can disrupt the TRD interaction and relieve the TRD-
mediated inhibition of DNMT3A. 
Finally, to study the influence of MeCP2 on DNA methylation in a biological relevant 
tissue, whole-genome bisulfite sequencing (WGBS) on genomic DNA isolated from the 
Figure 35| MeCP2 allosterically inhibits the activity of DNMT3A and this inhibition can be relieved 
by the unmodified histone H3. a)  Model of the structure of a DNMT3A fragment comprising ADD (red 
or orange) and catalytic domain (blue). The ADD domain can bind to the catalytic domain at two 
interfaces, at an allosteric site (ADD domain colored in red, Y526 is at the interface), which is stabilized 
by binding of the H3 tail, and at an inhibitory binding site (ADD domain colored in orange, D531 is at the 
interface). The image was taken from Figure 1, Appendix 2. b) Inhibition of DNMT3A2 wild-type (wt) 
and its conformationally locked variants by TRD. The inhibition is lost in the D531R variant carrying a 
mutation, which destabilizes the autoinhibitory conformation. c) DNA methylation activities of DNMT3A2 
and DNMT3A2 bound to H3 peptide (amino acid sequence 1-19, 25 µM) in the absence and presence 
of TRD (3 µM) showing the loss of TRD inhibition in the presence of H3 peptide. Error bars represent 
standard error of the mean for 2 biological replicates. Panels b) and c) were taken from Figure 5, 
Appendix 2. 
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whole brain of wild-type and Mecp2 knockout (KO) mice was performed (Guy et al., 
2001). Sequencing and bioinformatic analysis were performed in collaboration with the 
group of Dr. Alexander Meissner, at the Harvard Stem Cell Institute, USA. Unlike the 
overexpression experiments in HCT116 cells, no global effects on the DNA methylation 
levels could be observed in the brain of Mecp2 KO animals. This is in line with 
published whole-brain gene expression analysis where only minor changes could be 
detected upon Mecp2 knockout (Tudor et al., 2002). To investigate if the absence of 
MeCP2 is rather connected with locus-specific methylation effects, the data were 
binned in 1 Kb tiles to identify differentially methylated regions (DMRs). This analysis 
revealed that the site-specific effects of MeCP2 loss were ambivalent. Accordingly, 85 
hypomethylated regions were found, with 24 showing more than 50% reduction in 
methylation levels; 84 hypermethylation DMRs were discovered, 23 displaying more 
than 50% increase in methylation (Appendix 2, Figures 7b and c). Importantly, 48% 
(41/85) of all hypomethylated DMRs and 63% (53/84) of all hypermethylated DMRs 
were found to be associated with MeCP2 binding sites (statistically expected were 
<10%) (Appendix 2, Figure 7d). This indicates that the observed changes in DNA 
methylation are indeed a direct effect of MeCP2 loss.  
In summary, the data provided by this study propose MeCP2 as a novel and direct 
interactor of DNMT3. The discovered interaction was found to negatively affect the 
activity of the enzyme, through an allosteric mechanism. Importantly, the strong 
inhibitory effect could be relieved by addition of unmodified histone H3. Furthermore, 
WGBS on brain tissue isolated from Mecp2 KO animals showed that MeCP2 has a 
punctuate but strong effect on DNA methylation levels. It is anticipated that the in vivo 
effect of this interaction might be more accentuated if specific brain areas such as the 
hypothalamus and cerebellum were analyzed, as here the lack of MeCP2 was reported 
to have stronger effects on gene expression (Ben-Shachar et al., 2009; Chahrour et 
al., 2008; Sugino et al., 2014).    
In a recent study, Ebert and colleagues discovered that the interaction between 
MeCP2 and its interacting partner NCoR is modulated by activity-dependent 
phosphorylation of T308, within the MeCP2 TRD (Ebert et al., 2013). Importantly, the 
exchange of T308 to A in mice was shown to lead to the abnormal expression of 
activity-regulated genes and cause Rett-like symptoms. Molecularly, the alanine 
substitution was proposed to destroy a phosphorylation basophilic motif. Although the 
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kinase responsible for this modification was not identified, this paper proposed 
phosphorylation as a key chemical modification, through which the interaction between 
MeCP2 and other proteins can be regulated.  
A kinase that is strongly associated with the MeCP2 pathway is the S/T cyclin-
dependent kinase-like 5 (CDKL5). This is a nuclear protein whose expression in the 
nervous system was found to overlap with that of MeCP2, during neural maturation 
and synaptogenesis. Moreover, mutations in CDKL5 were reported to give rise to a 
Rett-like phenotype (Scala et al., 2005; Tao et al., 2004; Weaving et al., 2004). CDKL5 
was found to interact with and phosphorylate MeCP2 in vitro, although the 
phosphorylation site was not identified so far (Mari et al., 2005). By analogy to the T308 
site it might, however, be that, if occurring on the TRD domain, CDKL5 phosphorylation 
may mediate the interaction between MeCP2 and DNMT3A.  
To test if, the TRD domain of MeCP2 is modified by CDKL5, an in vitro phosphorylation 
assay with recombinant proteins and 32P-labeled ATP was performed. Taking into 
account that the R306C exchange is found in an S-rich ESSIRSVQE sequence motif, 
and thereby may act similarly as the T308A exchange, the wild type TRD domain as 
well the Rett R306C variant were included in the assay. As documented in Figure 36, 
a strong and specific phosphorylation activity of CDKL5 towards the TRD domain could 
Figure 36| CDKL5 phosphorylates the TRD domain of MeCP2 in vitro. Coomassie-stained SDS-
PAGE gel (top panel) and corresponding autoradiography (bottom panel) after in vitro phosphorylation 
of wild-type (WT), R306C TRD-GST and GST with γ-32P ATP and CDKL5. To exclude that the 
phosphorylation signal is caused by kinases co-purifying with the GST-tagged proteins, matching 
reactions with ATP, but without CDKL5 were performed. The red arrow denotes the expected size of 
the TRD-GST variants, while the black one denotes the position of CDKL5. The gel was exposed for 20 
min to film, before development.  
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be detected. The equally strong in vitro modification of the TRD R306C variant 
indicated nevertheless that this amino acid exchange did not negatively influence the 
CDKL5 target motif. The position of the modified residue as well as its potential effect 
on the association between the TRD and other interactors, such as DNMT3A, awaits 
further investigations.  
4.3 Modular fluorescence complementation sensors for live cell 
detection of epigenetic signals at endogenous genomic sites 
The sequence-specific investigation of chromatin marks is mandatory for a locus-
resolved understanding of epigenetic signaling cascades. To underpin the functional 
outcome of epigenetic modifications, as they are incorporated in highly dynamic and 
heterogeneous networks, methods that enable the live cell detection of epigenetic 
marks are essential. This technological development needs to satisfy two main 
requirements. First, epigenetic modifications have to be specifically detected at the 
level of endogenous, unmodified genomic sequences. This is important for a 
comprehensive understanding of the function of epigenetic marks, as they are set, 
maintained and erased in the native chromatin environment and not when incorporated 
in artificially introduced reporter sequence or on genetically engineered genomic loci 
(Hathaway et al., 2012; Stelzer et al., 2015). Second, owing to their high dynamics and 
large cell-to-cell heterogeneity, epigenetic modifications need to be assessed at the 
level of single living cells (Bheda and Schneider, 2014; Levsky et al., 2002; Meissner 
et al., 2008; Shalek et al., 2013; Stelzer et al., 2015). This is important for the accurate 
deconvolution of the dynamics and heritability of defined epigenetic states (Bheda and 
Schneider, 2014; Farlik et al., 2015). Despite their large impact on the development in 
the field of Epigenetics, methods that simultaneously satisfy these two important 
criteria are so far not available (Bheda and Schneider, 2014). In this project, this urgent 
and unmet technological need was addressed by developing an array of modular 
fluorescence complementation-based epigenetic sensors for live-cell microscopy 
applications. The results of this work were summarized in a manuscript submitted for 
review and attached here as Appendix 3. The main findings of this study are succinctly 
outlined in the following section.       
To achieve locus-specific readout of target epigenetic modifications in living cells, a set 
of modular bimolecular fluorescence (BiFC)-based sensors was designed. These 
consisted of pairwise combinations between an anchor module, for DNA sequence-
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specific recognition, and a detector module, specifically binding to a defined chromatin 
modification. For simultaneous access of DNA sequence and epigenetic information, 
both of these devices were fused with complementary non-fluorescent N- and C- 
terminal fragments of the monomeric Venus fluorophore (VenN and VenC, 
respectively) (Morell et al., 2009; Ohashi and Mizuno, 2014). The working hypothesis 
was that if the epigenetic modification of interest is present at or next to the target 
genomic locus, binding of the anchor and detector modules in close spatial proximity 
would lead to the reconstitution of a functional Venus fluorophore that would emit a 
stable, microscopically-trackable fluorescent signal (Figure 37a). This fluorescence 
complementation approach has several advantages over traditional co-localization 
microscopy and was already successfully employed by other groups to visualize 
various types of intermolecular interactions in living cells and even whole animals 
(Hudry et al., 2011; Kerppola, 2006, 2008; Kodama and Hu, 2012). Accordingly, while 
co-localization microscopy is limited by diffraction to a resolution of 200 nm, 
fluorescence complementation can only occur if both parts approach each other at 
intermolecular distances of 7 nm or less, dramatically improving the genomic resolution 
with which the epigenetic mark can be detected (Yu et al., 2013). To assess the 
chromatin mark-dependency of the novel BiAD (Bimolecular Acceptor Donor) sensors, 
binding pocket mutations in the detector module were used (Figure 37a), as well as 
Figure 37| Concept of the BiAD sensors for site-specific detection of DNA methylation. a) 
Schematic diagram depicting the concept of the BiAD sensors designed for locus-specific readout of 
DNA methylation. Simultaneous readout of DNA sequence (orange line) and epigenetic mark (purple 
lollypop) is achieved by transfecting mammalian cells with an engineered anchor module (shown in 
orange) for sequence specific DNA binding, and a detector module (shown in purple) specifically 
recognizing methylated CG sites. Both of these devices are fused to complementary N- and C- terminal 
parts of Venus. If transfected in a cell line where the DNA sequence of interest is methylated, the docking 
of the anchor and detector modules in close spatial proximity will lead to the generation of a stable 
fluorescent signal. By contrast, inactivating the methyl binding pocket of the 5mC reader (b) or 
transfecting the intact modules in a cell line with globally reduced 5mC levels (c) is expected to give rise 
to lower fluorescence signals, as the detector module cannot longer stably dock onto chromatin.  All 
panels of this figure were taken from Figure 1, Appendix 3. 
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cell lines with globally reduced levels of the investigated epigenetic mark (Figure 37b). 
In both settings, a strong reduction in the formation of the BiFC signal was expected, 
owing to the impaired docking of the detector module onto chromatin.  
To target endogenous genomic loci, different types of engineered DNA-binding 
domains, a viz. Zinc-finger, a TAL effector and a CRISPR-dCas9 system, were 
selected due to their high sequence specificity (Chen et al., 2016a; Kungulovski and 
Jeltsch, 2016). As detector domains, I took advantage of naturally occurring chromatin 
reading domains that bind specifically to defined epigenetic modifications (Kungulovski 
et al., 2015b; Musselman et al., 2012). Accordingly, the MBD of MBD1 was employed 
for the detection of 5mC, while the chromodomain of HP1β (HP1 CD) was used for the 
recognition of H3K9me3 (Bannister et al., 2001; Hendrich and Bird, 1998; Jacobs et 
al., 2002; Li et al., 2015a; Ohki et al., 2001). 
To establish the complementation system, the BiAD sensor 1 was designed to readout 
5mC found at major satellites of mouse pericentromeric heterochromatin. These sites 
were used as a proof-of-concept chromatin environment since they harbor large 
amounts of DNA methylation and form highly abundant tandem repeat arrays, that can 
be easily microscopically visualized by DAPI-staining (Appendix 3, Supplementary 
Fig. 1a). For the detection of major satellites, a zinc finger protein (ZF) designed to 
specifically bind the 5’-GGCGAGGAA-3’ motif within these sequences was used 
(Lindhout et al., 2007). As documented in Figure 38a, co-transfection of mouse 
fibroblasts with the VenN-fused-anchor together with the VenC-fused MBD detector 
gave rise to strong fluorescence signals that were specifically formed at satellites 
repeat sequences as concluded based on the co-localization of the BiFC signal with 
DAPI foci (Appendix 3, Fig. 2b, upper panel). The sensor displayed an excellent signal 
reconstitution with around 90% of the counted transfected cells showing productive 
BiFC fluorescence (Appendix 3, Fig. 2d). To test the 5mC specificity of the BiAD 
sensor, mouse fibroblasts were triple transfected with the BiAD modules and an MBD-
Cerulean construct. This experiment revealed that the BiFC signal was only formed at 
sites that were also bound by MBD-Cerulean, highlighting the 5mC specificity of the 
sensor (Appendix 3, Fig. 2b, lower panel). To further validate this result, the methyl 
binding pocket of the MBD detector module was inactivated by site-exchanging of the 
conserved R44 residue to Q  (Ohki et al., 2001). Implementation of this protein variant 
in the BiFC assay resulted in a dramatic reduction in the intensity of the reconstituted 
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fluorescence signal (Figure 38b, Appendix 3, Fig. 2c, d and Supplementary Figs. 
3b, 6). As a second negative control, the sensor was transfected in Dnmt1-/- mouse 
fibroblasts, cells that do not express the maintenance methyltransferase DNMT1, and 
consequentially display a severe reduction of global DNA methylation levels (Casas-
Delucchi et al., 2012). In line with the previous 5mC specificity data, the fluorescence 
complementation signal obtained with the BiAD sensor was strongly reduced also in 
this case (Figure 38c, Appendix 3, Fig. 2c, d and Supplementary Figs. 3b, 8, 9). 
Collectively, these results demonstrate the feasibility of the BiAD concept and indicate 
that the BiAD sensor 1 can be used to directly monitor the status of 5mC at repetitive 
DNA sequences in murine cells.  
Motivated by this outcome, the functionality of the system was next challenged by 
approaching a chromatin environment in which the anchor and detector modules do 
not co-localize optically. To this end, BiAD sensor 2 was designed for the specific 
detection of DNA methylation at alpha-satellite sequences found around human 
centromeres. Taking advantage of the modularity of the system, the already validated 
MBD module used for DNA methylation readout could be re-integrated into the human 
sensor. As anchor module, a TALE protein designed to specifically recognize the pan-
centromere target sequence 5’-TAGACAGAAGCATTCTCAGA-3’ was employed (Ma 
et al., 2013).  
Taking into account that human chromocenters are not as spatially defined as the 
murine ones, several variants of the detector and anchor modules where generated, 
in which the position of the VenN and VenC fragments was swapped around the core 
Figure 38| Development of the BiAD sensor 1 for specific detection of DNA methylation at mouse 
major satellite repeats. a) Representative fluorescence microscopy image of NIH3T3 cells captured 
48 h after transfection with the modules of the BiAD sensor 1. The bimolecular fluorescence 
complementation (BiFC) signal is shown in yellow. b) Representative fluorescence microscopy images 
documenting the 5mC-validation of the BiFC signals. The BiFC signal was lost with the MBD R44Q 5mC 
binding pocket mutant. c) Representative fluorescence microscopy images documenting the 5mC-
validation of the BiFC signals. The BiFC signal was lost in cells with globally reduced DNA methylation 
levels. A plasmid encoding for the red fluorophore mRuby2 was used as a transfection control. All panels 
of this figure were taken from Figure 2, Appendix 3. 
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modules. In addition, for increased protein flexibility, anchor variants with a longer 
linker separating the split fluorophore from the TALE protein were designed (Appendix 
3, Supplementary Fig. 12). The anchor-detector pair displaying the highest signal-to-
background ratio was selected for downstream specificity analysis, which 
demonstrated that alike BiAD sensor 1, this system displayed a high specificity for both 
the DNA sequence and the 5mC mark (Appendix 3, Fig. 3). Remarkably, despite the 
less compacted state of the pericentromeric chromatin in human cells in comparison 
to mouse cells, the optimized BiAD sensor 2 resulted in strong Venus reconstitution in 
circa 75% of the transfected cells (Appendix 3, Fig. 3d). 
Encouraged by the good performance of the BiAD sensor 2, the dynamic range of this 
tool was next explored. For this, two approaches were undertaken. 
In the first strategy, the sensor was transfected into the HCT116 DNMT1 hypomorphic 
cells with reduced global methylation, to test whether this change in DNA methylation 
is reflected in the BiFC yield of the sensor (Egger et al., 2006; Rhee et al., 2002). 
Indeed, transfection of the BiAD modules in this cellular background resulted in a 4-
fold reduction in the number of cells showing a strong and spotty BiFC signal by 
comparison to the wild-type cells (Appendix 3, Fig. 4a and c). Furthermore, the rescue 
of DNA methylation by re-introduction of an active DNMT1 protein in the hypomorphic 
cell line was successfully mirrored by a three-fold increase in the number of cells 
showing a strong spotty BiFC signal (Appendix 3, Fig. 4c). Importantly, no signal 
increase was observed when a catalytically inactive DNMT1 variant was used instead 
(Appendix 3, Fig. 4b and c). Together, these results provide strong evidence that the 
BiAD sensor can be used to detect changes in DNA methylation at alpha satellites in 
live human cells. 
In a second approach, the BiAD sensor 2 was used to monitor the changes occurring 
at alpha satellite sequences upon treatment of HEK293 cells with the strong DNA 
methylation inhibitor 5-aza-2'-deoxycytidine (5-aza-dC) (Fahy et al., 2012). In 
agreement with published literature and methylation-sensitive restriction digestion of 
genomic DNA isolated from the 5-aza-dC-treated cells, a strong decrease in the BiFC 
signal at 3 days after 5-aza-dC treatment and also at 2 days after drug removal could 
be detected (Appendix 3, Fig. 4d, e). Importantly, the effects of the drug were 
reversible, the signal of the sensor displaying a strong increase at 7 days post drug 
removal. After 2 weeks of recovery, a further increase in the number of cells with strong 
 96 
 
BiFC signals was noticed (Appendix 3, Fig. 4d, e). A comparable re-methylation 
kinetics was previously observed for Alu-repeats (Velicescu et al., 2002). Collectively, 
these data show that this BiAD sensor can be used to study locus-specific changes 
caused by epigenetic drugs in living cells.  
Motivated by the excellent performance of the BiAD approach, I aimed to increase the 
locus specific resolution of the detection system by incorporating the highly flexible 
nuclease-deficient Sp-dCas9 protein and its cognate sgRNA, to specifically target a 
pericentromeric sequence located only on human chromosome 9. As for the other 
tools, the newly generated BiAD sensor 3 also demonstrated an excellent 5mC and 
DNA-sequence specificity, as replacing the wild-type MBD for the MBD R44Q variant, 
as well as absence of the sgRNA, lead to a dramatic reduction in the number of cells 
displaying strong BiFC signals (Appendix 3, Fig. 5c, d and Supplementary Fig. 19). 
To evaluate the dynamic range of the novel BiAD sensor 3, 5-aza-dC was used to 
induce global DNA demethylation in the HEK293 cells. After 3 days of drug treatment, 
a ten-fold decrease in the number of strong BiFC-positive cells was observed 
(Appendix 3, Fig. 5e, f). All in all, these data clearly demonstrate that dCas9 can 
function as an anchor module and be incorporated into novel, 5mC-specific BiAD 
sensors. 
Having successfully developed several biosensors for the readout of DNA methylation 
at different target regions, I next aimed to develop a BiAD system to monitor the status 
of histone tail marks at endogenous genomic loci in living cells. As such, the BiAD 
sensor 4 was constructed, to specifically recognize the H3K9me3 marks that 
abundantly decorate mouse major satellite repeat sequences (Saksouk et al., 2015). 
To this end, the ZF module employed in BiAD sensor 1, was used as an anchor for the 
recognition of major satellite sequences, while the chromodomain of HP1β (HP1 CD) 
was employed as a specific H3K9me3 binder (Figure 39a). To test the chromatin mark 
specificity of the readout Suv39DKO cells were used, where H3K9me3 levels are 
globally reduced. Here, the stable docking onto chromatin of the HP1 CD should be 
impaired and the formation of the BiAD signal was expected to less efficient (Figure 
39b).  
It was expected that the readout of histone modifications imposes greater challenges 
on productive BiFC conformations due to the larger distance between the DNA binding 
site of the anchor module and the binding site of the detector module on the highly 
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flexible histone tails. For this reason, several versions of the two modules were 
generated, where the position of the split fluorophores was shuffled around the core 
modules (Appendix 3, Supplementary Fig. 22). The pair displaying the highest 
signal-to-background ratio was further selected for downstream specificity analysis 
using H3K9me3 antibody co-staining (Appendix 3, Figure 6a) and transfection of the 
modules in Suv39DKO iMEF cells (Appendix 3, Supplementary Fig. 21a, b). These 
experiments highlighted the H3K9me3 specificity of the novel sensor. The DNA 
sequence specificity was assessed by DAPI co-staining of BiAD-transfected cells, 
where the expected co-localization between the BiFC signal and mouse 
chromocenters was observed (Appendix 3, Fig. 6a). Remarkably, despite the higher 
Figure 39| Concept of the BiAD sensors for site-specific detection of H3K9me3 and development 
and application of BiAD sensor 4 to visualize dynamic changes in H3K9me3 levels at major 
satellite sequences. a) Schematic diagram depicting the concept of the BiAD sensor. Simultaneous 
readout of DNA sequence (orange line) and epigenetic mark (blue lollypop) information is achieved by 
transfecting mammalian cells with an engineered anchor module (shown in orange) for sequence 
specific DNA binding, and a detector module (shown in blue) specifically recognizing H3K9me3 marks. 
Both of these devices are fused to complementary N- and C- terminal parts of Venus. If transfected in 
a cell line where the nucleosome neighboring the DNA sequence of interest carry H3K9me3 marks, the 
docking of the anchor and detector modules in close spatial proximity will lead to the generation of a 
stable fluorescent signal. By contrast, transfecting the intact modules in a cell line with globally reduced 
H3K9me3 levels (b) is expected to give rise to lower fluorescence signals, as the detector module 
cannot longer stably dock onto chromatin. c) Application of the BiAD sensor to detect changes in 
H3K9me3 levels after dox induced expression of SUV39H1 in Suv39DKO iMEF cells. A BiFC signal 
could only be observed when the sensor was transfected in cells expressing SUV39H1 (middle panel). 
No BiFC signal could be detected in cells expressing the catalytically inactive H32L SUV39H1 mutant 
(bottom panel), or in the absence of dox (top panel). 
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mobility of histone tails, approx. 85% of the transfected cells displayed a strong BiFC 
signal (Appendix 3, Fig. 6c). This was comparable to what was obtained for the 5mC 
readout at these sites and documents the general applicability of BiAD sensors.  
Having been able to monitor the loss of H3K9me3 levels at major satellite repeats, I 
next tested whether the sensor can also be used to read out an experimentally induced 
gain in H3K9me3 at these sites. For this, stable Suv39DKO iMEF cells were generated, 
that express doxycycline (dox) inducible SUV39H1. The catalytically inactive (H324L) 
enzyme variant was included as a negative control. Remarkably, transfection of the 
BiAD modules in the wild-type SUV39H1-expressing cells 4 days after dox induction, 
gave rise to strong BiFC signals in around 65% of the counted transfected cells (Figure 
39c, Appendix 3, Fig. 6b, c). This corresponded to a 10 fold increase in the number 
of cells with strong BiFC fluorescence, by comparison to the signal obtained in the 
parent Suv39DKO iMEF cells. Importantly, this was directly dependent on the induction 
and activity of the SUV39H1 enzyme, with the induction of the SUV39H1 H324L variant 
not leading to an increase in fluorescence reconstitution (Figure 39c and Appendix 3, 
Fig. 6c). These data clearly demonstrate that the novel BiAD sensor can be used to 
specifically readout increasing H3K9me3 levels at major satellite repeats in live cells. 
In conclusion, in this study, a technological platform is presented allowing for the first 
time the direct assessment of the epigenetic status of defined genomic loci in living 
cells. The specificity and portability of the developed tools were assessed with several 
negative controls in several mammalian cell lines. Furthermore, with these devices, 
dynamic changes that occur in epigenetic marks upon drug treatment or induction of 
epigenetic enzymes, could be tracked for the first time in live cells and with locus 
specific resolution.  
While BiFC-based sensors are robust, highly sensitive and compatible with live cell 
imaging applications, this approach suffers from one inherent limitation: the production 
of the fluorescence signal reflects the binding of  the anchor and detector modules at 
the target site, but not their dissociation from the genomic locus (Buntru et al., 2016). 
Furthermore, some reports argued that the complementation of the fluorophore is 
irreversible, although this is still a matter of debate, and most probably depends on the 
type of proteins to which the split fluorophore is attached (Cole et al., 2007; Demidov 
et al., 2006; Guo et al., 2005; Morell et al., 2009). An alternative strategy to visualize 
dynamic protein-protein interactions relies of FRET. This is a distance dependent 
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process in which, through dipole–dipole interactions, an excited fluorophore molecule 
(the donor) transfers energy non-radiatively to another fluorophore molecule (the 
acceptor), resulting in acceptor emission (Buntru et al., 2016; Lakowicz, 2006). Since 
FRET relies only on the spatial proximity of the donor and acceptor fluorophores, the 
measured signal reflects both the association and dissociation of the interacting 
partners at the genomic target. For this reason, FRET-based approaches are more 
frequently used than BiFC techniques to study dynamic protein-protein interaction 
events (Piston and Kremers, 2007).  Nevertheless, because FRET signals are usually 
small, this readout requires sophisticated measurement techniques and is prone to 
data analysis artifacts (Hirata and Kiyokawa, 2015; Jares-Erijman and Jovin, 2003; 
Lindenburg and Merkx, 2014).  
To test whether a FRET-based readout is compatible with the BiAD approach, I next 
focused on the detection of H3K9me3 marks that abundantly decorate the major 
satellite repeats of mouse chromocenters (Saksouk et al., 2015). Owing to the high 
sensitivity observed with the BiFC-based readout, the anchor and detector modules 
used to construct the BiAD sensor 4, were re-purposed for a FRET-based 
measurement. To this end, the ZF anchor, recognizing major satellite sequences, was 
Figure 40| Concept of FRET-based BiAD approach for the detection of H3K9me3 marks at mouse 
major satellite sequences. The anchor module (ZF) was fused to the mCerulean, FRET donor 
fluorophore (in cyan), while the detector module (HP1CD) was fused to the mVenus, FRET acceptor 
fluorophore (in yellow). If the nucleosome found next to the DNA sequence of interest is decorated with 
H3K9me3 marks, the anchor and donor modules will dock in close spatial proximity, bringing the 
attached donor and acceptor fluorophores in a FRET-favorable distance. Accordingly, due to the 
transfer of energy from donor to the acceptor molecule, the fluorescence signal emitted by the donor 
(purple arrow) is decreased (a). By contrast, if the chromophore of the Venus acceptor is destroyed by 
bleaching, the signal emitted by the FRET donor increases (b).  
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fused to the mCerulean FRET donor fluorophore. The HP1 CD, binding specifically to 
H3K9me3 marks, was fused to the mVenus FRET acceptor fluorophore. To measure 
FRET, the acceptor photobleaching method was selected (Figure 40). This relies on 
evaluating the intensity of the signal emitted by the donor chromophore before (Figure 
40a) and after (Figure 40b) the acceptor is disrupted by illumination with a high -
intensity laser line (König et al., 2006). The working concept is that if the two 
chromophores are in proximity at steady state, the acceptor photobleaching would lead 
to an increased donor fluorescence, as the chromophore accepting the energy 
transferred by the donor is destroyed. By contrast, if the donor and acceptor do not 
meet the geometrical constraints required for FRET to occur, no change in the donor 
fluorescence is expected to occur between the two measurement points (Karpova et 
al., 2003; Vogel et al., 2006). While acceptor photobleaching is less suitable for live 
cell measurements, owing to phototoxicity effects associated with high-intensity 
illumination, this measurement method is among the most robust used to readout 
FRET. In addition, it requires fewer controls and is not as prone to technical and 
analysis errors as other FRET measurement methods such as the direct measurement 
of acceptor emission and fluorescence lifetime imaging (Busnelli et al., 2013; Van 
Munster et al., 2005).  
To establish this method, a construct encoding the Cerulean and Venus fluorophores 
fused together through a 5 amino acid long linker (C5V) was used (Koushik et al., 
2006). This fusion construct was shown to have a high average FRET efficiency of 
circa 30%, serving as a FRET reference standard (Koushik et al., 2006). As 
documented in Figure 41a, upon bleaching the acceptor fluorophore, a visible increase 
in the donor fluorescence was obtained. By contrast, performing the same experiment 
on cells transfected with HP1CD-Cerulean and NLS-Venus, where no interaction is 
expected, did not lead to a measurable increase in the mCerulean fluorescence 
(Figure 41b). Taken together, these results indicate that the setup of the FRET assay 
is functional as it allows a good discrimination between true interactors and proteins 
that meet by chance due to overexpression. In spite of this, applying these settings to 
measure the FRET signal produced upon co-transfection of the HP1CD-Cerulean and 
ZF-Venus modules, revealed no visible differences in-between the two measurement 
time points (Figure 41c). Here, based on the results obtained with BiAD sensor 4 
(Figure 39c) as well as published literature, a strong increase in the fluorescence of 
the chromocenter-localized donor was expected (Saksouk et al., 2015). Collectively, 
 101 
 
these data highlight the problematics of FRET-based readouts and underline the clear 
superiority of BiFC approaches.  
To further improve the applicability of the BiAD sensors, mVenus could be next 
replaced with the engineered monomeric Deinococcus radiodurans infrared 
fluorescent protein IFP1.4. Indeed, this was shown to be capable of reversible 
fluorescence complementation and was already successfully used to detect 
spatiotemporal dynamics of protein-protein interactions (Tchekanda et al., 2014). Due 
to its spectral properties, this protein is also suitable for whole-body imaging, opening 
up new avenues for the applicability of the sensors (Tchekanda et al., 2014).   
Figure 41| Establishment of the acceptor photobleaching FRET measurement technique for the 
readout of H3K9me3 marks at mouse major satellite repeats. a) Representative FRET 
measurement documenting an increase in the fluorescence of the Cerulean donor (pseudocolored), 
upon Venus bleaching. The Cerulean-5-Venus FRET standard was used for this measurement.                                             
b) Representative FRET measurement documenting no increase in the fluorescence of the HP1CD-
Cerulean signal upon bleaching the NLS-fused acceptor fluorophore. c) Representative readout of the 
FRET effect produced upon co-transfection of mouse cells with constructs encoding for HP1CD-
Cerulean and ZF-Venus. No visible change in the signal intensity of the Cerulean donor could be 
observed, in-between the two imaging time points. In all panels, the area selected for bleaching was 
marked with red. The fluorescence signal of the donor was pseudocolored to enhance visibility. The 16 
bit LUT scale is included in the lower right corner of the figure.  
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5 Discussion 
In my work I was aiming to shed light onto three major open questions in the field of 
Molecular Epigenetics, namely, how chromatin remodelers facilitate the access of 
epigenetic factors to chromatin, how epigenetic enzymes are controlled and regulated 
to establish and maintain defined epigenetic states and how the epigenetic state of a 
live cell can be dynamically detected. The main outcomes that resulted from each of 
these areas of investigation, together with the new directions of research that were 
opened by these findings, are discussed below in a project-specific manner.   
5.1 HELLS, a mysterious chromatin remodeler  
5.1.1 ATP hydrolysis regulates the release of HELLS from chromatin 
The role of HELLS as an important regulator of constitutive heterochromatin was 
discovered in genetic studies in mice as early as in 2001 (Dennis et al., 2001), shortly 
after the discovery of DNMT3 enzymes (Okano et al., 1999) and histone lysine 
methyltransferases (Rea et al., 2000). Follow-up investigations revealed that the 
protein is enriched at major satellite sequences, embedded in pericentromeric 
heterochromatin, as well as minor satellites, found at centromeres (Huang et al., 2004; 
Muegge, 2005). Depletion of Hells in mice was documented to lead to transcriptional 
reactivation of satellite sequences, culminating in extensive DNA damage and 
incomplete chromosomal synapsis (Huang et al., 2004; De La Fuente et al., 2006). 
This effect was largely attributed to the involvement of HELLS in the DNA methylation 
pathway. Indeed, knock-out of Hells in murine cells was reported to cause a global 
reduction in the DNA methylation levels, the strongest affected sites being repeat 
sequences, such as retroviral-like sequences (Dunican et al., 2013; Yu et al., 2014). In 
addition, recently HELLS was described to control cytosine methylation in a nuclear 
compartment that partially overlaps with lamin B1 attachment regions (Yu et al., 2014). 
Lamin B1 attachment domains (LADs) were identified based on the physical interaction 
of DNA sequences with the nuclear membrane protein, lamin B1, and shown to be 
important for controlling the organization of the genome and for providing a repressed 
chromatin environment (Guelen et al., 2008; Kim et al., 2011; Zheng et al., 2015). 
Interestingly, LADs were found to be rich in repeat elements with > 60% of repeats 
being located here, and for some types of satellite sequences and endogenous 
retroviral elements the frequency surpassing 80% (Yu et al., 2014). 
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Owing to its high sequence homology to SNF2 family members, which are ATP-driven 
chromatin remodelers that can translocate along the DNA and disrupt protein-DNA 
contacts, HELLS was proposed to be a chromatin remodeler and have critical roles in 
modulating the structure of compacted chromatin (Briones and Muegge, 2012; Meehan 
et al., 2001; Ryan and Owen-Hughes, 2011). Its plant homolog DDM1 was one of the 
first proteins in Arabidopsis, for which the knockout led to massive and global loss of 
DNA methylation, at a time when the DNA methylation field was still in its infancy 
(Vongs et al., 1993). HELLS is thought to be required for opening up the chromatin 
fiber at heterochromatic sites to provide developmental-controlled access to the DNA 
methylation machinery (Briones and Muegge, 2012; Pikaard, 2013; Zemach et al., 
2013). These findings were supported by the discovery that HELLS and DNMT3B are 
direct interactors (Myant and Stancheva, 2008). Nevertheless, while the A. thaliana 
HELLS homologues, DDM1, was found to be able to remodel chromatin in vitro 
(Brzeski and Jerzmanowski, 2003; Stroud et al., 2013) and mediate the access of 
DNMTs to linker H1-containg chromatin in vivo (Pikaard, 2013; Zemach et al., 2013), 
an ATP hydrolysis-dependent activity as well as a chromatin remodeling function has 
not been convincingly shown for HELLS to date. In this study, I took advantage of an 
ATPase-deficient HELLS variant K237Q described by (Burrage et al., 2012) to address 
the contribution of ATP hydrolysis to the interaction between HELLS and chromatin.  
Investigating the nuclear localization of wild-type and ATPase-deficient HELLS with 
fluorescent microscopy, revealed that both proteins accumulated at DAPI-dense 
pericentromeric heterochromatic foci, in line with the extensively-documented role of 
HELLS at these repetitive sites (Huang et al., 2004; De La Fuente et al., 2006; Muegge, 
2005; Yu et al., 2014; Zhu et al., 2006). Surprisingly, a strong discrepancy in the 
localization of wild-type HELLS was observed between live and formaldehyde-fixed 
cells, with the chemical treatment leading to a more than 10 fold reduction in the 
number of cells with pericentromeric-localized HELLS. Notably, similar differences in 
protein localization between live and fixed cells have been previously documented by 
Schmiedeberg and colleagues for the chromosomal protein MeCP2 (Schmiedeberg et 
al., 2009). Based on FRAP measurements and comparison of the localization patterns 
between live and fixed cells for several MeCP2 truncation variants, the authors found 
that proteins which reside on chromatin for less than 5 s cannot be efficiently captured 
by the formaldehyde cross-link chemistry. A formaldehyde-mediated eviction of 
transcription factors from the chromatin of mitotic cells has also been recently observed 
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in both plant and mammalian cells (Li et al., 2015b; Teves et al., 2016). Based on the 
localization of the transcription factor Sox2, Teves and colleagues proposed a 
mechanistic model to explain this formaldehyde-induced fixation artifact. Accordingly, 
as formaldehyde molecules cross the cell membranes, they rapidly cross-link the pool 
of free TFs, creating a steep fixation gradient. This creates a sink effect, where 
crosslinking of free molecules prevents their binding to DNA, while the DNA-bound TFs 
can still dissociate since protein-DNA cross-links take longer to form than protein-
protein cross-links.  Noteworthy, this fixation artifact was shown to be dose-dependent, 
with high formaldehyde concentrations causing a steeper fixation gradient and a 
stronger depletion of the transcription factor from chromatin (Teves et al., 2016). 
Importantly, a similar concentration-dependent effect could be observed also in the 
localization of wild-type HELLS. Accordingly, using 2% formaldehyde instead of 4%, 
resulted in an increased number of cells where HELLS displayed a spotty localization 
(Appendix 1, Figure S2a). Taken together, these results raise concerns about the use 
of formaldehyde as the chemical of choice for the cross-linking highly mobile nuclear 
proteins, and suggest that HELLS is dynamically interacting with heterochromatin. This 
hypothesis was confirmed by biochemical chromatin fractionation experiments with 
transfected cells, as well as FRAP measurements at chromocenters. These revealed 
that wild-type HELLS can be easily stripped off chromatin with detergent and that the 
protein rapidly exchanges at chromocenters between the chromatin-bound and 
unbound state, with a short half recovery time of only 0.8 s (Table 1, Results section). 
While quantitative measurements of the mobility parameters for chromatin remodeling 
proteins are still sparse in literature, this value is in the range of what has been 
previously reported for other chromatin remodelers such as the human ISWI family 
members, SNF2H/SNF2L and Acf1 (Erdel et al., 2010).  
Interestingly, by contrast to the wild-type protein, the ATPase-deficient HELLS variant 
did not display strong localization differences between fixed and live cells. The 
enrichment of the protein at DAPI-dense pericentromeres indicates that an intact 
ATPase activity is not required for the recruitment of HELLS to chromatin. Stimulated 
by the different sensitivity to formaldehyde fixation observed for the mutant HELLS, 
FRAP measurements were performed. These revealed that in contrast to the highly 
mobile wild-type HELLS, the ATPase-deficient mutant displayed an increased 
chromatin residence time and a slower exchange rate at pericentromeric sites (Table 
1). This result was in line with biochemical fractionation experiments documenting an 
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enrichment of the HELLS K237Q variant in the urea-solubilized chromatin fraction. 
Taken together, these experiments indicate that a functional ATPase domain is 
important for the release of HELLS from tightly compacted chromatin sites mediating 
the dynamic interaction of HELLS with chromatin.   
While the involvement of HELLS at pericentromeric heterochromatin has been 
extensively documented, the specific signal that leads to the recruitment of the protein 
to these sites has not been identified so far. Chromatin structure has been previously 
shown to be involved in the recruitment of HELLS to pericentromeres. Accordingly, 
disruption of higher-order chromatin organization by treatment with histone 
deacetylase inhibitors was reported to cause the dissociation of HELLS from chromatin 
(Yan et al., 2003a). Today we know that HDAC inhibitors do not only alter the 
compaction of chromatin but are also involved in the de-acetylation of non-histone 
proteins and were reported to disturb the interaction of HDAC enzymes with co-
repressor complexes (Ropero and Esteller, 2007). Therefore, the effect of HDAC 
inhibition on the localization of HELLS may be more complex. Since pericentromeric 
heterochromatin is known to be highly enriched in the H3K9me3 repressive 
modification, the involvement of this histone mark in the recruitment of HELLS to 
chromatin was tested (Aagaard et al., 1999; Lehnertz et al., 2003). Comparing the 
localization of the protein between wild-type and Suv39H1/H2 double-KO MEFs 
revealed an increase in the pericentromeric localization of HELLS in Suv39DKO cells. 
By contrast, the ATPase-deficient HELLS displayed a strong association with 
chromocenters independent of the presence of the H3K9me3 modification. 
Importantly, these results are supported by a recent mass spectrometry-based study, 
documenting an enrichment of HELLS at the pericentromeric heterochromatin of 
Suv39DKO mouse embryonic stem cells (Saksouk et al., 2014). The differences 
observed in the localization of wild-type HELLS indicate that while the H3K9me3 mark 
is not important for the recruitment of HELLS to chromatin, an intact H3K9me3 pathway 
is needed for the efficient release of the protein from pericentromeric sites. Further 
investigations will be needed to elucidate whether the H3K9me3 mark affects the 
chromatin release of HELLS directly, or indirectly via other members of the pathway. 
Collectively, the data presented in this study document for the first time the importance 
of an intact ATPase activity for the interaction between HELLS and chromatin, and 
support the chromatin remodeling function proposed for this protein. Interestingly, the 
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ATPase activity was found to be crucial for the release of HELLS from tightly 
compacted pericentromeric sites, but not for the recruitment of the protein to chromatin. 
Furthermore, experiments in Suv39DKO cells revealed that the release of HELLS from 
chromocenters is a multifactorial process, where in addition to the active ATPase 
module, an intact H3K9me3 pathway also plays a role.  
5.1.2 A model for the recruitment and release of HELLS from chromatin 
The results obtained in this project are in agreement with a continuous sampling 
mechanism proposed to explain how some chromatin remodelers are able to rapidly 
identify their target sites among the 30 million of nucleosomes found in the mammalian 
nucleus (Erdel et al., 2010; Längst and Manelyte, 2015). According to this, remodelers 
would freely diffuse throughout the nucleus with most of their binding events being 
transient and unproductive (Längst and Manelyte, 2015). During this time, the proteins 
would continuously sample the nuclear space, screening for high-affinity nucleosomes 
(‘good’ substrates) that can be converted, through remodeling, into low-affinity binding 
sites (‘bad’ substrates). This conversion would trigger the release of the remodelers 
from chromatin (Figure 42). Inactivating the ATPase activity of these proteins would 
lead to a preferential enrichment of the remodelers at their target nucleosomes, since 
in the absence of remodeling activity these sites would remain high affinity ‘good’ 
substrates (Figure 42). Such a mechanism was previously observed for the Isw2 
chromatin remodeler and is in good agreement with the FRAP data obtained here for 
HELLS (Erdel et al., 2010; Gelbart et al., 2005; Rippe et al., 2007). 
In addition to their short residence times and rapid diffusion, the efficient target 
searching mechanism of some remodelers was also shown to be supported by a 
transient upregulation of protein expression levels. Also for HELLS an increase in 
protein amount was detected at the onset of S phase (Geiman and Muegge, 2000). 
Interestingly, a fist wave of RNAPII-dependent transcription of major satellites was 
observed in the late G1 phase of the cell cycle, with a peak in early S phase (Lu and 
Gilbert, 2007). As this transcription occurs just before the replication of 
pericentromeres and HELLS was already shown to be able to bind RNA transcripts, it 
is tempting to speculate that these pericentromeric RNAs might trigger the initial 
recruitment of HELLS to chromatin and support the role of the protein in 
heterochromatin assembly (Wang et al., 2015). Noteworthy, a mild upregulation of 
pericentromeric transcription was also reported in Suv39DKO cells (Peters et al., 
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2003). These transcripts might stabilize the association of HELLS with chromatin and 
contribute to the increased accumulation of the protein at chromocenters, as observed 
in the microscopy experiments reported here. Once recruited at these sequences, the 
absence of an intact H3K9me3 environment would lead to the local accumulation of 
HELLS at these sites. Importantly, the fact that the ATPase-deficient HELLS was not 
observed to be affected by the deletion of the H3K9me3 pathway, suggests that the 
chromatin environment is important for the activation and not for the recruitment of the 
remodeling activity. This hypothesis is supported by a report documenting that HELLS 
is detected in a complex with HP1 by immunoprecipitation performed after 
formaldehyde crosslinking (Yan et al., 2003a). Collectively, the results presented in the 
present work together with the ncRNA based-recruitment mechanism suggested by 
literature (Wang et al., 2015), hint at a two-step model for the activation of HELLS. This 
involves the RNA-mediated recruitment of the protein to chromatin, where depending 
on the local epigenetic context, the remodeling activity can be initiated (Figure 42). 
This may prevent the protein to rapidly diffuse away from substrates that carry 
Figure 42| Model for chromatin-mediated recruitment and release of HELLS.  Chromatin 
environments where the nucleosomes carry appropriately-modified histones (in this case H3K9me3 
marks, shown as flags) mediate the recruitment of HELLS. This process could be supported by 
additional factors such as ncRNAs or members of the H3K9me3 pathways, like HP1. Left-handed panel: 
once recruited, the ATPase activity of HELLS may be stimulated by histone tail modifications. This will 
result in the exposure of the nucleosome-restricted DNA sequence (shown in green) and eviction of 
HELLS from chromatin. By contrast, in the absence of ATPase activity (middle panel) or an intact 
H3K9me3 pathway (right-handed panel) the release of the protein from chromatin is inhibited. The 
HELLS ATPase module is shown in dark blue, while the rest of the protein is depicted in red.   
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appropriately-modified nucleosomes and may propagate the downstream recruitment 
of epigenetic silencers.  
In parallel with continuous sampling mechanisms, remodeling complexes were also 
shown to be engaged in specific recruitment or immobilization at specific nuclear 
compartments (Längst and Manelyte, 2015). This was previously documented for the 
chromatin remodelers Brg1 and BRM, where dexamethasone treatment of the cells led 
to the concentration of these proteins in a single spot in the nucleus (Johnson et al., 
2008). Noteworthy, also in this work, a tight association with lamin B was observed for 
a subpopulation of HELLS-transfected cells (Appendix 1, Figure 1 and 3). Since LADs 
are enriched in repetitive DNA sequences, which are HELLS target regions, it is 
enticing to speculate that the recruitment of the protein to a stable nuclear landmark 
such as the lamina, would support the efficient silencing of the lamina-associated 
chromatin compartments. Here, through its remodeling activity, HELLS might open the 
highly compacted chromatin sites and recruit the silencing machinery (see below). 
Comparing the dynamics of HELLS at the nuclear lamina and pericentromeric 
heterochromatin might offer deeper insights into the HELLS-mediated regulation of 
these heterochromatin sites.  
5.1.3 Chromatin remodeling-dependent regulation of DNMT3 enzymes via 
HELLS 
Although in this work the involvement of the HELLS ATPase activity in regulating the 
activity of DNA methyltransferases was not directly addressed, the rapid exchange 
observed for HELLS at pericentromeric heterochromatin and its ATP hydrolysis-
dependent release suggest that the enzyme might mediate the recruitment of DNMTs 
at compacted chromatin sites such as chromocenters and LADs. Engagement with 
appropriately modified nucleosomes could lead to the local stabilization of HELLS at 
these sequences and recruitment of silencing complexes. Exposing the nucleosome-
constrained DNA sequence though remodeling might further positively enforce the 
association of the silencing machinery with the remodeled locus. By contrast, the high 
mobility of the freely diffusing HELLS would prevent the local nucleation of repressive 
complexes at loci that do not require epigenetic silencing. Consistent with the 
recruitment hypothesis, recent experiments from the group of Kathrin Muegge showed 
that the remodeling activity of HELLS is required in embryonic stem cells for de novo 
methylation of repetitive elements and for promoting the stable association of DNTM3B 
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with these sequences (Ren et al., 2015). This effect was later reported to be 
independent of the differentiation stage of the Hells-/- cells used for the rescue 
experiments, as similar results were obtained upon exogenous expression of HELLS 
in differentiated mouse fibroblasts (Termanis et al., 2016). These data show that, 
provided the expression level of DNMT3 enzymes is high enough, HELLS dependent 
de novo DNA methylation can occur in somatic cells in the absence of exogenous 
signals. Importantly, in both somatic and embryonic stem cells, the ability of HELLS to 
rescue the DNA methylation levels was dependent on its ATP binding and hydrolysis 
property (Ren et al., 2015; Termanis et al., 2016).  
Interestingly, Hells knock-out was documented to lead to the accumulation of 
H3K4me3 marks at satellite repeats (Dunican et al., 2013; Yan et al., 2003b). Taking 
into account that the enzymatic activity of DNMT3A and 3B is inhibited by K4me3-
modified H3 tails (Zhang et al., 2010), it is tempting to speculate that the severe 
reduction of DNA methylation observed at repetitive sequences upon Hells knock-out 
is not only due to the spatial inaccessibility of these sites but also to the local increase 
in histone modifications that antagonize DNA methylation. This hypothesis could be 
tested by employing synthetic chromatin substrates to dissect the effect of different 
histone modifications on the activity of DNMT3 enzymes, in the absence and presence 
of HELLS. Alternatively, cellular experiments could be performed by resorting to 
inhibitors of MLL activity to reduce H3K4me3 levels and test whether HELLS can 
rescue DNA methylation at these sites.  
5.2 Spatiotemporal control of DNMT3A activity by protein 
interactors 
5.2.1 MeCP2 allosterically regulates DNMT3A activity 
During the past decade, a large body of work has accumulated, indicating that the 
global DNA methylation patterns are highly dynamic and are the product of ongoing de 
novo methylation and demethylation events (Jeltsch and Jurkowska, 2014). This 
insight has brought about a revision of the elegant textbook DNA maintenance model 
,which was proposing that DNA methylation patterns are introduced by de novo 
DNMT3 enzymes during early development and maintained by DNMT1 after every 
replication cycle (Jeltsch and Jurkowska, 2014). The revised concept describes DNA 
methylation as a dynamic stochastic model in which the 5mC modification status at 
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each site is determined by the local activity of DNMTs, TET enzymes (which are 
involved in DNA demethylation) and the rate of DNA replication (Jeltsch and 
Jurkowska, 2014). Importantly, this conceptual update places chromatin and protein 
interactors at the core of targeting and regulation of DNMT activity. 
The dynamic DNA methylation landscape plays particularly important roles in non-
dividing cells, such as terminally differentiated neurons (Edwards et al., 2010; Heyward 
and Sweatt, 2015; Weaver and Bartolomei, 2014). Here, in the absence of cell division 
and DNA replication, DNA methylation profiles can only be controlled through a tight 
regulation of DNA methylating and demethylating enzymes. Despite their outmost 
importance, the regulatory processes that govern the targeting and activity of DNMT 
enzymes are not clear at present. Insights into the cascade of regulatory events would 
be beneficial for understanding how DNA methylation patterns are set and maintained 
both in healthy development and during pathogenesis (Bergman and Cedar, 2013; 
Sharma et al., 2016). In this work, I took a closer look at the regulation of DNMT3 
methyltransferases, in particular DNMT3A, by the chromosomal protein MeCP2. This 
project was based on previous results from our laboratory, documenting a direct 
interaction between the ADD domain of DNMT3 enzymes and the TRD domain of 
MeCP2, which was shown to translate into a strong inhibition of DNMT3A activity in 
vitro. 
By employing a combination of in vitro and cellular assays, I was successful in 
elucidating the mechanism through which this concentration-dependent inhibition 
occurs and demonstrated that the strong interaction between DNMT3A and MeCP2 is 
not an in vitro artifact, but can be also detected in mouse whole brain lysates. This 
tissue was used for investigation since it displays high levels of DNMT3A and MeCP2 
(Gabel et al., 2015). Using conformationally locked DNMT3A variants as a novel tool 
to investigate DNMT3A regulation, I could show that through its binding the TRD 
domain stabilizes the autoinhibitory conformation of the enzyme and inhibits catalysis 
on a broad range of substrates. Importantly, this strong interaction and its resulting 
inhibition were found to be overcome by the presence of unmodified H3 N-terminal 
peptide, indicating that the binding of the TRD and unmodified H3 to the ADD domain 
are mutually exclusive. 
To investigate the crosstalk between MeCP2 and DNMT3A in vivo, whole-genome 
bisulfite sequencing (WGBS) was performed on genomic DNA isolated from the whole 
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brain of adult wild-type and Mecp2 KO mice, respectively (Guy et al., 2001). The 
overlap in symptoms between the Mecp2 KO animals and Rett syndrome patients 
makes these KO mice a disease-relevant model system. For this experiment, 6-week 
old homozygous null males were chosen, owing to their earlier symptom onset and the 
homogenous population of MeCP2-negative cells (Guy et al., 2011). Interestingly, 
unlike the global effects observed upon overexpression of MeCP2 in the HCT116 
hypomorphic cells, WGBS analysis revealed only punctate changes in the DNA 
methylation landscape of the brain of Mecp2 KO animals. Moreover, overexpression 
of MeCP2 in HCT116 cells resulted in a dramatic two-fold reduction of global DNA 
methylation levels, in agreement with the inhibitory function of the protein. By contrast, 
WGBS analysis of the Mecp2 KO brain revealed both, hyper- and hypomethylated, 
DMRs, indicating that the MeCP2-DNMT3A interaction is more complex in the brain. 
Importantly, around half of the discovered DMRs displayed a change of more than 50% 
in methylation levels averaged over 1kb tiles and overlapped with MeCP2 binding sites, 
as extracted from a recent high-resolution ChIP-seq data set from olfactory epithelium 
(Rube et al., 2016) suggesting that they are directly related to the loss of MeCP2. 
These data suggest that MeCP2 has a local, but strong effect on the brain methylome. 
The discrepancies observed between the cellular and in vivo experiments, could be 
explained by the different expression levels of MeCP2 between the two systems. In 
addition, whereas the effects of MeCP2 overexpression were analyzed in clonally-
derived homogenous cell lines, the brain consists of a heterogeneous mixture of 
different cell types that express MeCP2 at different levels and where the regulatory 
roles of the protein may be more complex (Guy et al., 2011). In line with this, several 
studies already documented the large differences in MeCP2 expression between 
mature neurons and glial cells, with the latter cell type being more abundant and 
expressing relatively low amounts of MeCP2 (Ballas et al., 2009; Maezawa and Jin, 
2010; Maezawa et al., 2009). This heterogeneity may obscure the MeCP2-mediated 
DNA methylation effects in the WGBS analysis performed here. In line with this, 
transcriptional profiling studies using whole brain from Mecp2-null mice revealed only 
subtle changes in gene expression, whereas analysis of defined sub-brain regions 
such as the cortex, cerebellum and hypothalamus discovered up to thousands of 
significant gene expression changes, depending on the area selected for investigation 
(Ben-Shachar et al., 2009; Urdinguio et al., 2008). Still, in most cases the fold change 
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in the expression of the affected genes was rather mild, indicating that MeCP2 may 
rather act as a fine-tuner of gene expression (Ben-Shachar et al., 2009). 
Interestingly, comparing the gene expression patterns in the hypothalamus of Mecp2-
null and MECP2-Tg mice, which express 2-3 more MeCP2 than the wild-type animals, 
revealed that most genes were down-regulated in Mecp2-null and upregulated in 
MECP2-Tg mice (Ben-Shachar et al., 2009). This proposes an activating role of 
MeCP2 in gene expression and is in line with the inhibitory effect of MeCP2 on DNA 
methylation that is observed in the present work. Noteworthy, gene ontology (GO) 
analysis of the transcripts altered in cerebella of models of MeCP2 disorders found that 
genes upregulated by MeCP2 were more likely to be associated with specific 
processes and GO terms, by comparison, to downregulated genes. This is important 
since it suggests a closer functional relatedness between activated target genes 
compared with repressed genes. The fact that some of the categories that are enriched 
in the upregulated targets include transmission of nerve impulse, dendrite 
development, and neuroblast proliferation, support an important role in the 
pathogenesis of MeCP2 disorders. Noteworthy, these results could only be obtained 
by analyzing gene expression data stemming from isolated brain sub-sections and not 
when performed on single-cell derived wild-type and mutant MeCP2 expressing 
fibroblast clones, patient T lymphocytes, Mecp2-null mouse whole brain, post-mortem 
brain tissue from Rett patients or SH-SY5Y neuronal cell lines (Ben-Shachar et al., 
2009; Colantuoni et al., 2001; Delgado et al., 2006; Kriaucionis et al., 2006; Peddada 
et al., 2006; Traynor et al., 2002). This highlights the importance of appropriate model 
systems in dissecting the complex roles played by MeCP2 in gene regulation. Based 
on the evidence described above, it is expected that analyzing the methylomes of brain 
sub-regions where the absence of MeCP2 was already shown to cause more dramatic 
effects, might lead to more pronounced effects and providing a more defined picture of 
the role that MeCP2 plays in the regulation of DNMT3A in vivo. Since different types 
of neurons are interspersed through different brain regions, neuronal cultures that have 
been prepared from Rett patient cells using induced pluripotent stem cell technology, 
might provide a better defined study system for this purpose (Avior et al., 2016; Hotta 
et al., 2009; Marchetto et al., 2010).  
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In summary, the data stemming from this project propose a model in which DNMT3A 
is under the combined control of MeCP2-mediated targeting and inhibition and the 
modification state of histone H3 tail at genomic target sites (Figure 43). On the one 
hand, MeCP2 was found to act as an inhibitor of DNA methylation at some target sites 
in the brain, and after overexpression in a global manner in tissue culture (Appendix 
2, Figure 8A). On the other hand, at repetitive genomic sites such as satellite repeats 
and a subset of gene promoters, MeCP2 could also recruit DNMT enzymes (Appendix 
2, Figures 6 and 7). Depending on the modifications status of histone tails at the 
genomic locus, the TRD-mediated inhibition can then be either relieved or maintained. 
Such a mechanism would protect H3K4me3-rich promoters from abnormal de novo 
methylation while creating a positive 5mC writing-reading feedback loop at sites where 
the nucleosomes carry appropriately modified histone tails. The model resulting from 
this study, supports and mechanistically explains the previous findings proposing both 
positive and negative roles for the chromosomal protein MeCP2 on gene transcription. 
5.2.2 Further directions for dissecting the MeCP2-DNMT3A circuit  
While in the work documented here, I focused on analyzing the effect that the TRD 
domain of MeCP2 has on the activity of DNMT3A, it would be interesting to next 
explore the cross-talk between these two main epigenetic players, with full-length 
proteins. This would be important for understanding the role played by the MBD domain 
of MeCP2 in regulating the cross-talk between hydroxymethylated DNA substrates and 
DNMT3A activity at non-CG sites. As recently proposed by Greenberg and co-workers, 
Figure 43.  MeCP2 has a dual role in the regulation and targeting of DNMT3A. a) Binding of MeCP2 
(blue) to DNMT3A (green) inactivates the methyltransferase and prevents untargeted activity (red x). b) 
After MeCP2 binding to DNA at a genomic locus with appropriately modified H3 tail, H3 tail binding to 
DNMT3A leads to the dissociation of the DNMT3A-MeCP2 complex and subsequent DNA methylation. 
This can trigger more MeCP2 binding and by this initiate a positive feedback mechanism. This image 
was taken from Appendix 2. 
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the major accumulation of hydroxymethylated CG sites during brain development 
might serve as a ‘kick off’ signal to re-distribute MeCP2 from high-affinity CG sites to 
the newly methylated CA dinucleotides (Kinde et al., 2015). Taking into account that 
on HpaII pre-methylated DNA substrates the MeCP2-mediated DNM3A inhibition was 
maintained (Appendix 2, Figure 4A) it would be interesting to test if converting these 
sites to hydroxymethylated CGs would have any effect on DNMT3A activity at non-CG 
dinucleotides.  
In addition to the modification status of the histone H3 tail, the DNMT3A-MeCP2 
interaction could be regulated by other factors as well. For instance, MeCP2 was 
reported to be extensively phosphorylated in the brain, and loss of phosphorylation at 
specific sites was shown to have negative effects on mammalian brain maturation, 
learning and plasticity (Damen and Heumann, 2013). In this work, the S/T kinase 
CDKL5 was found to phosphorylate the TRD domain of MeCP2. Investigating the effect 
that this PTM has on the interaction between MeCP2 and other proteins, including 
DNMT3A, may offer deeper insights into the complex regulatory roles of this 
chromosomal protein. To this end, the CDKL5 phosphorylated residue/s could be 
identified via mass spectrometry, and phosphorylation mimics of MeCP2 could be 
expressed in neuronal cell culture to test the sensitivity of interacting partners to the 
phosphorylation state of the identified residue. Noteworthy, CDKL5 was shown to be 
involved in a negative feedback loop with MeCP2, where increasing MeCP2 protein 
levels by overexpression or stimulation of cells with serotonin or cocaine, was found to 
lead to a MeCP2-dependent repression of the Cdkl5 gene locus (Carouge et al., 2010; 
Damen and Heumann, 2013). It, would therefore, be interesting to test if in turn, the 
CDKL5-mediated phosphorylation has any effects on the stability and functions of 
MeCP2. 
5.3 Epigenetic biosensors for locus-specific visualization of 
epigenetic modifications in living cells 
5.3.1 Development and validation of locus and modification-specific BiAD 
sensors 
Covalent modifications of DNA and histone proteins regulate chromatin structure and 
play central roles in chromatin-templated biological processes such as transcription 
and DNA repair. Unlike the genome, epigenetic signatures are metastable, with 
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different epigenetic signals having different degrees of variability and stability. This 
results in a large heterogeneity in epigenetic profiles in-between cells, even when 
these are part of an apparently homogenous population (Bheda and Schneider, 2014). 
This non-genetic variation may be responsible, for instance, for the variability in 
responses observed between cells when these are stimulated with the same signal, 
and its analysis would improve our understanding of how epigenetic states are 
maintained and inherited during cellular differentiation and disease development 
(Tirado-Magallanes et al., 2016; Yu et al., 2016). 
Epigenetic heterogeneity is especially important to detect in cells that cannot be 
isolated in abundance. For this reason, rare cell types such as the oocyte and zygote 
were among the first objects of single-cell epigenomics (Guo et al., 2013, 2014b). An 
important observation derived from these studies was that individual pronuclei of the 
same cell type are highly heterogeneous, even if inspected at the same time point after 
intracytoplasmic sperm injection into oocytes (Guo et al., 2014b). A large heterogeneity 
in DNA methylation landscapes was also observed in ESCs cultured in different types 
of media (Guo et al., 2013; Smallwood et al., 2014). This was attributed to the dynamic 
balance between the primed and naïve states of ESCs cultured under serum 
conditions, by comparison to the rather homogenous population obtained in 2i media 
(Smallwood et al., 2014). Mapping epigenetic heterogeneity at the single cell level is 
equally important for instance, for tumor samples, where this can provide a valuable 
insight into cell type-specific deregulation of epigenetic pathways (Tirado-Magallanes 
et al., 2016). In addition to underpinning epigenetic heterogeneity via single cell 
analysis methods, equally critical are tools that allow the assessment of the temporal 
order in which epigenetic changes occur during cellular reprogramming, the role and 
importance of each regulatory step, as well as the dynamic connection between 
epigenetic changes and morphological or physiological alterations.  
Since epigenetic signals regulate chromatin functions in a genomic context-specific 
manner, analyzing their changes with locus-specific resolution is imperative for an 
operative understating of epigenetic regulatory cascades. The genomic context 
importance of epigenetic marks is, for instance, evident in diseases such as cancer. 
Here, selected CpG islands for example of tumor suppressor genes usually gain DNA 
methylation, while repetitive sequences such as heterochromatic DNA repeats, 
dispersed retrotransposons, and endogenous retroviral elements, become frequently 
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hypomethylated (Baylin and Jones, 2011; Bergman and Cedar, 2013; Gal-Yam et al., 
2008; Keshet et al., 2006). Stochastic epigenetic errors were also found to be 
associated with imprinting disorders or in vitro fertilization (Kalish et al., 2014; de Waal 
et al., 2014).   
Based on the arguments listed above, it is clear that methods that allow a dynamic 
readout of epigenetic signals at endogenous genomic loci, inside the nucleus of living 
cells, are essential for a better understanding of epigenetic mechanisms (Bheda and 
Schneider, 2014). In this project, this urgent and unmet technological demand was 
addressed by developing a set of novel BiFC-based epigenetic biosensors for live cell 
microscopy applications. In these tools, the high sequence specificity of engineered 
binding domains (ZF, TALE, and CRISPR/dCas9) was combined with the chromatin 
mark-specific recognition of epigenetic reading domains (MBD for 5mC readout; HP1 
chromodomain for H3K9me3 readout). Simultaneous readout of the DNA sequence 
and the epigenetic mark was achieved by fusion of the anchor and detector modules 
with complementary parts of the split Venus fluorophore. Accordingly, if the genomic 
locus of interest carries the candidate epigenetic modification, the docking of the 
anchor and detector modules in close spatial proximity would lead to the reconstitution 
of an optically trackable fluorophore. With these tools, the status of 5mC and H3K9me3 
marks at endogenous genomic sites in living cells could be directly detected for the 
first time, and the dynamic change of these marks upon drug treatment and induction 
of epigenetic enzymes could be followed over time.  
Several controls were included to validate the locus and modification specificity of the 
developed sensors. After ensuring that the functionality of the individual anchor and 
detector modules was not influenced by their fusion to the complementary Venus parts, 
the target site specificity of the sensors was validated by sequence-specific DNA 
staining with synthetic dyes or by co-transfection of the full-fluorophore tagged anchor 
modules together with the corresponding BiAD systems. The epigenetic mark 
specificity of the tools was confirmed by employing binding pocket mutants in the 
detector modules, or cell lines with globally reduced levels of DNA methylation or 
H3K9me3 marks.  
With this technology, the site-specific increase of DNA methylation and H3K9me3 
levels could be effectively monitored after exogenous expression of the responsible 
active epigenetic enzymes in the corresponding knock-out cell lines. These results 
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highlight the portability and specificity of the novel BiAD sensors, and demonstrate that 
the dynamic range of these tools covers the extent of biological relevant changes 
affecting the 5mC and H3K9me3 marks.  
5.3.2 Advantages of the BiAD approach over existing technologies 
To date, these novel sensors are the only available tools that enable the locus-specific 
detection of epigenetic modifications in the nucleus of living mammalian cells. Other 
biochemical methods that allow the locus-resolved mapping of DNA methylation or 
histone modifications depend on isolated DNA or chromatin as input material, thereby 
being unsuitable for studying dynamic epigenetic cascades (Bheda and Schneider, 
2014). Also, other microscopy-based approaches such as in situ hybridization and 
proximity ligation assays (PLA) make use of fixed cells (Ginart et al., 2016; Gomez et 
al., 2013; Li et al., 2013). Recently, a live-cell method was developed that uses the 
expression of a genomically inserted fluorescent reporter gene to measure the 
methylation state of the adjacent DNA (Stelzer et al., 2015). While this method was 
successfully applied to track locus-specific changes of DNA methylation in living cells, 
it comes with a set of disadvantages. Among the most important are the fact that the 
signal depends on the efficient spreading of DNA methylation and demethylation from 
the gene locus into the promoter of the reporter, which may vary between genomic 
sites and may not happen under certain conditions at all. Moreover, the method 
requires the engineering of the endogenous DNA locus, which may disturb the native 
chromatin state. In addition, the fluorescence-based readout limits the temporal 
resolution of the measurement because, after activation of the reporter gene, it needs 
to be transcribed, the mRNA processed, transported and translated. Furthermore, the 
reporter protein needs to maturate and accumulate to visible levels. By contrast, the 
BiAD sensors developed here allow a direct readoutout of the epigenetic marks present 
at the target epigenetic locus, without the need to engineer the genomic site. 
Furthermore, with this method, the spatial information is retained as the fluorescent 
signal is formed directly at the target locus and does not freely diffuse within the cell. 
Preserving the spatial relationship of epigenetic signals is important for understanding 
the connection between epigenetic marks and the spatiotemporal dynamics of the DNA 
sequences that these decorate and to enable the later parallel readout of several 
signals. 
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One of the clear advantages of the BiAD technology is its modularity, as demonstrated 
by the successful generation of ZF, TALE and CRISPR/dCas9-based biosensors in 
which the anchors could be successfully combined with two distinct detector modules. 
Although so far the system was only applied to visualize epigenetic modifications of 
repetitive genomic sites, implementation of the CRISPR/dCas9 anchor in novel 
sensors could facilitate the visualization of epigenetic marks at single copy loci. In line 
with this, Chen and colleagues demonstrated that a cocktail consisting of 26 ~ 36 
sgRNAs tiling a unique locus site was enough to detect the target locus by conventional 
confocal microscopy (Chen et al., 2013). While this would suffice to visualize the DNA 
methylation status of a heavily methylated, long CG islands, more effort needs to be 
put into further reducing the number of required sgRNAs, before shorter regulatory 
elements can be addressed. This could be accomplished by taking advantage of the 
recent developments in microscopy technologies and imaging processing methods 
(Coltharp et al., 2014; Kusumi et al., 2014; Mishin et al., 2015). For instance, in a recent 
study Chen et al. (2016) combined photoactivated localization microscopy (PALM) with 
fluorescence complementation to detect protein complex in live cells with nanometer 
resolution and single molecule sensitivity (Chen et al., 2016b). Noteworthy, by 
comparison to co-localization microscopy, the BiFC approach not only improves the 
spatial resolution of the signal, but it also results in lower background fluorescence 
since it requires the successful complementation of two non-fluorescent fluorophore 
parts before a visible signal is generated. By having a controlled expression of the 
individual BiAD modules, random fluorophore reconstitution events and thereby signal 
leakiness could be further minimized. 
5.3.3 Considerations on the design of BiAD modules 
In addition to a resorting to a comprehensive toolbox of versatile anchor domains, two 
distinct detector modules were used in this study to detect two central epigenetic 
marks. Accordingly, the MBD of MBD1 was employed for the detection of 5mC, while 
the chromodomain of HP1β (HP1CD) was used for the recognition of H3K9me3 marks 
(Bannister et al., 2001; Hendrich and Bird, 1998; Jacobs et al., 2002; Li et al., 2015a; 
Ohki et al., 2001). There are several advantages that these domains possess over 
other types of recombinant binders, such us immunoglobulin-derived fragments or 
DARPins, which are used in cell biology applications (Helma et al., 2015). Importantly, 
since both of the affinity reagents used in this study are part of naturally occurring 
nuclear mammalian proteins it might be that their synthesis, folding, and degradation 
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would pose a smaller burden for the cells, by comparison to synthetically designed 
proteins. To be kept in mind at the sensor selection/design stage was that both full-
length MBD1 and HP1β are multi-domain proteins that were already shown to take part 
in several main epigenetic pathways (Fujita et al., 2003; Hiragami-Hamada et al., 2016; 
Liu et al., 2013a; Mattout et al., 2015; Reese et al., 2003; Sarraf and Stancheva, 2004). 
To minimize the potential competition between the detector domains and the 
endogenous factors, the proteins were trimmed down to their core MBD and 
chromodomain respectively, by removing the domains which were not essential for 
their incorporation in the BiAD systems. This was particularly critical for HP1β, since 
the protein was reported to directly interact via its chromoshadow domain with the 
SUV39H N-terminus (Schotta et al., 2002; Yamamoto and Sonoda, 2003). By making 
use only of the chromodomain of HP1β, it was ensured that that the recovery in BiFC 
signal observed upon induction of active SUV39H1 in Suv39h1h2-/- iMEFs was caused 
by an increase of H3K9me3 levels at major satellite repeats, and not by the SUV39H1-
mediated recruitment of HP1 to these sequences. Development of novel affinity 
reagents to target epigenetic modifications needs to be built on a careful selection of 
protein domains, to keep the perturbation of endogenous epigenetic cascades minimal. 
Since for some epigenetic readers it was documented that their affinity for the target 
modification is enhanced by the presence of accessory protein domains or PTMs, it is 
possible that stripping the reader down to its core chromatin binding domain might 
produce a device with low binding affinity (Badugu et al., 2005; Canzio et al., 2011, 
2014; Maison et al., 2011). This aspect needs to be tested on a case-by-case basis 
and may be alleviated by selection of protein domains that are biochemically well 
characterized and are amenable to engineering approaches. This may not only result 
in chromatin binders with improved chromatin binding properties, but also lead to the 
development of affinity tools with novel specificities. For instance, in an early proof-of-
principle study the binding preference of the PHD finger-containing protein BPTF could 
be successfully altered from H3K4me3 to H3K4me2, by a single amino-acid exchange 
in the aromatic cage of the PHD finger (Li et al., 2007). Implementation of this 
methodology can result in the generation of affinity reagents that can specifically 
discriminate between modification states that are chemically only minutely different 
from each other, but which are involved in epigenetic signaling cascades with distinct 
biological outcomes. Taking into account that these modifications are present on 
peptides with identical amino-acid sequence, generating specific affinity reagents 
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through modifying naturally occurring chromatin domains is expected to be superior to 
antibody-based approaches. 
In addition to a high specificity for the targeted chromatin mark, other important 
parameters affecting the selection of detector devices used in this study was 
cytotoxicity and binding strength. These aspects are particularly critical for the 
successful implementation of the detector devices into functional BiAD sensors since 
the modules need to display a chromatin association that is stable enough to promote 
BiFC pairing, while in the same time only minimally perturb the local epigenetic 
landscape and ongoing chromatin-templated cellular processes. The MBD was 
selected for 5mC readout since the protein was shown to have a rapid turnover rate at 
mouse chromocenters (as revealed by FRAP), and it was successfully used to 
generate stably expressing cells lines and a DNA methylation mouse reporter (Ueda 
et al., 2014). Similarly, FRAP measurements also documented a high mobility of HP1β 
on chromatin, with a half recovery time t1/2 of ~ 4s (Manukyan and Singh, 2014). The 
results of the present work indicate that selection of detector modules with a chromatin 
binding kinetics similar to what was reported for HP1β and the MBD of MBD1, is 
beneficial for high-efficiency BiFC outputs. Of note, since chromatin readers usually 
display pools with different kinetic behaviors, a detailed kinetic modeling is required to 
be able to pinpoint the optimal mobility parameters of the most suitable detector 
modules (Manukyan and Singh, 2014). Importantly, due to their generally lower binding 
affinity and transient residence time, chromatin readers are expected to interfere less 
with cellular processes by comparison to mintbodies and nanobodies, which bind 
cellular structures tighter and for a longer time (Helma et al., 2015; Kungulovski et al., 
2014).  
Arguably, one the strongest advantage of the technological platform provided in this 
work stems out of using reading domains as detector modules. For instance, in 
proximity ligation assays, one antibody is used for the recognition of the biotin molecule 
attached to the probe that binding to the DNA sequence, while another antibody is 
needed for the recognition of the histone mark. Owing to this, PLA assays have a 
restricted in applicability since there is only a limited number of animal sources can be 
used for antibody production. By contrast, the only restriction of the BiAD system is 
that the reconstituted fluorophores need to be spectrally separable. This strongly 
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increases the flexibility of the approach and lays the basis of a platform that can be 
used for multiplexed assessment of distinct epigenetic marks at several genomic loci. 
5.3.4 Interdisciplinary applications of the BiAD technology 
Metabolic reprogramming resulting either directly or indirectly from oncogenic 
mutations is the hallmark of cancer development (Hanahan and Weinberg, 2011; 
Pavlova and Thompson, 2016). An increasingly large body of work has reinforced the 
view that metabolic features are highly heterogeneous, with each cancer cell likely 
exhibiting different metabolic profiles. This heterogeneity is to a large extent influenced 
by the epigenetic landscape and environmental conditions (Gao et al., 2016). 
Oncogenic transformation involved not only a massive rewiring of the metabolic profile 
but also dramatic alterations in the cellular behavior. Accordingly, in their transition 
from epithelial to mesenchymal state, cells lose their apico-basal polarity and tight 
contacts and gain an irregular, rounded morphology characterized by an increased 
number of filopodia and lamellipodia (Campbell and Casanova, 2016). While 
epigenomic profiling has significantly improved our understanding of cancer 
development, methods that allow simultaneous access to the epigenetic, metabolic 
and morphological information are currently lacking. 
Owing to the fact that the BiAD tools are compatible with live cell applications, these 
sensors can set the basis of a holistic methodology approach. Accordingly, the BiAD 
modules could be used in combination with glucose or hypoxia sensors to investigate 
whether the alterations in metabolic profiles translate into changes of epigenetic marks 
at candidate genomic loci (Danhier et al., 2015; Song et al., 2016). Importantly, the 
deregulation of metabolic pathways correlated to cancer progression was also 
frequently reported to be a direct modulator of the activity of epigenetic enzymes. For 
instance, in a recent study, methionine restriction was found to alter the metabolism of 
cellular SAM and impact gene expression reprogramming through histone methylation 
(Mentch and Locasale, 2016; Mentch et al., 2015). Overexpression of NNMT 
(nicotinamide N-methyltransferase) was also observed in a variety of cancers such as 
the lung, liver, kidney, bladder and colon, where it is thought to support tumor growth 
by acting as a methylation sink and diverting methyl groups away from other 
methylation processes (Gao et al., 2016; Roeßler et al., 2005; Ulanovskaya et al., 
2013). Based on these lines of evidence, combining the BiAD system with recently 
developed SAM sensors would provide a novel imaging platform that is expected to 
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connect with unprecedented insight, alterations in the one-carbon metabolism pathway 
with the methylation status of gene regulatory elements (You et al., 2015). 
Furthermore, by taking advantage of the recent technological revolution in 3D culture 
models, like organotypic cultures, the BiAD sensors could be used to correlate 
epigenetic changes with the alterations in cellular morphology that take place during 
oncogenesis (David et al., 2016; Golovko et al., 2015; Schweiger and Jensen, 2016).  
5.3.5 Current limitations of the BiAD approach  
Although the BiAD approach does not require the genetic modification of the target 
locus, the perturbing effects that this technology might have on the local chromatin 
environment are still a matter that requires deeper analysis. Conversely, the effects 
that the local geometry of the chromatin environment might have on the strength of the 
BiFC signal are not fully clear. For instance, studies in which the nuclease active Cas9 
protein was used for gene editing applications, revealed that Cas9 cutting was more 
promiscuous in vitro than in vivo (Cho et al., 2014). This could be explained by 
chromatin blockage of the accessibility of many off-target sites in vivo and suggests 
that the local chromatin environment may play important roles in the target selection of 
Cas9 (Horlbeck et al., 2016; Kuscu et al., 2014; O’Geen et al., 2015; Wu et al., 2014). 
In line with this, single-molecule imaging to track fluorescently labeled dCas9 in living 
mammalian cells revealed that Cas9 searches for target sites predominantly by rapid 
three-dimensional diffusion. Interestingly, the movement of the protein appeared to be 
slowed-down within compacted pericentromeric heterochromatin domains (Knight et 
al., 2015). These results indicate that Cas9 search efficiency is not eliminated in 
heterochromatic regions, in line with the high BiFC yields observed in the present work 
when dCas9 was targeted to alpha satellite sequences. Nevertheless, the study by 
Knight et al. (2015) raises a cautionary point about applying the BiAD technology to 
compare the modification status of genomic loci found within chromatin domains that 
have drastically different degrees of compaction. Accordingly, discrepancies in signal 
intensities between different DNA sites might be connected with different levels of the 
epigenetic mark or with the distinct search kinetics of the anchor devices within 
differentially compacted chromatin environments. This issue could be alleviated by 
visualizing the target searching behavior of full fluorophore-tagged Cas9 at the two 
different binding sites and adjusting the time given for the BiFC signal to form such that 
the imaging is performed at steady state.  
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An aspect which is more difficult to address is whether the status of the epigenetic 
modifications that is detected with the BiAD sensors truly reflects the native chromatin 
state at the target locus or if this is rather a reaction of the epigenetic landscape to the 
tools employed for readout. This issue might be particularly problematic when using 
large proteins such as TALEs and dCas9 as anchors. While in a recent study, TALEs 
developed to bind repetitive sequences found in Drosophila heterochromatic domains 
were documented to have no influence of the chromatin architecture of the target loci, 
the effects of dCas9 binding remain controversial (Yuan and O’Farrell, 2016). For 
instance, by designing sgRNAs that target dCas9 to 16 regions with low chromatin 
accessibility in mouse ESCs, Barkal et al. (2016) found that dCas9 binding resulted in 
an increased chromatin accessibility at the surrounding target sites (Barkal et al., 
2016). The opening was strongest within 20 bps of the target sites, and an increase in 
DNAse sensitivity could be detected up to 100 bps away. Although the increase in 
DNAase hypersensitivity was mild, of only 1.7 fold, these results highlight that in spite 
of the utility of dCas9 fusion proteins in a panoply of applications, including imaging, 
the effects that the protein has on the local chromatin environment need to be 
assessed on a locus-by-locus basis by a combinatorial methodology approach. 
The ultimate aim of the BiAD approach developed in this work is to enable the real-
time tracking of locus-specific epigenetic marks within the nucleus of single living cells, 
during cellular differentiation, pathogenesis or alterations in the cellular environment. 
Although so far the sensors could be successfully used to visualize locus-specific 
changes of epigenetic modifications upon drug treatment and overexpression of 
epigenetic enzymes, the tools had to be transfected freshly before each imaging time-
point. While this approach enables a better temporal resolution than ChIP-based 
methodologies, it does not yet allow the epigenetic tracking of individual cells during 
cellular transitions. For this, stable cell lines could be generated to express the sensors 
either constitutively or under inducible promoters. This direction of development is 
supported by the already successful implementation of the MBD to generate a DNA 
methylation reporter mouse allowing to visualize the dynamics of heterochromatin 
during cellular differentiation (Ueda et al., 2014). In addition, for an improved real-time 
imaging of locus-specific epigenetic changes, the Venus fluorophore, for which the 
reversibility of the complemented signal is still debated, could be replaced with IFP1.4 
(Kodama and Hu, 2012; Tchekanda et al., 2014; Yu et al., 2013). This protein was 
engineered to be capable of reversible fluorescence complementation and was already 
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successfully employed to analyze the spatiotemporal dynamics of hormone-induced 
signaling complexes in mammalian cells at nanometer resolution (Tchekanda et al., 
2014). Furthermore, due to its fluorescence in the infrared part of the spectrum, this 
protein is also suitable for whole-body imaging, opening up new avenues for the 
applicability of the BiAD sensors. 
5.3.6 Conclusions  
All in all, in this project a novel technological platform was designed, established and 
applied to enable for the first time the visualization of the status of epigenetic 
modifications at individual genomic loci in living cells. Two types of fluorescent readout, 
namely BiFC and FRET, were tested during the course of this work. While in both 
cases the methodological workflow could be successfully established in the laboratory, 
the BiFC approach demonstrated a superior performance and sensitivity and was 
thereby selected as the readout of choice. With these novel tools, site-specific changes 
that occur upon treatment of the cells with epigenetic drugs or overexpression of 
epigenetic enzymes could be monitored in living cells. Based on the results obtained 
in this work, stable cell lines and animals that can stably express the BiAD sensors 
could be generated. This will enable the locus-specific detection of epigenetic changes 
during development, transgenerational inheritance, cellular reprogramming, drug 
treatment or onset of disease. It is anticipated that either in their current form or through 
combination with the recent developments in gene targeting and microscopy 
technologies, these tools will contribute to a better understanding of how specific 
epigenetic signatures are set, erased and maintained during cellular development and 
pathogenesis.   
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5.4 Final conclusions and outlook 
Taken together, the results presented in this doctoral thesis demonstrate how a 
balanced combination of biochemical and cellular methods can be used to derive 
deeper insights into chromatin-templated and epigenetic cellular processes. My work 
was addressing three major questions in the field of Chromatin Biology and 
Epigenetics, namely, how epigenetic factors can get access to the chromatin through 
the support of chromatin remodelers, how epigenetic enzymes are controlled and 
regulated to establish and maintain defined epigenetic states and how the epigenetic 
state of a live cell can be detected. 
In the first topic of research, the importance of an intact ATPase activity for the 
interaction between HELLS and chromatin could be revealed. The existence of an 
ATP-dependent cycle of HELLS binding and release from heterochromatin points, for 
the first time, toward an ATP-dependent remodeling activity of the enzyme and opens 
up new avenues of research to understand the role that HELLS dynamics plays in the 
maintenance of repressive chromatin states.  
In the second topic of research, a strong and direct interaction between the 5mC-
reading chromosomal protein MeCP2 and DNMT3A could be mapped in vitro and 
confirmed in brain tissue. Mechanistic dissection of the inhibitory effect resulting from 
this interaction revealed that DNMT3A localization and activity are under the combined 
control of MeCP2 and H3 modifications and that depending on the modification status 
of the H3 tail at the target sites, MeCP2 can act as either repressor or activator. Taken 
together the results derived from this study provide a unifying framework that can 
successfully explain that activating and repressive roles previously documented for 
MeCP2. In addition, these data add protein interactors to the list of molecules that are 
able to regulate the activity of DNMT3 enzymes through an allosteric mechanism. 
Collectively, these findings enforce the role of allosteric control at the center of DNMT3 
targeting and regulation and highlight the importance of characterizing novel DNMT3 
interactors and their effects on the enzymatic activity. 
In the third topic of research, a novel readout method was developed and applied to 
visualize for the first time the dynamic status of 5mC and H3K9me3 marks with locus 
specific resolution in live mammalian cells. This technological platform successfully 
solves an urgent and unmet need for tools that enable the live cell tracking of 
epigenetic modifications at the level of endogenous genomic loci and satisfies three 
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main criteria. First, the method is compatible with live cell imaging, therefore preserving 
the temporal dimension and allowing the dynamic tracking of epigenetic signals. 
Second, the microscopy-based readout enables the single cell dissection of epigenetic 
profiles and a better understanding of cell-to-cell heterogeneities in relation to the 
cellular environment. Third, by taking advantage of the recent development in genomic 
targeting technologies, the epigenetic status of endogenous DNA sequences can now 
be assessed at an unprecedented resolution. Based on all these, it is anticipated that 
either in its current form or through combination with the recent developments in gene 
targeting and microscopy technologies, this novel toolbox will greatly contribute to a 
better understanding of how specific epigenetic signatures are set, erased and 
maintained during embryonic development or the onset of disease. 
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Abstract 
 
Despite their importance in mammalian development, the mechanisms controlling the 
generation of genomic methylation patterns are still poorly understood. Here, we identify 
MeCP2 as a direct and strong interactor of DNMT3A and map interaction to the the ADD 
domain of DNMT3A and the TRD domain of MeCP2. We observe a strong inhibition of 
DNMT3A by MeCP2 in vitro and a global reduction of DNA methylation after overexpression 
of MeCP2 in human cells. By using conformationally locked DNMT3A variants, we show that 
binding of MeCP2 allosterically stabilizes the autoinhibitory conformation of DNMT3A. This 
interaction and its resulting inhibition could be relieved by histone H3 binding to DNMT3A. 
We performed whole genome methylome analysis in MeCP2 knock-out mice brain and 
identified both hypo- and hypermethylated regions overlapping with MeCP2 binding sites. 
Hypermethylation was mainly observed at CpG promoters, suggesting that MeCP2 contributes 
to the protection of these regions from methylation in brain. Our data suggest that DNMT3A 
localization and activity are under the combined control of MeCP2 and H3 tail modifications 
and, depending on the modification status of the H3 tail at target sites, MeCP2 can act as either 
a repressor or activator. 
 
Keywords: DNA methylation / DNMT3A / MeCP2 / enzyme regulation / epigenetics / Rett 
syndrome 
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Introduction 
In mammals, DNA methylation is established during embryogenesis by the de novo DNA 
methyltransferases DNMT3A and DNMT3B (1,2). The correct establishment and maintenance 
of DNA methylation patterns depends on the accurate targeting and regulation of these enzymes 
(3). Mammalian DNMTs comprise two parts, a large multi-domain N-terminal part and a C-
terminal catalytic domain (CD), which is conserved between eukaryotic and prokaryotic 
cytosine-C5 DNA methyltransferases (4,5). The N-terminal parts of DNMTs guide their nuclear 
and sub-nuclear localization and mediate interactions with other proteins, DNA and chromatin, 
thereby regulating the catalytic activity. The N-terminal parts of DNMT3A and DNMT3B 
contain two defined sub-domains (Fig. 1A), a PWWP domain, an H3K36me3 binder (6,7), and 
an ADD domain, which binds the N-terminus of histone H3 if K4 does not carry modifications 
larger than monomethylation (8-11). Structural and biochemical work has shown that the ADD 
domain of DNMT3A binds to the CD at two distinct interfaces (Fig. 1B) (12), an autoinhibitory 
site in which ADD blocks catalytic activity, and an allosteric site where binding does not lead 
to inhibition. Different ADD residues are contacting the CD in the two conformations: Y526 
only contacts the CD in the allosteric conformation and D531 only contacts the CD in the 
autoinhibitory conformation, while it interacts with the H3 peptide in the allosteric 
conformation. Binding of the H3 peptide to the ADD domain consequently favors the allosteric 
conformation and activates DNMT3A (10,12,13). Several studies have recently shown that the 
activity of DNMT3 enzymes is regulated by H3 tail interaction not only in vitro, but also in 
cells (7,14,15). 
The biological role of DNA methylation is mediated by proteins, which specifically bind to 
DNA carrying methylated cytosines (16). One important reader of DNA methylation is the 
chromatin regulator MeCP2 (Fig. 1A) (17-20). It is the founding member of a group of proteins 
containing a so called methyl-binding domains (MBD), which bind to DNA in a methylation 
specific manner (21). MeCP2 binds methylated DNA with a preference for CpG dense islands 
(19,22), but its binding strength is strongly influenced by the flanking sequence of the 
methylated CpGs (23,24) and it also binds methylcytosine in a non-CpG context (25,26). In 
addition to the MBD domain, MeCP2 contains a Transcriptional Repression Domain (TRD), 
which serves as a protein recruitment platform and shows methylation-independent DNA 
binding (20,27). MeCP2 is known to interact with various transcriptional repressors and co-
repressors, including HDACs, DNMT1, ATRX and Sin3A (28-31). Functionally, MeCP2 is 
involved in numerous cellular processes, like methylation-induced gene repression (in 
particular of long genes), control of repetitive elements, chromatin compaction and looping and 
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splice site regulation (20,26,27,32-35). In addition to its role in gene silencing, gene expression 
studies performed in specific brain sub-regions showed altered expression levels of hundreds 
of genes after loss of MeCP2, most of which upregulated by MeCP2 (36-38) indicating that 
MeCP2 can function as both a gene activator and repressor depending on the genomic context 
(39). 
Both DNMT3A and MeCP2 are highly expressed in neurons (32,40) (EBI expression atlas 
http://www.ebi.ac.uk/gxa/) and they have important functions in the brain. DNMT3A has been 
implicated in neuromuscular control, synaptic plasticity, learning and memory (41-43). MeCP2 
functions as structural protein in neurons and forms a specific type of chromatin, which is 
depleted of histone H1 (20). It plays an essential role in brain plasticity (32) and inactivating 
mutations of the X-linked mecp2 gene were shown to cause Rett syndrome, a severe 
neurodevelopmental disease associated with developmental disorders and autism-like 
symptoms in females(27,31). 
Since it has been observed frequently that readers of epigenetic modifications interact with 
enzymes setting these modifications (Suppl. Text 1) and DNMT3A and MeCP2 both were 
known to bind to pericentromeric heterochromatin, we investigated their potential interaction 
in this work. We observed a strong binding of MeCP2 to DNMT3A in vitro, in cells, and in the 
mouse brain and mapped the interaction interface to the TRD domain of MeCP2 and the ADD 
domain of DNMT3A, respectively. Binding of MeCP2 to DNMT3A strongly inhibited its 
enzymatic activity by favoring the autoinhibitory conformation of DNMT3A. Interestingly, this 
interaction was disrupted and the DNMT3A inhibition relieved by addition of unmodified H3. 
These results indicate that MeCP2 can function as a negative regulator of global DNA 
methylation by reducing untargeted DNA methylation. Conversely, after binding of the 
MeCP2-DNMT3A complex to MeCP2 target sites marked by appropriately modified H3 tails, 
H3 binding to DNMT3A can disrupt the interaction with MeCP2 and activate DNMT3A. This 
will initiate a positive feedback loop, in which increased DNA methylation will lead to 
increased MeCP2 binding. In conclusion, our data show that MeCP2 interaction controls 
DNMT3A activity and localization and that this interaction has dual and opposing roles in the 
control of DNA methylation patterns by either inhibiting or stimulating DNA methylation 
activity, depending on the local chromatin context. 
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Materials and methods 
Generation of DNMT3A2 mutants and MeCP2 domain constructs 
The murine DNMT3A and MeCP2 proteins and protein domains were prepared as indicated in 
Fig. 1A. The MeCP2 domains and mutants proteins were cloned in pGEX-6P2 vector using 
BamHI and XhoI cloning sites. All constructs were verified by DNA sequencing. The site 
directed mutagenesis were carried out by rolling circle PCR using a primer carrying point 
mutation (44). The presence of the mutations was confirmed by restriction marker analysis and 
by DNA sequencing. 
 
Expression and purification of MeCP2 proteins and DNMT3A proteins 
The MeCP2 domains and mutants proteins were expressed E. coli BL-21 cells. Cells were 
cultivated in LB medium at 37 °C while shaking until an OD (600 nm) of 0.6 – 0.7 was reached. 
Then, protein expression was induced by addition of 1 mM of isopropyl-β-D-thiogalactoside 
(IPTG) and the culture was incubated at 18 °C shaking at 200 rpm overnight. The cells were 
harvested by centrifugation (15 min at 4600 rpm) and the pellet resuspended in sonication 
buffer (20 mM HEPES pH 7.5, 500 mM KCl, 1 mM EDTA, 1 mM DTT, 10% glycerol) 
including protease inhibitor (Sigma). The cells were lysed by sonication and centrifuged at 
18000 rpm for 1 h to prepare a clear lysate, which was applied on a GST-sepharose column 
(GE Healthcare). After washing with sonication buffer, the protein was eluted with sonication 
buffer containing 50 mM reduced glutathione and dialyzed first against dialysis buffer I (20 
mM HEPES pH 7.5, 200 mM KCl, 1 mM EDTA, 1 mM DTT, 10% glycerol) for three hours, 
then against dialysis buffer II containing 60% glycerol overnight. The purified proteins were 
analyzed on 12% SDS-PAGE gel stained with colloidal Coomassie BB. The murine DNMT3A2 
and DNMT3A-C proteins were expressed and purified as described previously (45-47). Since 
all DNMT3A structures were annotated with numbers for the human proteins, we use human 
numbering here. The residue numbers corresponding to human Q527, D528, and D531 in 
murine DNMT3A are Q523, D524, and D527, respectively. 
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GST pull-down experiments 
For GST pull-down experiments, 20 μL of Glutathione-Sepharose 4B beads were washed with 
200 μL of interaction buffer (25 mM Tris pH 8.0, 100 mM KCl, 5 mM MgCl2, 10 % Glycerol, 
0.1 % NP40, 200 μM PMSF). The beads were incubated for 1 hour at 4 °C with 10-15 µg of 
the different GST-tagged proteins, washed three times with interaction buffer and incubated 
with His- or MBD-tagged proteins (15 µg) for 1 hour at 4 °C with shaking. Then, the beads 
were washed three times with wash buffer containing high salt (25 mM Tris pH 8.0, 5 mM 
MgCl2, 300 mM KCl, 10 % Glycerol, 0.1 % NP40, 200 μM PMSF). The interaction of 
DNMT3A ADD and MeCP2 TRD domains was also investigate using buffer containing 600 
mM KCl. Finally, the beads were resuspended in SDS gel loading buffer and incubated for 10 
min at 95 °C. After centrifugation of the beads at 14,000 rpm for 10 min the supernatant was 
loaded on a 12 % SDS PAGE gel. Proteins were detected by Western blotting or Coomassie 
BB staining as indicated. Some experiments were conducted in the presence of recombinant 
histone H3.1 (M2503S, NEB), as detailed in the results section. 
 
Co-immunoprecipitation assay 
For co-immunoprecipitation of DNMT3A and MeCP2, pcDNA DNMT3A (expressing myc 
tagged DNMT3A) and pEYFP-MeCP2 plasmids were co-transfected in HEK293 cells. The 
pEYFP plasmid was used as control. After 48 h, the cells were collected and the cell pellets 
stored at -80 °C. The cells were lysed as recommended by the GFP trap protocol (ChromTek). 
Using GFP trap YFP tagged MeCP2 was pulled-down and the complex washed with buffer (10 
mM Tris/Cl pH 7.5, 0.5 mM EDTA, 0.5% NP-40, 200 mM NaCl). The MeCP2 and DNMT3A 
proteins were separated on a 12 % SDS-PAGE and transferred to nitrocellulose membrane. To 
detect DNMT3A, the blot was probed with anti-myc antibody (Santa Cruz, 1:1000 dilution) for 
1 h at room temperature. 
For immunoprecipitation of endogenous DNMT3A and MeCP2, whole brains from sixteen-
week old C57Bl/N female mice were used. Following mechanical disruption, the tissue was 
lysed following a published protocol (48) with some modifications. Three brains were 
homogenized in NP-40 lysis buffer (10 mM HEPES, pH 7.9, 3 mM MgCl2, 10 mM KCl, 10 mM 
NaF, 1 mM Na3VO4, 0.5 mM DTT, 0.5% NP-40, 1× complete EDTA-free protease inhibitor 
cocktail (Roche)), by douncing 30× with a tight pestle, and pelleted at 1,000g. Lysates were 
next diluted 1:1 with Benzonase buffer (10 mM HEPES, pH 7.9, 3 mM MgCl2, 280 mM NaCl, 
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0.2 mM EDTA, 10 mM NaF, 1 mM Na3VO4, 0.5 mM DTT, 0.5% NP-40) supplemented with 
1× complete EDTA-free protease inhibitor cocktail (Roche) and sonicated with EpiShear 
(Active Motif) for 2 min 30 sec (15 sec ON, 30 sec OFF cycles, 20% power, 3.2 mm microtip). 
The homogenate was then digested with 500 units of Benzonase (Novagen) for 2 h rotating at 
4 °C. Chromatin proteins were separated by centrifugation at 17.000g for 20 min at 4 °C. For 
each pull-down, 2.5 mg lysate were pre-cleared for 1 h at 4 °C with 20 mg Protein A Sepharose 
CL-4B (GE Healthcare), followed by overnight incubation with 15 µg anti-Dnmt3a antibody 
(sc-2070, Santa Cruz). For negative control, an equivalent amount of non-related rabbit IgG 
anti-myc (ab9106, Abcam) antibody was used. The antibody-bound proteins were immobilized 
to 100 mg Protein A Sepharose CL-4B, blocked in 10% BSA (Roth) for 6 h rotating at 4 °C. 
After five washes with immunoprecipitation buffer, the immune complexes were eluted from 
the beads by boiling in 100 µL Laemmli sample buffer. The samples were next analyzed by 
western blot as described above. For detection, anti-MeCP2 monoclonal primary antibody 
(#3456, Cell Signaling) was used, followed by incubation with HRP-linked anti-rabbit IgG light 
chain specific secondary antibody (211-032-171, Jackson ImmunoResearch). Western lighting 
Ultra (Perkin Elmer) was used as ECL HRP substrate. 
 
Fluorescence microscopy 
For sub-nuclear localization studies, NIH3T3 cells were seeded on glass slides and transfected 
with plasmids expressing CFP and YFP tagged DNMT3L, DNMT3A-ADD and MeCP2 using 
Fugene HD (Promega) according to the manufacture´s instructions. After 48 h, the cells were 
fixed with 4% formaldehyde, mounted in Mowiol and Z stacks images were collected using a 
Zeiss LSM 710 confocal microscope. 
 
Substrates used for DNA methylation 
The following oligonucleotide substrates were used for DNA methylation assays: a biotinylated 
unmethylated 30mer containing one CpG site (um30mer: TTG CAC TCT CCT CCC GGA 
AGT CCC AGC TTC / Bt-GAA GCT GGG ACT TCC GGG AGG AGA GTG CAA), the same 
sequence hemimethylated at the CpG site with the methylation in the lower DNA strand 
(hm30mer: TTG CAC TCT CCT CCC GGA AGT CCC AGC TTC / Bt-GAA GCT GGG ACT 
TCmC GGG AGG AGA GTG CAA), a biotinylated hemimethylated 30mer with optimized 
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flanks for methylation with DNMT3A (49) (hmF30mer: GAA GCT GGA CAG TAC GTC 
AAG AGA GTG CAA / Bt-TTG CAC TCT CTT GAmC GTA CTG TCC AGC TTC) and a 
non-CpG substrate (nonCpG: GAA GCT GGT CCA TTmC GAT GAT GGA GTG CAA / Bt-
TTG CAC TCC ATC ATmC GAA TGG ACC AGC TTC). The oligonucleotides were annealed 
by heating to 86 °C for 5 min and slowly cooling down to ambient temperature. In addition, a 
biotinylated 585mer DNA substrate obtained by PCR was used which contains 8 HpaII sites 
(CCGG) and 45 CpG sites (um585mer). The 585mer was amplified from lambda DNA by PCR 
using the following primers Bt-GAA GGA CAA CCT GAA GTC CAG GTTG and GTG TAT 
GAC CAC CAG AGC CTT TTGC and purified by PCR purification kits (Qiagen). To prepare 
partially methylated 585mer (pm585mer), the DNA was methylated with M.HpaII (NEB) 
following the protocol of the provider and afterwards purified by PCR purification kits. 
Successful pre-methylation at HpaII sites was confirmed by HpaII (NEB) restriction digestion. 
 
DNA methylation activity assay 
The avidin-biotin microplate DNMT activity assay was used to monitor the activity of different 
DNMT3A variants in the methylation of biotinylated DNA substrates, basically as described 
(50). Each well of the microplate was coated with 1 μg of Avidin dissolved in 100 μL of 100 
mM NaHCO3 (pH 9.6) and incubated overnight at 4 °C. Before starting the assay, the wells 
were washed five times with 200 μL of 1xPBST (140 mM NaCl, 2.7 mM KCl, 4.3 mM 
Na2HPO4, 1.4 mM K2HPO4, 0.05% v/v Tween 50, pH 7.2) containing 0.5 M NaCl. The reaction 
mixtures were prepared containing 2.5 μM DNMT3A2 or DNMT3A-C and 3 μM MeCP2 (or 
any of its domains) in methylation buffer (20 mM HEPES pH 7.2, 1 mM EDTA, 50 mM KCl, 
1.25 mg/ml bovine serum albumin). For the control reactions without MeCP2, the same volume 
of dialysis buffer II was added instead of the MeCP2. The reaction mixtures were incubated on 
ice for 20 minutes and the wells of the plate were filled with 5 μL of 0.5 M unlabeled AdoMet 
(Sigma) dispensed in 35 μL 1x PBST/0.5 M NaCl. Then, 1 μM 30mer oligonucleotide DNA or 
100 nM of 585mer DNA and 0.76 μM [methyl-3H]-AdoMet (PerkinElmer Life Sciences) were 
added to the reaction mixture and the samples incubated at 37 °C. In order to follow the time 
course of the reaction, aliquots of 2 μL were removed from the reaction mixtures in duplicates 
at time points between 2’ and 30’ and applied to one well of the microplate where the 
incorporation of labeled AdoMet was quenched by an excess of unlabeled AdoMet. This 
mixture was incubated while slightly shaking for 30 minutes to 1 hour. 200 μL of 1 x PBST 
and 0.5 M NaCl were used to wash the wells five times. 40 μL of unspecific nuclease from 
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Serratia marcescens was added, diluted 1:2500 in 50 mM Tris/HCl pH 8.0, 5 mM MgCl2 were 
added per well and the mixture was incubated for 30 to 60 minutes with slight shaking. Finally, 
the released radioactivity was measured using liquid scintillation counting and the average 
count per minute of the duplicates was plotted against time. Linear regression was used to obtain 
the slopes of the initial linear parts of the time courses. The data are reported as averages and 
SEM of at least two independent experiments. 
 
DNA methylation analysis in HCT116 DNMT1 hyphomorph cells 
To study the effect of MeCP2 on DNMT3A mediated methylation in cells, we used HCT116 
DNMT1 hyphomorphic cells (kindly provided by Prof. Bert Vogelstein, HHMI, USA), which 
have a reduced DNA methylation (51,52). HCT116 cells were cultivated in McCoy’s 5A 
medium (Gibco cat no: 16600) supplemented with 10% heat-inactivated calf serum and 2 mM 
L-glutamine (Sigma), at 37 °C in a saturated humidity atmosphere containing 5% CO2. For 
stable cell line generation, pEYFP-NLS or pEYFP-MeCP2 plasmids were transfected into 
HCT116 cells using jetPRIME (peqlab), following standard protocols. At 24 hours post-
transfection the cells were subjected to selection with 0.5 mg/mL G418 (Sigma-Aldrich). For 
the pEYFP-MeCP2-transfected cells, stable clonal populations were derived by clonal 
expansion of single cell dilutions. For pEYFP-NLS, a mixed clonal population was derived. 
The cultures, together with untransfected control cells, were passaged for 2 months before 
genomic DNA isolation. LC-ESI-MS/MS analysis of DNA methylation in genomic DNA was 
performed as described (53,54). 
 
WGBS library preparation and analysis 
200 ng of genomic DNA was fragmented using a Covaris S2 for 6 min according to the 
following program: duty cycle 5%; intensity 5; cycle per burst 200. The sheared DNA was 
purified using the DNA Clean & Concentrator kit from Zymo Research per the manufacturer’s 
recommendations. Bisulfite conversion of DNA was then conducted using the EZ DNA 
Methylation-Gold kit (Zymo Research) followed the instructions, eluting to 15 µl low TE 
buffer. To minimize continual loss during storage, the converted DNA was immediately 
processed for generating WGBS libraries using the Accel-NGS Methyl-Seq DNA library kit 
(Swift Biosciences) following the manufacturer’s protocol. The libraries were sequenced for 
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100-bp paired-end reads on an Illumina HiSeq 2500 sequencer. Reads were aligned to the mm9 
build of the mouse genome using bsmap (55). Methylation calls for CpGs were assigned using 
mcall from the MOABS package (56). Methylation for each 1kb tile was calculated as the 
coverage-weighted mean of methylation at CpGs within the tile. Differentially methylated tiles 
were identified by using a coverage weighted t-test (57) with the methylation values of the 
CpGs within the tile as samples. Q-values were calculated using the R qvalue package (58). 
The overlap of DMR regions with MeCP2 binding sites was determined using MeCP2 ChIP-
seq data set GEO GSE71126 (59). Enrichments for genomic features were calculated by first 
counting the number of DMRs overlapping each feature set (including partial overlaps), and 
then using –log10(p-value) from Fisher’s exact test as the degree of enrichment. 
 
Results 
DNMT3 proteins interact with MeCP2 
To test whether DNMT3A and MeCP2 interact, we first performed GST-pull-down assays 
using recombinant murine full-length (FL) proteins (Fig. 1A). MeCP2 could be obtained with 
good purity after generating a version that lacked the N-terminal unstructured domain 
(MeCP2N) (Suppl. Fig. 1). As shown in Fig. 2A, a robust pull-down of DNMT3A by GST-
MeCP2N could be detected. Similar experiments demonstrated the interaction of GST-
MeCP2N with DNMT3A2 (Fig. 2B, Suppl. Fig. 2), a naturally occurring isoform of 
DNMT3A (60). Furthermore, MeCP2N binds to DNMT3L, a non-catalytic member of the 
DNMT3 family with important regulatory functions (Fig. 2C, Suppl. Fig. 2). However, no 
interaction of MeCP2N with the C-terminal domain of DNMT3L (DNMT3L-C) could be 
detected (Fig. 2D, Suppl. Fig. 3) suggesting that the interaction is mediated by the ADD 
domain. Pull-down experiments with DNMT3A-C were inconclusive, because this protein 
showed unspecific binding to the GST beads. 
We next tested the interaction of DNMT3A and MeCP2 in HEK293 cells by transient co-
expression of Myc-tagged DNMT3A and EYFP-tagged MeCP2 followed by EYFP targeted 
purification. As shown in Fig. 2E, co-purified Myc-DNMT3A was detected after co-expression 
with EYFP-MeCP2, but not with the EYFP control. To exclude potential artifacts related to 
protein over-expression, we finally performed immuno-precipitation of endogenous DNMT3A 
from mouse brain protein extracts. As shown in Fig. 2F, MeCP2 could be specifically detected 
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in the pulled-down material, but not in the IgG control. Together, these results demonstrate that 
DNMT3A and MeCP2 interact in vitro, after transient expression in cells and in brain extracts. 
 
Mapping of the MeCP2-DNMT3 interface 
The fact that MeCP2 interacts with the full-length DNMT3 proteins, but not with DNMT3L-C 
suggested that MeCP2 binds to the ADD domain of DNMT3A and DNMT3L. To test this 
hypothesis, we performed pull-down assays with GST-tagged N-terminal domains of 
DNMT3A (Suppl. Fig. 3) as baits and a GST-cleaved MeCP2N as prey. As documented in 
Fig. 3A, MeCP2N showed a specific interaction with the ADD domain of DNMT3A, but not 
with its NTD or PWWP domains. To dissect which part of MeCP2 is responsible for the 
interaction with DNMT3A, we performed pull-downs with GST-tagged MeCP2 domains 
(Suppl. Fig. 4). As shown in Fig. 3B, interaction was detectable only for the TRD domain. The 
MeCP2 TRD also showed interaction with DNMT3A2, which was stable even under high salt 
conditions indicating that it is not driven by electrostatic interactions (Fig. 3C). Pull-downs 
using the isolated MeCP2-TRD and DNMT3A-ADD domains confirmed the direct and strong 
interaction of these domains (Fig. 3D). Since MeCP2 is mutated in Rett syndrome, we also 
tested the effect of the R306C Rett mutation in the TRD domain of MeCP2 on the interaction 
with DNMT3A, but did not observe any change when compared with the wild type TRD (Fig. 
3D). 
 
The interaction with MeCP2 inhibits the catalytic activity of DNMT3A 
To elucidate the function of the interaction between MeCP2 and DNMT3A, we measured the 
in vitro rates of DNA methylation by DNMT3A2 in the presence of MeCP2 or its TRD domain 
with 6 different DNA substrates: 1) An unmethylated 30mer oligonucleotide (um30mer). 2) A 
hemimethylated state (hm30mer). 3) A hemimethylated 30mer with an optimized flank for 
DNMT3A (hmF30mer) (49). 4) A 585mer PCR fragment (um585mer, Suppl. Fig. 5). 5) The 
585mer PCR fragment pre-methylated at HpaII sites (pm585mer). 6) A 30mer oligonucleotide 
non-CpG substrate. 
Using 2.5 µM DNMT3A2 and 3 µM MeCP2, we consistently observed that the interaction of 
MeCP2 with DNMT3A2 resulted in about 40-60% reduction in DNMT3A2 enzymatic activity 
with the unmethylated substrates (Fig. 4A). A similar reduction in activity was observed with 
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DNMT3B2, a truncated form of DNMT3B corresponding to DNMT3A2 (Suppl. Fig. 9). The 
activity of DNMT3A2 was further reduced by about 80% with methylated substrates, which 
can be attributed to a better binding of MeCP2 to methylated DNA via its MBD domain. We 
speculated that binding of MeCP2 to pre-methylated DNA might target DNMT3A2. To test 
this hypothesis, a partially methylated 585mer DNA substrate was prepared by methylation of 
the DNA substrate with the HpaII methyltransferase, which methylates CG sites in a CCGG 
context, but leaves the remaining CG sites unmethylated (Suppl. Fig. 5). However, even on this 
substrate, we observed inhibition of the activity of DNMT3A2 by MeCP2 (Fig. 4A, 
pm585mer). 
As a control, we used DNMT3A-C, which lacks the ADD domain and therefore cannot interact 
with MeCP2, and observed that MeCP2 did not inhibit its activity (Fig. 4B). In addition, we 
tested whether the isolated TRD domain also inhibits the activity of DNMT3A2 and observed 
40-70% inhibition with the different substrates (Fig. 4C). We have discovered previously that 
DNMT3A also methylates cytosine in non-CpG sites, preferably in a CA context (61). Non-
CpG methylation has recently been detected in considerable amounts in human ES cells and 
neurons and it was connected to DNMT3A activity (25,62-64). We, therefore, also investigated 
the influence of MeCP2 on the non-CpG methylation activity of DNMT3A2 using a 30mer 
oligonucleotide substrate which contains one already methylated CpG site, such that additional 
methylation could only occur at non-CpG sites. As with the other DNA substrates, we observed 
a similar inhibition of DNMT3A2 activity by TRD (Fig. 4C, non-CpG 30mer), indicating that 
CpG and non-CpG methylation are equally inhibited by the TRD interaction. 
Finally, we tested the activity of DNMT3A2 in the presence of increasing amounts of TRD and 
observed that the methyltransferase activity was strongly inhibited (>95%) using a 2.4 fold 
excess of TRD (6 µM with 2.5 µM DNMT3A2) (Fig. 4D). As a control, the same experiments 
were conducted with DNMT3A-C, but here only a very weak reduction of activity was observed 
(Fig. 4D). This result indicates that the inhibition of DNMT3A2 by TRD is not caused by 
competition for the DNA substrate, which is an important control, since TRD has been reported 
to bind DNA (65,66). In summary, our results indicate that the interaction between the TRD 
domain of MeCP2 and the ADD domains of DNMT3A and DNMT3B results in a direct and 
very strong inhibition of their DNA methylation activity at CpG and non-CpG sites. 
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The TRD domain inhibits DNMT3A2 activity by an allosteric mechanism 
Next, we aimed to elucidate the mechanism of DNMT3A inhibition by the TRD domain of 
MeCP2. As described above, structural studies showed that the ADD domain of DNMT3A 
binds to the CD at an allosteric and an autoinhibitory site (12). Binding of the H3 peptide to the 
ADD domain stabilizes the allosteric conformation and thereby activates DNMT3A (12,13) 
(Fig. 5A). To investigate the mechanism of the repression of DNMT3A by the TRD domain, 
we prepared DNMT3A2 variants containing mutations at Y526 or D531 in the ADD domain, 
two critical residues involved in the two binding sites at the CD (Fig. 1B, Suppl. Fig. 7). 
In order to selectively disrupt or strongly destabilize one of the two DNMT3A conformations, 
we designed mutations that would cause large changes of the physiochemical properties of the 
corresponding amino acids. Y526E was introduced to disrupt the allosteric and D531R to 
disrupt the autoinhibitory conformation. After confirming that both mutants still interact with 
MeCP2-TRD (Suppl. Fig. 8), we investigated if these conformationally locked DNMT3A 
variants still respond to the presence of the TRD. As shown in Fig. 5B, the inhibitory effect of 
MeCP2 was specifically lost in the D531R variant that cannot adopt the autoinhibitory 
conformation. This finding suggests that MeCP2 reduces the activity of DNMT3A by an 
allosteric mechanism, in which TRD binding favors the autoinhibitory conformation. To 
investigate if TRD and histone H3 binding to the ADD domain influence each other, we 
conducted pull-down experiments using GST-TRD and DNMT3A2 in the presence of 
increasing concentrations of recombinant histone H3. As shown in Fig. 5C, addition of histone 
H3 abolished the ADD-TRD interaction, suggesting that binding is mutually exclusive and no 
ternary complex is formed. We next conducted DNA methylation experiments with DNMT3A2 
and DNMT3A2 pre-incubated with the unmodified H3 (1-19) peptide in the absence and 
presence of TRD, and again observed that the inhibitory effect of the TRD domain was lost in 
the presence of the H3 peptide (Fig. 5D). This indicates that the binding of H3 to the ADD 
domain can disrupt the TRD interaction and relieve the TRD-mediated inhibition of DNMT3A. 
 
MeCP2 influences the sub-nuclear localization of the DNMT3A ADD domain and DNMT3L 
To study the cellular effect of the interaction of DNMT3 proteins with MeCP2, we investigated 
the sub-nuclear localization of both proteins and protein domains. DNMT3A (47,67) (and 
references therein) and MeCP2 (19,48) are both known to localize to DAPI-stained 
heterochromatin, which forms characteristic spots in mouse NIH3T3 cells. This natural co-
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localization precluded direct studies of the mutual effect of both proteins on their sub-nuclear 
localization. However, DNMT3L was shown to have an almost homogenous nuclear 
distribution (67). Expression of both DNMT3L and MeCP2 with fluorescence tags confirmed 
the published localization patterns (Fig. 6A). Interestingly, co-expression of DNMT3L with 
MeCP2 led to a clear redistribution of DNMT3L towards the heterochromatic spots (Fig. 6B). 
This finding confirms the intracellular interaction of DNMT3L and MeCP2 and indicates that 
interaction with MeCP2 changes the sub-nuclear localization of DNMT3L. Next, we performed 
localization studies with the fluorescently tagged DNMT3A-ADD domain, which showed a 
diffuse nuclear localization (Fig. 6C). Similarly to DNMT3L, after co-expression with CFP-
tagged MeCP2, the ADD domain showed a preferential localization to heterochromatic spots, 
indicating that MeCP2 targets it to heterochromatin (Fig. 6D). These results confirm that the 
ADD domain interacts with MeCP2 in cells and demonstrate that binding of MeCP2 recruits 
DNMT3L and DNMT3A-ADD to pericentromeric heterochromatin. 
 
MeCP2 overexpression reduces DNA methylation in HCT116 cells 
To study the effect of MeCP2 on the DNA methylation activity of DNMT3A in human cells, 
we used the HCT116 DNMT1 hypomorphic cell line, which contains a truncated DNMT1 with 
reduced activity, but active copies of DNMT3A and DNMT3B (51,52). Because of the impaired 
maintenance DNA methylation activity, these cells have an about 20% reduced amount of DNA 
methylation and show increased levels of hemimethylation. Due to the reduced activity of 
DNMT1, the DNA methylation in these cells is more dependent on the activity of DNMT3A 
and DNMT3B, making this cell line a suitable model system to study the effect of the inhibition 
of DNMT3A by MeCP2. After generating stable cells lines expressing EYFP-fused MeCP2 or 
EYFP as control for two months (Suppl. Fig. 6), genomic DNA was isolated and the global 
levels of 5-methylcytosine were quantified by LC-MS/MS. As shown in Fig. 7A, we observed 
a roughly twofold decrease in the global methylation of DNA isolated from two independent 
clones expressing EYFP-MeCP2. Since DNMT1 interaction with MeCP2 did not cause a 
reduction in catalytic activity (29), this result indicates that overexpression of MeCP2 reduces 
the activity of DNMT3 enzymes in cells. 
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Genome-wide bisulfite methylation analysis in brain tissue from MeCP2 KO mice reveals 
hyper- and hypomethylated DMRs 
To study the influence of MeCP2 on DNA methylation in a biologically relevant context, we 
performed whole genome bisulfite sequencing (WGBS) on genomic DNA isolated from the 
whole brain of wild type and MeCP2 KO mice (68). The overlap in symptoms between the 
MeCP2 KO animals and Rett syndrome patients, makes these KO mice a disease-relevant 
model system. A global analysis of the WGBS data revealed similar levels of global DNA 
methylation (77%) for both samples. To assess whether the absence of MeCP2 leads to locus-
specific changes in DNA methylation, we binned the data in 1kb tiles and identified 
differentially methylated regions (DMRs, see Methods).  
We observed hypermethylated and hypomethylated DMR regions, indicating that the loss of 
MeCP2 can lead to both gain and loss of DNA methylation (Fig. 7B and C). Although the 
number of DMRs in WGBS was limited, the methylation changes were rather large, because 
out of 85 regions that lost methylation in the KO sample, 24 showed more than 50% reduction 
in methylation levels. In turn, out of 84 identified hypermethylated DMRs, 23 displayed more 
than 50% increase in methylation. Together, these data indicate that the chromatin regulator 
MeCP2 affects DNA methylation in a punctuate but notable manner. To check if the identified 
DMRs are sites of MeCP2 binding, we next used published MeCP2 high resolution ChIP-seq 
data from main olfactory neuroepithelia (59). We observed that 48% (41/85) of all 
hypomethylated DMRs and 63% (53/84) of all hypermethylated DMRs were associated with 
MeCP2 binding sites (statistically expected were <10%) (Fig. 7D). The highly significant 
enrichment of MeCP2 binding sites in both groups of DMRs, in particular in the 
hypermethylated DMRs, suggests that the observed methylation changes are direct effects of 
the loss of MeCP2 in the KO tissue. To determine whether the affected DMRs cluster with 
particular genomic features, we next analyzed their association with other chromatin elements 
(Fig. 7E). Next, we analyzed whether the affected DMRs correlate with any genetic and 
chromatin regulatory elements, showing that regions with gain in DNA methylation in the 
MeCP2 KO are enriched in gene promoters, in particular high CpG density promoters HCPs. 
By contrast, hypomethylated DMRs were moderately enriched in CGI and HCPs but not at low 
CpG density promoters (LCPs) (Fig. 7E). These data indicate that MeCP2 controls DNA 
methylation at a subset of CGIs and HCPs.  
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Discussion 
During the past decade compelling experimental evidence has accumulated, indicating that 
DNA methylation patterns are highly dynamic and result from ongoing de novo methylation 
and demethylation events (3). This dynamic landscape plays particularly important roles in non-
diving cells, such as terminally differentiated neurons (69-71). In the absence of cell division 
and DNA replication, the DNA methylation profiles in these cells are only controlled through 
a tight regulation of the targeting and activity of DNA methylating and demethylating enzymes. 
However, despite their importance, the regulatory processes of DNMTs are not yet fully 
understood. In this work, we took a closer look at the DNMT3 methyltransferases, factors that 
play essential roles in mammalian development and disease (1,2,72). We show that DNMT3 
proteins directly and strongly interact with the chromatin regulator MeCP2, an important reader 
of 5mC and 5hmC, in vitro with recombinant proteins, in mammalian cell lines and by co-
immunoprecipitation in brain lysates and that this interaction is mediated by the TRD domain 
of MeCP2 and the ADD domain of DNMT3 proteins. Based on the fact that MeCP2 is highly 
expressed in neurons and functions mainly in this cell type, we investigated whether the 
DNMT3A-MeCP2 interaction likely plays an important role in controlling DNA methylation 
patterns in the brain. 
By employing in vitro methyltransferase assays using recombinant proteins and a variety of 
DNA substrates, we observed an almost complete, concentration-dependent inhibitory effect 
caused by MeCP2 binding to DNMT3A (Fig. 4D). Inhibition on both CpG and CpA substrates 
was obtained. DNMT3B activity was comparably reduced, indicating a conserved mode of 
action. Using conformationally locked DNMT3A variants as a novel tool to investigate 
DNMT3A regulation, we show that the inhibition of DNMT3A by MeCP2 occurs by an 
allosteric mechanism, in which binding of MeCP2 stabilizes the autoinhibitory conformation 
of DNMT3A (Fig. 1B and 5A). Interestingly, binding of the unmodified H3 N-terminal tail 
peptide to the ADD domain of DNMT3A was shown to have the opposite effect, by precluding 
the autoinhibitory conformation and leading to the activation of DNMT3A (12,13). We 
mechanistically addressed this cross talk and show that binding of H3 and TRD to DNMT3A 
are mutually exclusive and the MeCP2-mediated inhibition of DNMT3A2 can be overcome by 
addition of the unmodified H3 tail peptide. 
To understand the effects of the MeCP2 on the function of DNMT3A in vivo, we have 
performed WGBS in the mouse brain, a tissue where MeCP2 and DNMT3A have important 
biological roles. Although these experiments are limited by the fact that relevant brain regions 
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or cell types and critical developmental stages may not be sampled, differences in DNA 
methylation were observed. We observed that MeCP2 knock-out leads to both hyper- and 
hypomethylation of DNA at specific 1kb tiles indicating that MeCP2 has both positive and 
negative effects on DNMT3A activity. These results are in agreement with the documented role 
of MeCP2 as both gene activator and repressor. The overall number of DMRs in WGBS was 
limited, which is in agreement with the dominant role of DNMT1 for maintenance methylation 
and the fact that DNMT1 is not influenced by MeCP2 (29). However, the methylation changes 
at the affected regions were rather large; around half of the discovered DMRs showed a change 
of more than 50% in methylation levels averaged over the 1kb tiles. Regions gaining DNA 
methylation in the MeCP2 KO are enriched in gene promoters, in particular HCPs, while 
hypomethylated DMRs were moderately enriched in CGI and HCPs. Overall, our data indicate 
that MeCP2 controls DNA methylation at a subset of CGIs and HCPs, which is particularly 
relevant, because expression of genes with HCPs is often regulated by DNA methylation 
(73,74). Interestingly, while WGBS demonstrated that MeCP2 functions as repressor and 
stimulator of DNA methylation at a rather small number of sites in mouse brain tissue, DNA 
methylation analysis after overexpression of MeCP2 in HCT116 DNMT1 hypomorphic cells 
resulted in a much more prominent global decrease in methylation. The stronger inhibition 
observed in the HCP116 cells can be explained by the larger contribution of the DNMT3 
enzymes to overall methylation levels in this cell line. 
In summary, our data suggest a model in which DNMT3A is under the combined control of 
MeCP2-mediated targeting and inhibition and the modification state of histone H3 tail at 
genomic target sites, unravelling one part of the intricate regulatory network, which controls 
DNA methylation. On the one hand, the interaction with MeCP2 inhibits DNMT3A activity 
and reduces DNA methylation at a subset of HCP gene promoters in the mouse brain and after 
overexpression of MeCP2 in a global manner in tissue culture (Fig. 8A). On the other hand, at 
defined CGIs and a subset of HCP promoters, MeCP2 can act as a recruiter of DNMT3A. As 
shown by our biochemical data, this leads to a relief of the allosteric inhibition of DNMT3A by 
the interaction of the DNMT3A ADD domain with appropriately modified histone tails, which 
do not contain activating marks. Therefore, the specific delivery of DNMT3A to such regions 
by MeCP2 can target DNA methylation (Fig. 8B). Afterwards, the elevated DNA methylation 
will increase the methylcytosine-dependent MeCP2 recruitment to these loci, initiating a 
positive feedback loop, which can contribute to the stable maintenance of methylation at these 
sites. In neurons, this process may be further supported by the non-CpG (mainly CpA) 
methylation introduced by DNMT3A which is bound by MeCP2 as well. 
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Figures and figure legends 
 
Fig. 1: Structures of DNMT proteins and MeCP2. A) Domain architecture of mouse DNMT3A, 
DNMT3L and MeCP2 and domain boundaries used in this work. B) Model of the structure of 
a DNMT3A fragment comprising ADD (red or orange) and catalytic domain (blue). The ADD 
domain can bind to the catalytic domain at two interfaces, at an allosteric site (ADD domain 
colored in red, Y526 is at the interface), which is stabilized by binding of the H3 tail, and at an 
inhibitory binding site (ADD domain colored in orange, D531 is at the interface). The image 
was generated using pdb files 4U7P and 4U7T (12). 
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Fig. 2: GST pull-down experiments with DNMT3 proteins and MeCP2. A) Pull-down of His-
DNMT3A by GST tagged N-terminal truncated MeCP2 (MeCP2N, residues 104-486). Note 
that MeCP2 carries an endogenous His-tag. The bands labelled with *1 and *2 correspond to 
degraded DNMT3A and MeCP2N, respectively. B) Pull-down of His-DNMT3A2 by GST 
tagged N-terminal truncated MeCP2 (MeCP2N, residues 104-486). C) Pull-down of His-
DNMT3L by GST tagged MeCP2. D) Pull-down of His-tagged C-terminal domain of 
DNMT3L by GST tagged MeCP2N showing absence of interaction. E) Pull-down of Myc-
tagged DNMT3A by EYFP-tagged MeCP2 after transient co-expression of both proteins in 
human HEK293 cells. Lane 1: -YFP pulldown after co-expression of EYFP and Myc-
DNMT3A. Lane 2: -YFP pulldown after co-expression of EYFP-MeCP2 and Myc-DNMT3A. 
Lane 3: -YFP pulldown after expression of EYFP-MeCP2. Lane 4: empty lane. Lane 5: 10% 
input of lane 2. F) Pull-down of endogenous MeCP2 by immunoprecipitation of endogenous 
DNMT3A using mouse brain protein extracts. An immunoprecipitation using -Myc antibody 
was conducted as control. 
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Fig. 3: Mapping of the DNMT3A-MeCP2 interaction. A) Pull-down of MeCP2N with 
different GST-tagged DNMT3A domains, showing an interaction with the ADD domain. B) 
Pull-down of DNMT3A with different GST-tagged MeCP2 domains showing interaction with 
the TRD domain. Note that MeCP2 contains an endogenous His-tag in its CTDb domain. C) 
Pull-down of His-DNMT3A2 with GST-tagged TRD domain. Efficient interaction could be 
observed even in the presence of 600 mM KCl. D) Pull-down of MBP-tagged ADD domain by 
GST-tagged TRD domain (wt) or TRD domain containing the R306C Rett mutation (RC). 
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Fig. 4: Inhibition of DNMT3A2 by addition of MeCP2 (A and B) or MeCP2 TRD domain (C 
and D). In A-C) 2.5 µM DNMT3A2 or DNMT3A-C was used and 3 µM MeCP2 or TRD 
domain were added. Identical control reaction without addition of MeCP2 were used to 
calculate relative activities. Different DNA substrates were used as indicated. D) Inhibition of 
DNMT3A2 by addition of increasing concentrations of TRD using the um30mer substrate. 
Control refers to a reaction without added TRD. All error bars indicate the SEM based on two 
independent experiments. 
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Fig. 5: Mechanism of the inhibition of DNMT3A by the TRD domain of MeCP2. A) Schematic 
picture of the conformational changes of DNMT3A showing that the ADD domain can bind to 
the catalytic domain (CD) at an allosteric site in which DNMT3A is active. The allosteric 
conformation is stabilized by Y526 indicated by a yellow triangle. Binding of the H3 peptide 
(orange) to the ADD domain stabilizes the allosteric binding mode (12,13). ADD can also bind 
to CD at an autoinhibitory site, which renders DNMT3A inactive. The autoinhibitory 
conformation is stabilized by D531 indicated by a green asterisk. Binding of MeCP2 to the 
ADD domain of DNMT3A via its TRD domain stabilizes the autoinhibitory binding mode, 
leading to inhibition of DNMT3A. B) Inhibition of Dnmt3a2 wild-type (wt) and its 
conformational variants by TRD. The inhibition is lost in the D531R variant carrying a 
mutation, which prevents the autoinhibitory conformation. Error bars indicate the SEM based 
on three independent experiments. C) Pull-down of His-DNMT3A2 (0.25 µM) by GST-TRD 
in the presence of increasing concentrations of recombinant histone H3 (0, 0.26, 1.3 and 3.9 
µM) indicating that the H3 binding to DNMT3A2 interferes with the TRD interaction. D) DNA 
methylation activities of DNMT3A2 and DNMT3A2 bound to H3 peptide (amino acid 
sequence 1-19, 25 µM) in the absence and presence of TRD (3 µM) showing the loss of TRD 
inhibition in the presence of H3 peptide. Error bars indicate the SEM based on three 
independent experiments. 
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Fig. 6: Cellular localization of fluorescently tagged DNMT3L, ADD domain and MeCP2 after 
transient expression in NIH3T3 cells. A) DNMT3L shows a homogenous nuclear distribution 
(67). B) The YPF-ADD domain of DNMT3A shows a homogenous nuclear distribution. C) 
YFP and CFP tagged MeCP2 localizes to defined foci, which correspond to heterochromatic 
DAPI dense regions (19,48). D) DNMT3L is recruited to heterochromatic foci when co-
expressed with MeCP2. E) The DNMT3A ADD domain is recruited to heterochromatic foci 
when co-expressed with MeCP2. E) Fraction of cells showing spotty and diffuse localization 
patterns in the experiments shown in panels A-E (based on analysis of >20 individual cells in 
each case). See also Suppl. Fig. 10. 
 
  
30 
 
 
Fig. 7: Effect of MeCP2 on DNA methylation in cells. A) Global DNA methylation levels after 
expression of MeCP2 in human HCT116 cells containing a DNMT1 hypomorphic allele. 
Different clonal populations expressing MeCP2 showed an approximately 2-fold reduction of 
global DNA methylation. The error bars represent the SEM based on three technical repeats. 
B-E) Results of whole genome bisulfite methylation analysis in mouse MeCP2 KO brain tissue. 
B) Two dimensional density plot of methylation levels at nonrepetitive 1kb genomic tiles in 
KO and WT tissues. The DMRs are indicated by black dots. C) Heatmap of the methylation 
levels of nonrepetitive 1kb DMRs in KO tissue. D) Overlap of hyper- and hypomethylated 
DMRs with MeCP2 binding site regions. E) Enrichment of selected genomic features at hyper- 
and hypomethylated DMRs (CGI, CpG islands; HCP, high CpG density promoters; LCP, low 
CpG density promoters). 
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Fig. 8: Model of the dual role of MeCP2 in the regulation and targeting of DNMT3A. A) 
Binding of MeCP2 (blue) to DNMT3A (green) inactivates the methyltransferase and prevents 
untargeted activity (upper scheme). B) After MeCP2 binding to DNA at a genomic locus with 
appropriately modified H3 tail, H3 tail binding to DNMT3A leads to the dissociation of the 
DNMT3A-MeCP2 complex and subsequent DNA methylation. This can trigger more MeCP2 
binding and by this initiate a positive feedback mechanism. 
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Supplemental Text 1. Literature examples of the interaction of 
epigenetic readers and writers. 
Previous studies have shown that readers of epigenetic marks often interact with enzymes which 
introduce the same mark. For example, HP1 which reads H3K9me2/3 interacts with 
SUV39H1/H2 (an H3K9 PKMT) (Schotta et al., 2002), G9a (an H3K9 PKMT) contains an 
ankyrin repeat domain which binds to H3K9me2 (Collins et al., 2008), and EZH2 (an H3K27 
PKMT) forms a complex with EED, which is a K27 methylation reader (Margueron et al., 
2009). Similarly, MeCP2, which binds methylated DNA interacts with DNMT1 (Kimura and 
Shiota, 2003), and UHRF1, which binds hemimethylated DNA with its SRA domain (Achour 
et al., 2008; Arita et al., 2008; Hashimoto et al., 2008), interacts with DNMT1 as well (Bostick 
et al., 2007; Sharif et al., 2007) and stimulate its methyltransferase activity by an allosteric 
mechanism (Bashtrykov et al., 2014; Berkyurek et al., 2014). 
 
  
Supplemental Figures 1-8 
 
Suppl. Fig. 1: Purification of GST tagged N-terminally truncated MeCP2 and GST-TRD 
domain proteins. The image shows examples of the purified proteins loaded on SDS 
polyacrylamide gels and stained with Coomassie BB. 
 
 
  
Suppl. Fig. 2: Purification of Dnmt3 proteins. The image shows examples of the purified 
proteins loaded on SDS polyacrylamide gels and stained with Coomassie BB. 
 
 
Suppl. Fig. 3: Purification of Dnmt3 domains. The image shows examples of the purified proteins 
loaded on SDS polyacrylamide gels and stained with Coomassie BB. 
 
 
  
Suppl. Fig. 4: Purification of MeCP2 domains. The image shows examples of the purified 
proteins loaded on SDS polyacrylamide gels and stained with Coomassie BB. 
 
 
  
Suppl. Fig. 5: Sequence of the 585mer (left part) and HpaII digestion of unmethylated and pre-
methylated 585mer. Samples were loaded on an agarose gel and stained with Ethidium bromide. 
 
 
  
Suppl. Fig. 6: Images of the HCT116 cell lines with stable expression of EYFP-MeCP2. Scale 
bar: 200 µm. 
 
 
  
Suppl. Fig. 7: Purification of Dnmt3 mutants. The image shows examples of the purified 
proteins loaded on SDS polyacrylamide gels and stained with Coomassie BB. 
 
 
  
Suppl. Fig. 8: Pulldown of His-Dnmt3a2 wild type and mutants by GST-tagged TRD showing 
that the Dnmt3a2 Y526E and D531R mutants still interact with TRD.  
 
  
Suppl. Fig. 9: Inhibition of DNMT3B2 by MeCP2 TRD. The DNMT3B2 is a truncated form of 
DNMT3B cloned to correspond to DNMT3A2. A) Coomassie-stained SDS-PAGE of the 
purified DNMT3A2 and DNMT3B2. The expected size of the full-length proteins is indicated 
with red arrows. Both of the protein preps show comparable high purity. B) Enzymatic activity 
assay with DNMT3B2 in the absence or presence of the TRD domain of MeCP2. The activity 
of DNMT3B2 in the absence of TRD was normalized to 100%. The error bar represents 
standard error of the mean for three independent experiments. 
 
 
  
Suppl. Fig. 10: Absence of crosstalk between the YFP and CFP channels in fluorescence 
microscopy. YFP tagged MeCP2 and CFP tagged DNMT3L were individually transfected into 
NIH3T3 cells and images were captures in the YFP and CFP channels. 
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